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1MINISTER’S 
FOREWORD
This National Cancer Strategy is all about people.  It is 
about preventing cancer across our population, diagnosing 
cancer early, providing optimal care to patients and 
maximising their quality of life. 
Ireland has made significant progress under the previous 
strategy.  We now aim to take on the challenge of making 
further strides in cancer control such that survival rates can 
reach the top quartile of European countries by the end of 
the Strategy period.  
Cancer prevention is a cornerstone of this Strategy as it 
offers the most cost-effective, long-term approach for 
cancer control. Cancer prevention sits fully into the Healthy 
Ireland approach in my Department.  
As in other health matters, particular focus will be put on 
achieving integration across primary, acute and social care 
services.  A key element in ensuring this is the strengthened 
governance and oversight role envisaged for the National 
Cancer Control Programme in providing leadership across 
the continuum of care.  
The primary aim for all cancer services is to provide 
evidence-based care that is effective, safe, of high 
quality and patient-centred, supported by national 
standards and clinical guidelines.  Annual reports on 
the implementation of this Strategy, together with the 
broader healthcare quality reporting system, will help in 
this regard, as well as keeping the public informed on 
progress.  
With cancer survivorship numbers increasing 
significantly, optimising peoples’ quality of life is a 
particular focus of patients.  This emphasis on quality 
of life will be central in the implementation of the 
Strategy. 
The Cancer Patient Forum made a huge contribution 
that impacted on all involved and resulted in a 
better Strategy.  I thank the Forum members for 
their most willing engagement and I am committed 
to the continued involvement of patients in the 
implementation phase.
I would also like to acknowledge the contribution 
of the Cancer Strategy Steering Group, chaired 
most effectively by Professor John Kennedy.  They 
worked enthusiastically, aided by inputs from many 
invited participants at their meetings, to finalise 
recommendations for a comprehensive Strategy.
I fully endorse this Strategy and I was delighted to 
present it to Government for approval.  Now it’s all 
about implementation.
Simon Harris, T.D.
Minister for Health
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CHAIRMAN’S 
FOREWORD
The first Cancer Strategy, entitled Cancer Services in Ireland: A National 
Strategy, was published in 1996. Under the leadership of the late Professor 
James Fennelly, the Cancer Strategy Group identified the inferior Irish mortality 
figures for cancer compared to the European average and proposed a series of 
measures to reduce the death rate from cancer in the under 65 age group by 
15 per cent in the ten year period to 2005.  The extensive appointment of a 
broad range of cancer specialists, and the reorganisation of services, under the 
Strategy resulted in this goal being achieved well before the target date. The 
implementation of the recommendations in the Hollywood report, published in 
2003, also had a hugely significant impact on the delivery of radiation therapy 
in Ireland. 
Informed by the work of the National Cancer Forum chaired by Professor Paul 
Redmond, the second National Cancer Strategy, A Strategy for Cancer 
Control in Ireland, was published in 2006. This Strategy embraced the 
concept of cancer control that had emerged internationally and it included 
recommendations in relation to organisation, governance, quality assurance 
and accreditation across the continuum of cancer care.  The establishment 
of the National Cancer Control Programme (NCCP) to ‘formulate a whole 
population, integrated and cohesive approach to cancer’ followed in 2007.  In 
parallel with the establishment of the NCCP, we have seen the embedding of 
cancer screening programmes in the healthcare system and the very significant 
improvements in delivery of radiation therapy.  All of these developments have 
delivered continuing improvements in outcomes for Irish patients with cancer.
We are now faced with a different set of opportunities and challenges.  
Improving therapies have gratifyingly resulted in a greatly increased number 
of people who have survived cancer.  Breathtaking advances in basic and 
translational science have resulted in a proliferation of novel diagnostics 
and therapeutics and this trend will continue. Such advances present great 
opportunities, but their integration into cancer care will present organisational 
and financial challenges. At the same time, our population is aging rapidly, 
driving a relentless increase in cancer incidence, and challenging clinicians to 
treat patients who have complex medical needs. Meanwhile, much of our 
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infrastructure is not up to international standards, at 
capacity and struggling to cope with the demands placed 
on it.
In this Strategy we map a route for cancer care over the 
next decade.  However, given the accelerating rate of 
progress in the cancer field, the increasing recognition of 
the degree of complexity of cancer cases and the ten year 
Strategy period, issues will be addressed incrementally 
as short, medium and long-term goals.  For example, 
immediate needs might involve addressing deficiencies 
in specialist cancer nursing and strengthening the role 
of the NCCP, while the development of comprehensive 
electronic patient records might be seen as a medium-term 
issue.  Also, the centralisation of cancer surgical services, 
commenced several years ago, must be completed as 
expeditiously as possible.  
However, it is more difficult to define the challenges which 
will arise in the later years of the Strategy period and so is 
proposed that the recommendations of the Strategy will be 
reviewed towards the end of 2021 to ensure that our aims 
and direction are appropriate to deliver optimum outcomes 
for patients.
In the words of Dr Christopher Wild, Director of the 
International Agency for Research on Cancer (IARC), ‘we 
cannot treat our way out of the cancer problem’.  It is 
essential that we act now to reduce the incidence of cancer 
in the medium to long term.  Aggressive programmes 
of public education, risk reduction, prevention and early 
detection must be promoted by the Department of Health 
and the NCCP, with extensive coordination across all 
stakeholders, notably primary care and the voluntary sector. 
We must also continually strive for earlier diagnosis of 
cancer in patients. Only if we are successful in achieving 
these goals will we be able to minimise the extent of the 
cancer problem in the coming decades.
As is the case across the Strategy, I strongly believe that 
the most strenuous efforts must be made to target more 
deprived populations in cancer prevention and early 
diagnosis interventions.  There is incontrovertible evidence 
of the enormous impact of socioeconomic status and 
deprivation on death rates from some cancers in Ireland.  
The causes are multifactorial, ranging from high smoking 
levels, and poor diet to inadequate access to timely 
diagnostic services.  Apart from being the just approach, 
this represents the most effective way to ensure future 
optimal value for money for the health service. 
Finally, I would like to acknowledge the extensive work 
undertaken by the members of the Cancer Strategy 
Steering Group and the Cancer Patient Forum in developing 
this report.  In discharging the remit given to them by 
the Minister for Health, they were ably supported by the 
Department of Health team, comprising Michael Conroy, 
Keith Comiskey, Clodagh Murphy and Stephen McGettrick 
from the Cancer, Blood & Organs Policy Unit.
Prof. M. John Kennedy
Chairman
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EXECUTIVE 
SUMMARY
The Need for this Strategy
This Cancer Strategy aims to meet the needs of cancer 
patients in Ireland for the next decade. The number of 
cases of cancer is expected to increase over the period 
of the Strategy, and to almost double by 2040. This is 
mainly due to an increasing and an aging population 
- cancer is a disease where the risk increases with age.  
The percentage of deaths attributable to cancer has 
risen from 20% in the 1980s to over 30% at present.  
At the same time, there are over 150,000 cancer 
survivors in Ireland now and a greater focus on the 
increasing numbers living with and beyond cancer is 
required. 
Rapid advances have been made in cancer diagnostics 
and treatments. The objective is to ensure that cancer 
services respond to both the challenges and the 
opportunities for future development so that care 
is of a uniformly high quality across our population. 
This Strategy provides direction in developing and 
implementing policies for the control of cancer.
Many advances have been made in cancer control in 
the past decade. The previous strategy, A Strategy 
for Cancer Control in Ireland (2006), led to the 
establishment of designated cancer centres and the 
reform of how cancer is diagnosed and treated. The 
National Cancer Control Programme, established 
in 2007, has led on the development of cancer 
services, such as rapid access clinics to improve early 
diagnosis, advances in hospital-based treatment 
and developments in more specialised areas such 
as hereditary cancer services.  Other developments 
include the expansion of cancer screening and an 
emphasis on healthier lifestyles. Smoking cessation 
efforts have increased and the rate of daily smoking 
in the population over the age of 15 has now fallen to 
below 20%.
However, many challenges remain. Increased demand 
has led to capacity and resourcing issues, particularly 
in relation to staffing.  There is now an increased 
awareness and demand for additional support for 
cancer patients after diagnosis, including survivorship 
programmes and psychosocial services. Greater 
integration with primary care and local services is 
required to ensure seamless patient pathways before, 
during and after treatment. 
These and other issues were highlighted in an 
evaluation of A Strategy for Cancer Control in Ireland 
(2006) and in the public consultation undertaken 
to inform the development of this Strategy. 
While the Evaluation Report acknowledged that 
substantial progress had been made, it saw a need 
for improvements in the model of service delivery, 
increased staffing in nursing, health and social 
care professionals and physicians, increased focus 
on survivorship and a more robust infrastructure 
for research.  Other priorities for a new Strategy 
identified through the Public Consultation include 
prevention, service reconfiguration and social and 
financial support.
Reducing the Cancer Burden
Cancer prevention will be a cornerstone of this Cancer 
Strategy as it offers the most cost-effective, long-
term approach for cancer control. The proportion of 
cancer incidence attributable to modifiable lifestyle 
and environmental factors is estimated to be in the 
30% to 40% range. Of these risk factors, smoking 
has by far the biggest impact and, in implementing 
this Strategy, we will work towards the goal of 
making Ireland tobacco-free by 2025.  We also need 
to increase our efforts to reduce the number of 
avoidable cancers through the promotion of healthy 
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lifestyles, in areas such as improved diet, more exercise 
and reduced alcohol intake.  Prevention measures will 
be integrated with the overall health and wellbeing 
initiatives under the Healthy Ireland programme. 
Reducing health inequalities is a priority of this 
Strategy, as lifestyle risk factors generally follow 
social, deprivation, gender and age patterns.  Health 
inequalities are also associated with poor symptom 
awareness, delayed presentation and low uptake of 
services, including screening.
Detecting and diagnosing cancer early is a critical 
step in reducing mortality as a result of cancer.  
Efforts will continue to ensure that people take up 
the offer of cancer screening when invited through 
the BreastCheck, CervicalCheck and BowelScreen 
programmes. Broadened aged-based cohorts are 
envisaged for both BreastCheck and BowelScreen. 
Further improvements in overall survival rates will 
require an emphasis on increasing the proportion of 
patients diagnosed at an earlier stage of their disease.  
Early diagnosis is influenced by many factors. Public 
and health professional awareness of the importance 
of early presentation is critical, and is complemented 
by clear, evidence-based GP referral guidelines, clear 
pathways to specialist care and timely access to 
diagnostic services.  This Strategy sets out ways to 
strengthen the care pathway to diagnosis through 
Primary Care, and to provide additional diagnostic 
capacity for GPs, guided by referral criteria. 
Provision of Optimal Care
A broad objective of the Strategy is to have models 
of care in place that ensure that patients receive the 
required care, in a timely fashion, from an expert 
clinical team in the optimal location.  The concept 
of a continuum of care will underpin the approach 
to patient services, from prevention, early diagnosis 
and evidence-based, high quality patient-centred 
treatment, to appropriate follow-up and support.  
Much of our cancer treatment takes place in acute 
hospitals under the direction of specialist clinicians 
and multidisciplinary teams. This Strategy builds 
on progress made to date by supporting the 
key role of designated cancer centres in cancer 
treatment. Multidisciplinary team (MDT) working is 
a cornerstone of modern cancer care.  MDT working 
has led to improved decision-making, more co-
ordinated patient care and improvements in the 
overall quality of care.  It is recommended that all 
patients diagnosed with cancer will have their case 
formally discussed at an MDT meeting.  
Current services are coming under pressure and 
patient numbers will continue to increase across 
the period of this Strategy.  A rolling plan of capital 
investment will be required to ensure that high-
quality facilities are available for patients and staff, 
that our health personnel can progress in line with 
developments in cancer worldwide and that the 
potential for on-going improvements in outcomes is 
maximised.
Advances in molecular technology have resulted in 
improved cancer diagnosis, the use of more targeted 
therapies and better monitoring of treatment 
outcomes.  The role of inherited predisposition to 
cancer is also being increasingly defined through the 
use of genetic testing. Developments in genomics 
have impacts far wider than cancer, but are key 
to improving cancer outcomes. The challenge is 
to ensure that the potential benefits of molecular 
cancer diagnostics and cancer genetics/genomics 
will be realised for all patients across the ten year 
strategy period.  
Service improvements will be underpinned by 
evidence and best practice, and the centralisation of 
surgical services for more cancers will be progressed 
to ensure that optimal treatment is provided and 
outcomes are improved.  Radiation oncology services 
will expand to meet demand.
7
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The growth in both the incidence of cancer, and 
the prevalence of patients on active treatment with 
new drugs, is giving rise to a significant increase in 
the volume and complexity of medical oncology and 
haematology work. As treatments become more 
complex, there will be a need for medical oncologists 
and haematologists to specialise in particular cancer 
sites and treatment modalities. The total number of 
patients in receipt of Systemic Anti-Cancer Therapy 
(SACT) is expected to grow even faster than the 
number of new patients, as new drugs come on stream, 
as the duration of some treatments increases and as 
patients with advanced disease survive longer. In order 
to meet this rising demand, and to allow for a greater 
level of site specialisation, the number of medical 
oncologists and haematologists in Irish hospitals will 
need to be increased.
New-to-market cancer therapeutics are exceedingly 
expensive. The NCCP, with the wider HSE and the 
Department of Health, work together in advancing the 
process of securing such drugs at affordable cost once 
the European Medicines Agency (EMA) has approved 
them for clinical use.  The scale of the costs involved, 
set against expectations of the availability of the latest 
effective drugs, will pose an on-going management 
challenge during the period of the Strategy.   
Rare cancers, defined as those with an annual incidence 
of less than six cases per 100,000 comprise about 20% 
of all cancers, with approximately 5,200 new cases 
annually.  There is a need for clear care pathways for 
the diagnosis and treatment of patients who have rare 
cancers, with particular emphasis on timely treatment 
planning at national MDT level, involving subspecialty 
expertise in diagnosis and treatment and with linkages 
to international centres of excellence for specialist 
advice and intervention.
Approximately 200 children and young adolescents 
(0-16 years of age) are diagnosed with cancer each 
year.  All of these children are referred to the National 
Paediatric Haematology and Oncology Centre (NPHOC) 
to have their diagnosis established, treatment planned 
and follow-up mapped out.  NPHOC also acts as an 
advisory and response service for 16 shared care centres 
throughout the country.  The development of a new 
children’s hospital will provide the opportunity to 
establish an age-appropriate facility for adolescents 
and young adults with cancer.  Services for this cohort, 
and transition arrangements to adult services, are a 
particular focus of this Strategy. 
A primary aim of all cancer services is the provision 
of safe, high quality and patient-centred care. This 
involves care that is safe, evidence-based, appropriate, 
timely, efficient, effective, equitable and person-
centred.  Safety is fundamental to quality healthcare 
and cancer services will be enabled to deliver safe care, 
while balancing competing pressures and demands.
  
Maximise Patient Involvement  
and Quality of Life
The development process for the Strategy saw the 
establishment of a Cancer Patient Forum, to provide a 
strong patient input and to consider how patient input 
into cancer services can be facilitated more broadly.  
It is proposed to establish a Cancer Patient Advisory 
Committee to facilitate continued patient input into 
cancer control measures. The Department of Health 
will ensure that patient representatives are involved 
in policy making, planning, practice and oversight of 
cancer services at local, regional and national levels.  
Service providers, including hospital groups, designated 
cancer centres and community healthcare organisations 
will also be encouraged to develop structures to 
facilitate patient and public input into cancer services. 
Many people are now living significantly beyond cancer 
diagnosis and treatment and this trend will continue. 
Definitions of cancer survivorship differ, but it is 
broadly accepted that cancer survivorship begins at the 
time of diagnosis and continues until end of life.  
In many cases the aim will be to return to work or to 
play a full part in life in whatever way is appropriate 
to the person.  The needs of individuals will differ 
greatly.  Cancer survivors can require life-long, 
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evidenced-based health care, both preventive and 
general medical, as well as psychosocial care and care 
specific to the cancer diagnosis involved.  The NCCP, 
working with the cancer centres, the Irish College of 
General Practitioners, primary care services, patients 
and voluntary organisations, will develop and 
implement survivorship programmes for patients with 
cancer.  These programmes will emphasise physical, 
psychological and social factors that affect health and 
wellbeing, while being adaptable to people with more 
specific survivorship needs following their treatment.  
Patients will also be offered Patient Treatment 
Summary and Care Plans as part of their support that 
will guide them towards self-management of their 
care. The emphasis in the Strategy is on maximising 
the quality of life of individuals diagnosed with cancer 
for as long as they live. 
Enabling and Assuring Change
The NCCP will continue to provide leadership and 
direction to the cancer system to ensure that service 
priorities are aligned with desired outcomes. They 
will work closely with the HSE Directorates, Hospital 
Groups and community healthcare organisations 
to lead service reorganisation and to ensure that 
integrated care pathways are provided for those 
affected by cancer. In working to ensure that the 
objectives of the Strategy underpin decisions on 
cancer care across the health services, the NCCP will 
lead service improvements, focusing in particular on 
funding and commissioning, as well as on oversight 
and performance review.
The positive impact of research activity, including 
clinical trials, on the care of patients is evident.  
An aim will be to develop a culture in the cancer 
care system that values research and is supportive 
of those who actively engage in it.  Steps will be 
taken to build on progress already made to ensure 
that cancer research is aligned with cancer control 
priorities and integrated with cancer care. The NCCP 
will establish a National Cancer Research Group to 
improve the coordination of cancer research and to 
foster a supportive environment for research within 
the health service and the universities. This Group will 
also develop proposals for a coherent and integrated 
approach to cancer biobanking, in line with broader, 
national developments in the area.
Change is required across our cancer services to give 
effect to the Strategy vision. A major focus will be 
placed on workforce planning, underpinned by service 
specifications that embrace a major and increased 
role for clinical nurse specialists and advanced nurse 
practitioners, as well as for health and social care 
professionals, in patient assessment, delivery of 
treatment, survivorship and end-of-life care.  An early 
emphasis will be placed on addressing workforce 
gaps in areas such as medical oncology, urology and 
nursing.
A focus on delivering results will be maintained 
throughout the Strategy period.  An annual report 
will be published by the Department of Health, with 
input from other stakeholders, on the implementation 
of the Strategy, with particular focus on the 
implementation of the recommendations and the 
degree to which Key Performance Indicators are 
being met.  The recommendations will themselves 
be reviewed at the halfway point of the Strategy, to 
assess their continued relevance and effectiveness 
in the delivery of optimum outcomes for patients. 
International co-operation in relation to the various 
aspects of cancer prevention, care, research and 
survivorship will be promoted and strengthened.
NATIONAL CANCER STRATEGY  2017-2026
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INTRODUCTION 
1.1. Developments in Cancer Services
Nearly every household in Ireland has been touched by 
cancer in some way, whether that is through our own 
health, or that of a relative, neighbour or friend. In 2013, 
cancer caused about one-third of all deaths in Ireland. It is 
important that we take a national, strategic approach to 
cancer control. The first cancer strategy, Cancer Services 
in Ireland: A National Strategy was published in 1996.  
That strategy brought coherence to the development of 
cancer services and involved the appointment of a broad 
range of cancer specialists. A 15% reduction in premature 
(under 65 years) cancer mortality was achieved by 2003.
The second Strategy, with a population health approach, 
followed in 2006 - A Strategy for Cancer Control in 
Ireland. This strategy focused on population needs, 
reform and reorganisation of the way cancer services 
were delivered with a particular focus on centralisation of 
confirmatory diagnosis, treatment planning and surgery.  
Clear, evidence-based policy direction, strong leadership, 
the establishment of the National Cancer Control 
Programme (NCCP) and strong working relationships all 
contributed to the progress made under this strategy.  The 
main areas of achievement include the designation of 
cancer centres, equal access to high quality treatment, 
multidisciplinary management of cancer patients, the 
development of rapid access clinics, developments across 
cancer screening, radiation oncology and medical oncology, 
as well as reduced smoking levels. 
Following the publication of that Strategy, the NCCP was 
established as an executive arm of the Health Service 
Executive (HSE) in 2007. The objective of the NCCP was 
to establish a comprehensive system of cancer control, 
primarily covering prevention, early detection, treatment 
and follow-up.  The NCCP also set standards and guidance 
for the delivery of cancer care and ensured the monitoring 
and oversight of cancer services.  It provided leadership for 
a change programme to ensure that cancer services were 
organised and delivered in an effective manner, based on 
clinical criteria and international evidence. 
The NCCP’s 2015 Report on the Implementation of ‘A 
Strategy for Cancer Control in Ireland 2006’1 provides 
a comprehensive report on the work of the NCCP to that 
point.  This report was a key source in informing members 
of the Evaluation Group on the organisation of cancer 
services in Ireland prior to the evaluation process outlined in 
Section 3.2.
CHAPTER 1
DID YOU KNOW?
The five year  
survival rate for 
breast cancer is 82%
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1 https://www.hse.ie/eng/services/list/5/cancer/pubs/reports/7%20year%20report.pdf 
NATIONAL CANCER STRATEGY  2017-2026
14
1.2. Development of this Strategy
In April 2015, the Minister for Health established a 
Steering Group under the chairmanship of Professor M. 
John Kennedy to provide guidance and advice to the 
Department in the development of a new cancer strategy.2 
The establishment of the Steering Group was supported 
by the publication of the report of the Evaluation Group 
on A Strategy for Cancer Control in Ireland (2006).  
That report was commissioned by the Department and 
conducted during 2014 in preparation for the development 
of a new strategy.
2 The list of Steering Group members and Terms of Reference is at Appendix A 
3 The list of Cancer Patient Forum members and Terms of Reference is at Appendix B.
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Also in April 2015, a Cancer Patient Forum3 was established 
to represent the views of patients and patient groups, and 
to provide them with a meaningful role in the development 
of the Strategy. Members of the Forum represented 
patients or organisations with experience of many cancer 
types and from various parts of the country. The Forum was 
represented on the Steering Group to more readily facilitate 
a patient input and to ensure that all members of the 
Forum were always fully informed on issues relating to the 
development of the Strategy. 
The Department of Health conducted a public consultation 
in June and July 2015 to obtain the views of the public and 
of organisations on current cancer services and priorities for 
the future.
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CANCER IN IRELAND
CHAPTER 2
2.1. Introduction
Cancer is a major cause of mortality in Ireland.  Cancer and cardiovascular disease were each responsible for about one-
third of all deaths in 20134.  In the population under 65, cancer was the cause of half of all deaths in women, and the 
cause of over one-third of all deaths in men.  The percentage of deaths attributable to cancer has risen from 20% in the 
1980s to over 30% at present. The most recent summary statistics for cancer in Ireland are displayed in Table 2.15.
Table 2.1          Summary statistics for cancer in Ireland 2012-2014
4  Unless otherwise stated, data in this chapter are sourced from the National Cancer Registry. 
5  Unless otherwise stated, all cancer statistics in this Strategy refer to invasive cancers, excluding non-melanoma skin cancer. 
6  A National Cancer Registry study (funded by the Health Research Board) published in 2016, estimated that the projected deaths from  
    all invasive cancers in Ireland between 2011 and 2030 will result in lost productivity valued at €73bn;  €13bn in paid work and  €60bn in  
    household activities: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2854-4
Females Males Total
Number of new cases per year* 9,703 11,101 20,804
Incidence rate (cases per 100,000 per year) 384 483 -
Cumulative lifetime risk of diagnosis (to age 74) 27% 33% -
Number of deaths per year (2011-2013) 4,065 4,590 8,655
Mortality rate (deaths per 100,000 per year, 2011-2013) 149 204 -
Cumulative lifetime risk of death (to age 74) 10% 13% -
Number of people with cancer alive in 2014 (diagnosed 
1994-2014)
71,062 68,464 139,526
Percentage of national population with cancer in 2013 3% 3% 3%
* all invasive cancers, excluding non-melanoma skin cancers. Source NCR.
Apart from the obvious losses to individuals, families and society, such mortality rates have significant economic 
consequences6.
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2.2. Cancer Types
Four cancer types make up more than half of all newly diagnosed cancers (excluding non-melanoma skin cancer) - breast, 
colorectal, lung, and melanoma in women (56%), and prostate, colorectal, lung and melanoma in men (57%) (Figure 
2.1).
2.3. Trends in Cancer Incidence
The number of cancer cases has been increasing by about 3% a year since 1994, but the age-standardised incidence 
rate, a measure of the risk of developing cancer at any given age, has been increasing by only about 1% a year (Figure 
2.2; Table 2.2).  Trends in death rates have been downwards over the same period (by 1.5% per year in men and 1.1% 
per year in women on average). There are a number of reasons why cancer incidence rates have been increasing slightly, 
including increases in risk factors such as obesity, alcohol consumption and sun exposure and the impact of screening.  
Much of the increase in the number of cancer cases and deaths is attributable to the growth in the population over 
65 years of age; 62% of male patients with cancer and 53% of female patients during 1994-2014 were aged over 65 
(Figure 2.4). 
Figure 2.1 Percentages of the common cancer types, 1994-2014
MaleFemale
BREAST
29%
COLORECTAL
12%
LUNG
10%
ALL OTHER
INVASIVE
44%
5%
MELANOMA
COLORECTAL
14%
LUNG
13%
ALL OTHER
INVASIVE
43%
3%
PROSTATE
27%
MELANOMA
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The rate of increase varied by cancer site (Table 2.2). The increase was higher for numbers of cases than for age-
standardised rates. For the common cancers, trends in rates ranged from a fall of 0.8% annually for lung cancer in 
men to an annual increase of 5.0% for melanoma in men and 3.7% for prostate cancer.  Most of the latter increase is 
believed to be due to increased diagnosis, as a result of widespread Prostate Specific Antigen (PSA) testing, rather than 
any increase in the underlying risk of developing the cancer.  On the other hand, the increase in melanoma risk seems to 
be due to changing patterns of sun exposure and has been accompanied by an increase in death rates of 5% per year for 
men.
Table 2.2 Average annual increase in numbers and age-standardised rates for the five commonest cancers, by gender, 1994-2014
Number Rates
Males Females Males Females
All cancers 3.4% 2.9% 1.0% 0.9%
Colorectal 2.4% 1.8% 0.0% -0.1%
Lung 1.6% 4.1% -0.8% 2.3%
Melanoma 7.5% 4.7% 5.0% 2.5%
Breast (female) - 3.6% - 1.4%
Prostate 6.1% - 3.7% -
 
Figure 2.2 Trends in cancer incidence, 1994-2014
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There is a higher incidence of cancer in more deprived populations. Overall cancer incidence is slightly but significantly 
higher in the most deprived 20% of the population, by approximately 10% for males and 4% for females, having 
adjusted for age7 (Figure 2.3, below). Of the individual cancers examined, cervical, lung and stomach cancers show strong 
patterns of increasing incidence with increasing deprivation, with age-standardised rates about 120%, 60% and 40% 
higher, respectively, in the most deprived compared with the least deprived fifth of the Irish population. Breast cancer and 
melanoma show the opposite pattern, i.e. decreasing incidence with increasing deprivation, with age-standardised rates 
about 15% lower and 30% lower, respectively, in the most deprived populations. 
Figure 2.3 Relative incidence rates of some cancers in the most affluent and most deprived areas, 2008-2012.
7  Data in relation to deprivation are provided by the NCR.The Pobal Haase-Pratschke 2006 Index of Deprivation at Electoral Division level is  
    used, i.e. an area-based measure of deprivation incorporating information from the 2006 national Census; this describes populations and  
    is assigned to patients based on their place of residence. 
8  Based on data from Census 2011 (CSO). 
9  The data in Table 2.3 are based on projections published by the National Cancer Registry 
    http://www.ncri.ie/sites/ncri/files/pubs/Cancer%20projections%20for%20Ireland%202015%20-%202040.pdf
2.4. Projections of Cancer Incidence
The population over 65 years is estimated to more than double, from 536,000 to 1,146,000, in the 25 years from 2011 
to 20368.  This ageing of the population will drive a large increase in the number of new cancer cases over the next few 
decades.  Table 2.3 shows the increases expected if no changes are assumed in risk factor prevalence in the near past or 
future9.
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Table 2.3 Projections of cancer numbers to 2025 and 2040 and % increase from 2010; demographic factors only
 
All excluding 
NMSC
Colorectal Lung Breast Prostate
Est 
number
% 
increase
Est 
number
% 
increase
Est 
number
% 
increase
Est
number
% 
increase
Est 
number
% 
increase
Females
2010 9,266 - 1,041 - 957 - 2,891 - - -
2015 10,192 10% 1,185 14% 1,013 6% 3,209 11% - -
2025 12,849 39% 1,550 49% 1,334 39% 3,937 36% - -
2040 16,787 81% 2,178 109% 1,862 95% 4,701 63% - -
Males
2010 10,436 - 1,430 - 1,307 - - - 3,222 -
2015 11,816 13% 1,686 18% 1,477 13% - - 3,541 10%
2025 15,639 50% 2,277 59% 2,012 54% - - 4,687 45%
2040 21,655 108% 3,224 125% 2,889 121% - - 6,426 99%
While demographic change will be the main factor driving an increase in cancer numbers, trends in risk factor prevalence 
will also have an impact. In the UK population, 40% of the total cancer risk (44% in males, 35% in females) has been 
attributed to five lifestyle factors - tobacco, diet, overweight/obesity, alcohol and low physical activity10. The attributable 
risks in Ireland are likely to be similar. 
2.5. Age at Diagnosis of Cancer
Cancer is largely a disease of older people.  As outlined in Figure 2.4 below, 62% of cancers in men and 53% in women, 
were diagnosed in those aged 65 and over.  The median age at diagnosis ranged from 32 years for testicular cancer to 72 
years for bladder cancer in men, and from 45 years for cancer of the cervix to 76 years for cancer of the lip in women.
Figure 2.4  Age at diagnosis, all malignant cancers (excluding NMSC) 1994-2014
10 Parkin, D.M., L. Boyd, and L.C. Walker. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. British Journal of  
 Cancer. 2011.
Female Male
0-49
18%
50-64
29%65-74
23%
75+
30%
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2.6. Cancer Stage at Diagnosis
Stage11 at diagnosis, that is how much the cancer has 
grown and spread, is probably the most important 
determinant of survival (Table 2.4).  
Table 2.4 Survival at one and five years for cancers diagnosed  
 2008-2012; by stage at diagnosis
Cancer 
type
Survival at one year 
after diagnosis
Survival at five years 
after diagnosis
Stage I Stage IV Stage I Stage IV
Colorectal 
cancer
98% 49% 95% 10%
Lung 
cancer
71% 16% 40% 3%
Breast 
cancer
99% 48% 94% 19%
Prostate 
cancer
99% 78% 93% 36%
Pancreatic 
cancer
37% 14% 17% 4%
Ovarian 
cancer
95% 51% 83% 15%
Stage at presentation varies with cancer site, but has not 
changed much over time (Figure 2.5). One challenge is to 
increase the proportion of patients diagnosed at an earlier 
stage of their disease.  If this can be achieved, for example 
by improving access to diagnostics, by expansion of rapid 
access clinics, by improved education of the population and 
by greater uptake of available screening programmes, then, 
not only will survival be improved, but significant efficiencies 
will be achieved in the health system. Indeed, since the 
introduction of BreastCheck, the national cancer screening 
programme for breast cancer, there has been an increase in 
the percentage of cancers diagnosed at an early stage12.
It should be noted that the apparent gradual increase in late 
stage cancer for some cancer types seen over the last few 
years in Figure 2.5 is probably due to improved diagnostic 
methods, which show up cancer spread much more 
sensitively than in the past, rather than to any real change in 
stage distribution. This is referred to as stage migration.
11  Cancer staging is the process of determining how much cancer is in the body and where it is located. Staging describes the severity of an individual’s  
      cancer based on the magnitude of the original (primary) tumour as well as the extent to which the cancer has spread in the body. Understanding the  
      stage of the cancer helps doctors to develop a prognosis and design a treatment plan for individual patients. 
12  National Cancer Registry of Ireland, Cancer Projections for Ireland 2015 – 2040 (2014).
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Figure 2.5  Percentage of late stage (III and IV) cancers by site and year of diagnosis
There is only limited evidence of any variation in stage at presentation with deprivation of the area of residence, including 
lower proportions of early-stage or higher proportions of later-stage cancers among more deprived populations for breast 
and prostate cancer (see Figure 2.6 below). 
Figure 2.6  Percentage of cases at each stage (I-IV), by cancer type and area deprivation category, 2008-2012.
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2.7. Cancer Survival
2.7.1 One-, five- and ten-year net survival for patients followed up in 2010-2014
Overall net survival from invasive cancer (excluding non-melanoma skin cancer) is currently estimated as 76% at one year 
from diagnosis, 61% at five years, and 57% at ten years (Figure 2.7).  For the common cancers the best ten year survival 
is for prostate cancer (89%) and the worst for lung (15%).  
Figure 2.7  One-, five- and ten-year net survival (age standardised)  
for the more common cancers (2010-2014 )13
There has been a steady increase in five-year survival since the period 1994-
1998 (Figure 2.8).  The largest relative increase has been in lung cancer, and the 
smallest in breast cancer.  This is quite probably because there is more potential 
for improvement in cancers with a poorer survival.  
Figure 2.8  Five-year net survival (age standardised), 1994-2014
13 This is the most up-to-date available estimate of survival for recent cancer patients, and is based on follow-up of all cases alive at any point during  
     2010-2014, supplemented by follow-up 2009-2014 for cases diagnosed in 2009.  The estimate includes medium/longer-term follow-up information from  
     pre-2010 – for example, patients diagnosed in 2001 who survive nine years up to 2010 contributed to the survival estimate between nine and ten years.
10 YEAR 
SURVIVAL 
RATE FOR
PROSTATE 
IS 89%
10 YEAR 
SURVIVAL 
RATE FOR
LUNG 
IS 15%
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2.8. International Comparisons
The main cancer control data sets used internationally are incidence, mortality and survival.  International comparisons 
provide important pointers towards our rates of progress, though differences between how health systems are structured, 
and the availability of useable, timely comparative data need to be borne in mind. 
2.8.1 Incidence
OECD reports show variations in the incidence of cancer in the OECD 34 countries (Figure 2.9)14. Incidence rates for 
breast and prostate cancer in Ireland are above the OECD 34 average, as is the overall cancer incidence rate. This 
emphasises the necessity of developing prevention and health promotion policies aimed at reducing cancer incidence.
Figure 2.9  Cancer incidence rates in OECD 34 countries, 2012 (age standardised).
 
2.8.2 Mortality
OECD reports confirm that cancer continues to be a major cause of mortality internationally. When compared with OECD 
34 countries, the overall cancer mortality rate in Ireland is above the average (Figure 2.10).  Early detection of cancer and 
effective treatments are priorities in this strategy to address our mortality rates.
14  OECD, Health at a Glance (2015)
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Figure 2.10  Cancer mortality rates in OECD 34 countries, 2013 or latest year available (age standardised).
2.8.3 Survival
The CONCORD 215 project has provided comparative 
survival data for a number of European countries for 2000-
2004 and 2005-2009 (Table 2.5).  Survival for Irish patients 
improved for all cancer types studied over these periods.  
However, these international comparisons show that, with 
the exception of prostate cancer, Irish survival rates for the 
common cancers remained below the median. Although 
Irish survival rates improved in all cases over the period, our 
ranking changed very little. International comparisons of 
cancer survival rates across countries will always be subject 
to time lags, and the main impacts of the 2006 National 
Cancer Strategy had not been felt in the period up to 2009. 
2.8.4 Lessons from international comparisons
While the provision and organisation of cancer services 
in Ireland has been transformed over the course of the 
last two decades, and outcomes for Irish patients have 
been substantially improved, there is still much scope for 
improvement.  Chapter 3 assesses the impact of previous 
cancer control strategies and identifies priorities for the 
future. This includes consideration of the cancer control 
strategies in other countries, many of which have lower 
mortality and higher survival rates. An aim of this Strategy 
is that cancer survival rates will be in the top quartile 
of European countries by 2025 (see Key Performance 
Indicators, Chapter 17).    
15 Claudia Allemani et al., Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based 
registries in 67 countries, The Lancet (2015). 
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Table 2.5 Net survival (%) for common cancers by country and year of diagnosis 
Country Colon Lung Breast Prostate
2000–04 2005–09 2000–04 2005–09 2000–04 2005–09 2000–04 2005–09
Austria 60 63 16 18 81 83 90 91
Belgium 64 65 15 17 85 85 92 93
Czech 
Republic
51 55 11 12 78 80 76 83
Denmark 52 56 10 11 81 82 64 77
Estonia 49 52 11 12 70 72 67 73
Finland 61 63 12 12 87 87 90 93
France 60 60 14 14 87 87 89 91
Germany 62 65 15 16 84 85 89 91
Iceland 61 65 15 15 88 85 80 84
Ireland 54 59 10 13 78 80 84 88
(rank) 15 14 19 15 18 17 11 10
Italy 60 63 14 15 86 86 89 90
Latvia 42 45 14 16 70 71 65 74
Lithuania 52 52 8 8 70 72 81 92
Malta 58 56 9 11 76 76 83 85
Netherlands 58 60 12 15 84 85 83 86
Norway 58 62 12 15 84 86 82 86
Poland 46 50 12 13 72 74 69 74
Portugal 56 60 10 13 81 83 87 89
Romania 58 16 75 80
Russia 36 41 15 16 62 71 64 70
Slovakia 50 50 10 11 74 72 63 66
Slovenia 53 56 10 11 78 80 73 78
Spain 56 59 12 13 82 84 85 87
Sweden 59 63 13 16 86 86 86 89
Switzerland 61 63 15 17 84 86 86 88
UK 51 54 9 10 79 81 80 83
(Note: some countries are represented by one or more regional registries without national population coverage)
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STRATEGIC CONTEXT 
CHAPTER 3
3.1. Introduction
The development of this Strategy included an examination 
of the current state of cancer care and a consideration of 
the requirements for the future. These included:
1 An evaluation of the A Strategy for Cancer Control 
in Ireland (2006). 
2 A public consultation process.
3 An examination of international models of cancer 
control.
3.2. Evaluation of ‘A Strategy for Cancer 
Control in Ireland’, 2006
In preparation for the development of the third strategy, an 
independent evaluation of the 2006 strategy, A Strategy 
for Cancer Control in Ireland, was commissioned by 
the Department of Health.  The purpose of this evaluation 
was to assess the outcomes of the recommendations from 
the 2006 strategy and to assess the overall impact of the 
Strategy on the burden of cancer.  The evaluation also 
considered Ireland’s position in terms of developments 
internationally and made a number of recommendations 
for the future.   
The Evaluation Group16 found that significant progress had 
been made across the whole cancer control system in Ireland 
since the publication of the 2006 strategy.  The Group 
noted that cancer prevention policies had been developed, 
progress had been made in the early detection of cancer 
through screening programmes and dedicated clinics had 
been established for symptomatic breast, lung and prostate 
referrals.  The Group also noted that national referral 
guidelines and pathways had been developed for many 
cancers and that quality assurance programmes had been 
developed for histopathology, endoscopy and radiology.
They singled out the establishment of the NCCP as the most 
significant factor in driving the required change in the cancer 
system. They also identified a number of areas that required 
attention and made a number of recommendations to 
improve the cancer control system.  These are listed in detail 
in the Report of the Evaluation Group17.
Patient and public 
involvement in strategy 
formulation, service 
development and 
evaluation should be 
integral to the next 
national cancer strategy
EVALUATION GROUP 
16 The Evaluation Group comprised Professor Pádraig Warde (Chairman, Interim Vice President of Clinical Programs & Quality Initiatives of Cancer Care),  
 Professor Harry de Koning (Professor of Public Health and Evaluation of Screening at the Erasmus University Medical Centre, Rotterdam) and Professor  
 Alison Richardson (Clinical Professor of Cancer Nursing and End-of-Life Care at the University of Southampton and Southampton General Hospital).
17 The Evaluation Report is available from the Department of Health website at the following location: http://health.gov.ie/blog/publications/national- 
 cancer-strategy-2006/
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The Group made a number of recommendations on how 
the cancer system should be organised, including hospital 
admissions policies, the organisation of hospital care 
and palliative care.  The recommendations encompassed 
a range of areas within cancer control from prevention 
and primary care to treatment, post treatment care, and 
patient involvement.  Staffing issues were considered, and 
deficiencies in oncology nursing and medical oncology 
in particular were highlighted.  The report also outlined 
a number of structural or legislative measures that were 
considered important to allow the cancer system to operate 
to its full capabilities, including mandatory notification of 
cancer diagnoses.
The Evaluation Group was impressed with progress in 
the cancer control system in Ireland since the publication 
of A Strategy for Cancer Control in Ireland in 2006. 
However, they also clearly identified key areas that require 
further attention. Their view was that while progress had 
been made, we remain significantly behind the countries 
that are leading the way in cancer control.
3.3. Public Consultation 2015
A public consultation process was launched by the Minister 
for Health in summer 2015. The consultation utilised a 
questionnaire which sought the views and priorities of the 
public and interest groups on a number of key issues that 
were identified by the Steering Group as being relevant for 
a new strategy. 
A total of 221 submissions was received. The majority of 
submissions (67%) were submitted by individual members 
of the public. The remaining submissions were submitted 
by organisations, or on behalf of organisations.18
3.3.1 Consultation findings 
Figure 3.1 below illustrates the main themes that 
emerged in the submissions. There was considerable 
overlap between the views of individuals, and those of 
organisations and healthcare professionals.
Figure 3.1  Issues identified in the public consultation 
• Need for local support 
services/centre linked with 
treating cancer centres
• Continue to improve cancer 
services and build on gains
• Financial burdens and need 
for medical card support
• Communication and 
integration between services 
along patient pathway
• ICT infrastructure is a limiting 
factor
• Attention to patient pathways 
and clinical guidelines will 
standardise and improve quality
• Research culture is important 
for quality
• Rarer cancers need service 
development
• Shortage of palliative care 
supports in some areas
• Psycho-social services needed 
across the cancer continuum
• Pressure on infrastructure and 
stang in all services
• Importance of on-going prevention 
initiatives at all levels
• Early diagnosis will be increased by 
more timely access to diagnostics
• Side e ects and long term 
e ects of treatment
• Direct access to oncology - 
not through ED
Individuals Organisations, incl.
Healthcare Professionals
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Social and Financial Support, Community Services
Prevention, Awareness
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Research
Quality Indicators
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Screening
Access to Treatment and Diagnostics
Psychological Support
Equality of Access
Rare and Childhood Cancers
Patient Pathway
Other
The main priorities identified are illustrated in Figure 3.2 below.
Figure 3.2  Identified public submission priorities for new cancer strategy
The three priorities most commonly identified were:
• service reconfiguration, both human and physical 
infrastructure;
• social and financial support for patients with cancer 
and development of community based services; and
• cancer prevention and continuing increase in public 
awareness.
3.3.2 Conclusions from public consultation
The public submissions recognised and appreciated 
that progress has been made in the last two decades in 
the development of cancer services and that there are 
opportunities to build on that progress. Several issues 
emerged as being important to both organisations and 
individuals. These included the pressure on infrastructure 
and staffing at all levels; the importance of prevention 
initiatives; the lack of psycho-social services available to 
patients and families; the impact of the side effects and 
long-term effects of treatment; and the importance of 
direct access to re-admission to oncology services for 
patients with cancer (rather than through Emergency 
Departments). Individuals making submissions saw the 
new strategy as continuing and accelerating the reforms 
initiated in previous strategies. 
The results of the public consultation were presented to 
the Strategy Steering Group and the Patient Forum. Full 
consideration was given to the views expressed in the 
public consultation in the development of this National 
Cancer Strategy.
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3.4. International Context for Cancer Control  
In recent years a European Commission Joint Action - 
European Partnership for Action Against Cancer (EPAAC) 
- was established and its remit included providing guidance 
and assistance to Member States in formulating cancer 
strategies and establishing cancer control programmes.  
National Strategies are now in place in almost all Member 
States. In 2014, a new Cancer Control Joint Action 
(Cancon) was initiated, with the aim of reducing the cancer 
burden in the EU, raising cancer survival rates and reducing 
cancer mortality.
An Expert Group on Cancer Control was also established 
by the European Commission in 2014.  This works to assist 
with drawing up legal instruments, policy documents, 
guidelines and recommendations on cancer control at the 
request of the Commission.   It also facilitates the exchange 
of information on experiences, policies and practices.
In addition to participating in the collaborative work 
at European level, Ireland is also a member of the 
International Agency for Research on Cancer (IARC) which 
is the dedicated cancer research agency of the World 
Health Organisation.  IARC coordinates and conducts 
research on the causes of cancer and develops scientific 
strategies for cancer prevention and control.  
The World Health Organisation Policies and Managerial 
Guidelines provide a framework for the development of 
national cancer programmes underpinned by evidence-
based policy.  It has long been recognised internationally 
that a comprehensive approach to cancer programmes at 
national level offers an effective way to bring together the 
dedicated leadership and resources that are necessary to 
develop and implement policies to reduce the burden of 
cancer.  
3.5. A Strategic Approach to Cancer Control in 
Other Jurisdictions
Cancer strategies are being developed and updated 
in various countries on an on-going basis. The specific 
goals of these strategies vary depending on the cancer 
services that are already in place, the efficiency of these 
services, how services are linked with one another and the 
stakeholders involved in monitoring and implementing 
those services. However, the overall aim of these strategies 
is similar: to provide essential cancer services to the 
population, in as integrated and efficient a manner as 
possible. A number of key themes have emerged in cancer 
strategies around Europe in recent years. These include:
• increased focus on prevention and early diagnosis;
• safe, high quality and patient-centred care;
• service delivery;
• addressing inequalities;
• supporting those living with and beyond cancer; 
• measurement of outcomes; and
• innovation and modernisation.
3.5.1 Prevention and early diagnosis
Prevention, both primary and secondary, is identified 
internationally as key to reducing the burden of cancer 
in the population. A population approach, supported by 
policy and legislative measures, is required to encourage 
and support people to live healthier lives, and to reduce 
the prevalence of cancer risk factors such as tobacco and 
alcohol consumption, obesity, lack of physical activity and 
UV radiation exposure.  
The large evidence base that exists to demonstrate that 
exposure to tobacco products leads to an increased risk 
of cancer has ensured that anti-tobacco programmes 
form a key part of cancer control programmes around 
the world. The World Health Organisation’s Framework 
Convention on Tobacco Control seeks to limit the use of 
tobacco worldwide and has been signed by 180 countries. 
In addition to this Framework, individual countries have 
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enacted their own policies for tobacco control, for 
example the introduction of bans on workplace smoking 
in Ireland, the UK and Denmark, the ban on the point of 
sale display of tobacco products in Ireland and the UK and 
the ban on smoking in cars where children are present in 
Ireland. The enactment of legislation which requires plain 
packaging to be used for tobacco products is another 
example. In Australia, all tobacco products must be sold in 
plain packaging, and France and the UK have introduced 
standardised or plain packaging legislation. Standardised 
packaging of tobacco products is scheduled to commence 
in Ireland in late 2017.
Prevention measures to address alcohol consumption, 
diet and physical activity levels and occupational and 
environmental risk factors are also commonly in place in 
countries with national cancer control plans. For example, 
Sweden has reduced alcohol consumption through the use 
of policies regulating where alcohol can be sold and how it 
is taxed. Scotland’s Supporting Healthy Choices Voluntary 
Framework supports consumers to make healthier choices 
and reduce their sugar intake. The ASA registry in Finland 
requires companies to report on what carcinogens they 
use and which workers are exposed to them. Since its 
establishment, there has been a significant reduction in the 
number of employees exposed to carcinogens in the course 
of their work.
In addition, diagnosing cancer at an early stage improves 
survival and leads to less aggressive forms of treatment. 
Evidence-based screening programmes can identify 
precancerous lesions and facilitate the early diagnosis 
of cancer, and are essential to a comprehensive cancer 
strategy.  In 2003, the Council of the European Union 
recommended that member states implement screening 
programmes for colorectal, breast and cervical cancer, and 
this has been adopted in many countries including Ireland. 
Increasing access to, and the capacity of, diagnostic 
services, as well as creating rapid referral pathways, are 
also recognised as crucial to early diagnosis. 
 
 
3.5.2 Patient-centred care
Patient-centred care is widely recognised internationally 
as best practice and a core component of a high quality 
health service. Patients must be provided with the 
appropriate information to make informed decisions. 
Effective communication is highlighted as crucial to ensure 
understanding and to facilitate a partnership approach 
to care between patients and their healthcare providers. 
Patients must know what is happening, and the reason 
why it is happening, at each step of their care. 
National cancer control plans in countries such as Norway, 
England and France have emphasised that patient 
involvement in cancer care is crucial to a high-quality 
cancer service. For example, Norway has committed to 
developing an online resource that makes it easier for 
citizens to interact with the healthcare services, and that 
will in time allow patients to access information about their 
health and to contact healthcare professionals.
3.5.3 Service delivery
It is agreed internationally that patients should have 
timely access to safe, high quality care that incorporates 
evidence-based best practice and sustainable models of 
care. Patients should have equitable access to the most 
advanced treatments available in their jurisdiction, based 
on individual clinical need. In the era of personalised 
medicine, a programme to ensure that new cancer 
treatments are evaluated in a standardised manner is 
vital to ensure that the introduction of new treatments is 
equitable and sustainable.
In this regard, the Norwegian Directorate of Health, in 
collaboration with the hospitals, the Norwegian Knowledge 
Centre for the Health Services and the Norwegian 
Medicines Agency, is in the process of developing a new 
national system for the evaluation of the methods used 
within the health service. This system will cover medicines, 
medical equipment, procedures and diagnostic methods, 
and will be used in prevention, assessment, diagnosis, 
treatment, follow-up and rehabilitation. 
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Similarly, Achieving World Class Cancer Outcomes: A Strategy for England 
2015-2020 recommends that NHS England and Public Health England should 
work with Monitor (the sector regulator for health services in England) and 
other bodies to consider how to develop better health economic evaluation of 
new service models and interventions. 
3.5.4 Addressing inequalities
Inequalities in cancer care are recognised internationally and it is clear that 
cancer risk factor prevalence is disproportionately distributed in society.  
Variation in screening uptake rates and in access to diagnostics and treatment 
are widespread.  Identifying ways to address these inequalities is an essential 
part of a national cancer strategy. 
The Detect Cancer Early programme in Scotland aims to reduce differences in 
cancer survival rates between the most affluent and least affluent areas. Since 
its introduction, this programme has seen a 14% increase in stage I diagnoses 
in the most deprived areas of Scotland. Also, an objective of the Norwegian 
strategy Together – Against Cancer is to ensure that cancer prevention is 
undertaken in a way that counteracts inequalities in health.
3.5.5 Support for those living with and beyond cancer
More people are surviving with, and living beyond, cancer. Recognition of the 
on-going health and wellbeing needs of survivors, as well as the consequences 
of their treatment, is important. The development of individualised ‘care plans’ 
is put forward in many jurisdictions as an enabler to addressing  the physical, 
psychological and social needs of patients beyond the treatment phase. The 
provision of appropriate end-of-life care is also seen as an essential part of a 
modern cancer strategy.
England’s cancer strategy recommends the development of a national metric 
on quality of life by 2017, which would enable better evaluation of long-term 
quality of life after treatment. Scotland’s Beating Cancer: Ambition and Action 
aims to identify how best to ensure that all patients are given a Treatment 
Summary so that they are informed about the care they received and can use 
that information in interactions with other clinicians and health and social care 
professionals in the future. 
FOUR  
CANCER TYPES 
MAKE UP 
½ OF ALL 
CANCERS
5 YEAR 
SURVIVAL 
RATES HAVE 
IMPROVED 
FROM 45% TO 
61% IN THE 
PAST DECADE 
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3.5.6 Measurement of outcomes
Measurement of outcomes is a vital part of the 
implementation of a cancer strategy. It is important that 
outcome targets are put in place from the beginning and 
that performance is measured against these. Review of 
performance against targets is an on-going process, and 
targets themselves may need to be changed over time.
An example is the New South Wales Cancer Plan 
Performance Index, against which progress in meeting their 
objectives is measured. Also, the Cancer Quality Council 
of Ontario has developed indicators to track progress on 
outcomes in cancer care on a range of areas, including 
prevention, screening, diagnosis, treatment, recovery and 
end of life care.
3.5.7 Innovation and modernisation 
It is recognised internationally that considerable resources are 
required to fund a comprehensive cancer service. The provision 
of modern equipment, more personalised medicine and access 
to the latest technologies and treatments comes at a high initial 
cost. In addition, the provision of the appropriate skill mix of 
staff, not only in the direct cancer treatment services, but across 
primary care and in areas such as radiology and pathology 
requires additional investment. Training and retention of 
sufficient numbers of staff to address current workforce deficits 
is most important. However, this is very challenging in the 
context of the international market for such trained personnel. 
Cancer care is evolving rapidly and it is vital to ensure that 
research is a strong component of cancer services.  The aim 
is to devise clear programmes of research within available 
resources, targeted at priority areas and leading to improvements 
in outcomes and the patient experience. The importance 
of encouraging patient involvement in clinical trials has 
been emphasised in cancer control plans from a number of 
jurisdictions, such as France, England and Slovenia.
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3.6. Priorities for the Next Ten Years
A number of high level conclusions can be drawn from this 
analysis which allow clear priorities to be established for 
the third National Cancer Strategy. Overall, the progress 
seen to date justifies the continuation of the current 
overall approach to cancer control. This involves a whole of 
population approach that deals with all aspects of cancer 
in a planned way. It emphasises the need for high quality 
cancer care that is equitably available to all cancer patients. 
It also involves continuous monitoring, with a view to 
improving the quality of cancer care.
The projected growth in incidence and prevalence of cancer 
illustrates the need for a range of cancer control actions 
to prevent and treat cancer in an effective manner and 
to support those living beyond cancer. While prevention 
strategies can have a significant impact on cancer 
incidence, it will take some time before this impact is seen. 
Already most cancer services in Ireland are at full capacity. 
Further actions, such as improving earlier detection, 
providing more effective treatments, and transforming how 
we provide services to those with a cancer diagnosis across 
the patient pathway, are required in order to reduce the 
burden of cancer.  
Significant reorganisation of cancer services in particular 
in relation to diagnosis, treatment planning and initial 
treatment has taken place since the 2006 Cancer Strategy. 
This is evident in the case of breast cancer and rare cancers. 
However, progress remains to be made on a number of 
common malignancies. 
There is growing appreciation nationally and internationally 
of the positive role that can be played through the 
involvement of informed and empowered patients and 
citizens in cancer care. This should involve meaningful roles 
in the development, oversight and operational planning 
of cancer services. Patients with cancer are in a unique 
position to inform, to personalise and to improve the co-
ordination of their own care.
There have been many significant scientific, technological 
and therapeutic advances in cancer diagnosis and treatment 
in recent years. In particular, diagnostics and treatments 
that exploit a better understanding of the molecular basis of 
cancer biology offer great hope for the future. It is essential 
that this Strategy provides a clear and structured mechanism 
to evaluate the evidence in respect of the efficacy and 
effectiveness of each of these developments and to ensure 
their incorporation into well organised patient centred care 
pathways that are fully audited and evaluated. Existing 
services, particularly diagnostic services, are challenged by 
limits on access. 
The NCCP must play a strong role in ensuring the 
incorporation of evidence based care pathways into the 
delivery of the services offered to patients with cancer in a 
manner which ensures that issues of access are appropriately 
addressed. The end goal must be that access to, and 
experience of, cancer diagnosis and treatment is related only 
to the clinical need of patients who must use these services. 
This will require that future provision for molecular diagnostic 
services, histopathology, radiological services, endoscopic 
services and other diagnostics are strategically planned so 
that they can achieve these goals within the resources that 
are and will be made available for cancer.
A particular existing challenge in respect of cancer and other 
services is ensuring that they are delivered equitably and that 
patients achieve equity in outcomes irrespective of age, sex, 
geographic location and social class. It follows that significant 
enhancement of our information capacity is required to 
enable transparent public reporting of process and outcome 
indicators in a way that allows us to assess the degree to 
which equity is being achieved across our cancer services. 
Significant work has been done in recent years to strengthen 
our procedures for the incorporation of evidence based 
diagnostics and treatments into routine clinical practice 
through the National Clinical Effectiveness Committee 
(NCEC) and nationally mandated Clinical Guidelines. Further 
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developments in this regard will be required in respect of 
cancer care to ensure that the goals of equal access and 
equal outcome for clinical need can be met. Additionally, 
the policies and procedures in respect of prioritisation of 
new drugs and new technologies must continue to be 
strengthened and made more transparent and explicit 
to ensure access is determined by clinical need and that 
maximum value in terms of cancer outcomes can be 
achieved for a given level of investment.
Much progress has been made in establishing links with 
health authorities in Northern Ireland to improve cancer 
services for people on the island of Ireland. Opportunities 
for cross-border co-operation in relation to cancer services 
will continue to be pursued with a view to achieving mutual 
benefit. Similarly, international co-operation in relation to 
the various aspects of cancer prevention, care, research and 
survivorship will also be promoted and strengthened.
Healthy Ireland - A Framework for Improved Health 
and Wellbeing 2013-2025 provides for a co-ordinated 
cross-government means of tackling social determinants 
of health and major lifestyle risks for cancer. There is 
encouraging evidence of progress in respect of many of 
the common lifestyle related risk factors, in particular in 
relation to tobacco consumption. It is clear however, that 
further progress is needed through effective, strategic 
and operational alignment between the National Cancer 
Control Programme and the goals of Healthy Ireland.
The NCCP has existed since 2007. It is reasonable that this 
Strategy give consideration to how best to strengthen the 
authority of the NCCP, which seeks to achieve a common 
standard of prevention, diagnosis, treatment and outcome 
in respect of cancer care across the country, when there 
is clear evidence that progress in respect of centralisation 
of many cancer services has not been universal. Aligning 
investment, new developments, staffing, indemnity 
and performance management and regulation with the 
objectives and requirements of the structure, process and 
outcome of cancer care pathway delivery is essential to 
ensure that the governance and management of cancer 
control services is fully aligned with the requirement to 
reduce the burden of cancer in all its manifestations.
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Challenges 
• The projected increase in 
cancer cases
• The requirement to address 
the needs of  cancer 
survivors
• The need to ensure that 
cancer control measures are 
delivered equitably - and 
achieve equitable outcomes 
• The pressure on 
infrastructure and resources
• The difficulties in attracting 
and retaining qualified 
people to work across our  
cancer services
• To achieve a balance 
between the benefits 
and costs of new drugs/
treatments
• To achieve a continuum 
of care across primary, 
secondary and tertiary 
services 
• To attain a strong focus 
on outcomes through the 
integrated model of care 
Lessons 
• Integrated approach to cancer 
control 
• Cancer prevention as a key area 
of focus
• Importance of improving early 
detection and diagnosis
• Centralisation of care provides for 
optimal treatment
• Survivorship care and psycho-
social support needs to be 
developed 
• Importance of patient input
• Need for on-going evaluation 
• Value of learning from 
international developments
• Importance of strong governance 
and management
What has worked well in 
cancer control in Ireland
• Clear, evidence-based  
policy direction
• Strong leadership and oversight
• Programmatic approach 
to cancer control and 
establishment of the NCCP
• Designation of eight cancer 
centres
• Screening programmes
• Rapid Access Clinics
• Multidisciplinary team working
• Treatment standards and 
protocols 
• Strong community support for 
cancer care
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VISION 
CHAPTER 4
4.1. Introduction
Progress seen to date justifies maintenance of the approach 
of cancer control: that is a whole population, broad 
approach that deals with all aspects of cancer in a planned 
way stressing the measurement of need and ensuring 
that high quality cancer care is consistently available to all 
cancer patients.
Ireland is currently placed around mid-table (See Table 2.5, 
Chapter 2) in the survival by country statistics for common 
cancers across Europe. Survival rates are an important 
measure of performance. We must now aim to make 
further strides in cancer control such that survival rates can 
reach the top quartile of European countries by the end of 
the Strategy period. Fulfilling this aim will be particularly 
challenging given the expected continued improvements 
in other countries. This aim is reflected in the table of Key 
Performance Indicators in Chapter 17. 
Our vision is one in which all aspects of cancer control, 
from the promotion of healthy living, more specific 
prevention measures, optimum treatment and quality of life 
measures across the patient cancer journey and beyond, 
are addressed, backed up by solid governance, workforce 
planning and research.  
VI
SI
ON
Together we 
will strive 
to prevent 
cancer and 
work to 
improve the 
treatment, 
health and 
wellbeing, 
experiences 
and outcomes 
of those 
living with 
and beyond 
cancer. 
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The following goals and their associated objectives have been identified as being critical to the achievement of the vision:
Goals and Objectives
1Reduce Cancer BurdenEnsure prevention 
programmes are 
prioritised to reduce 
cancer incidence 
Improve symptom 
awareness in the 
population 
Increase early diagnosis
Focus on social 
inequalities
2 3Maximise Patient Involvement and Quality of LifeStrengthen the role 
of patients in the 
planning and delivery 
of cancer care, 
including through 
the establishment of 
structures for patient 
involvement
Develop and 
implement survivorship 
care programmes
Provide Optimal 
Care
Ensure effective and 
equitable treatment 
throughout the care 
pathway to improve 
outcomes for all 
patients
Further develop 
treatment facilities and 
infrastructure 
Maintain a strong focus 
on patient safety and 
quality assurance
Ensure that 
appropriate palliative 
care supports are in 
place
4Enable and Assure ChangeStrengthen the 
role of the NCCP 
in the oversight of 
cancer control and 
in implementing the 
recommendations of 
the Strategy.
Ensure ongoing 
workforce planning to 
fulfill changing needs
Utilise technology, 
research and data to 
create a sustainable, 
high quality and 
accountable cancer 
service 
Build better systems 
and processes to 
ensure evidence-based 
prioritisation and 
service delivery.
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4.2. Goal: Reduce the Cancer Burden
The population over 65 years of age is estimated to more than double, from 0.536m to 1.146m in the 25 years from 
2011 to 2036.  Given the relationship between ageing and cancer incidence, this will lead to a significant increase in the 
number of new cancer cases.
It is projected that the number of cancer cases (excluding non-melanoma skin cancer) will increase by 50% in men and by 
39% in women in the 15 years from 2010 to 2025.  This can be expected to accelerate beyond that time period.
These projections confirm the challenge we face in dealing with cancer over the coming years.  This Strategy will highlight 
three key areas of focus that will impact positively on cancer incidence rates and stage at diagnosis in the future: 
• the implementation of prevention programmes to reduce the incidence of cancer; 
• an increase in symptom awareness and health care seeking behaviour in the population; and 
• an increase in the number of cancers diagnosed at an early stage.
It is estimated that 30% to 40% of cancer incidence is attributable to modifiable risk factors. Supporting Irish people to 
stop smoking, lose weight, eat healthily, take more exercise, moderate their alcohol intake and reduce their exposure to 
the sun will have a major impact on future rates of cancer incidence. Encouraging those who are eligible to participate in 
screening programmes will contribute to early diagnosis. Creating awareness around warning signs suggestive of cancer 
will also help to ensure that more cancers are diagnosed at an early stage. A significant effort is required to ensure that 
prevention and awareness campaigns have a particular focus on addressing health inequalities. Targeted efforts will also 
be made by the National Screening Service (NSS) to achieve as high an uptake rate as possible for cancer screening by 
those affected by social inequalities.
4.3. Goal: Provide Optimal Care
The concept of a continuum of care will underpin the approach to patient services, from prevention, early diagnosis, and 
evidence-based high quality patient-centred treatment, to appropriate follow-up and support. Achieving a true continuum 
of care will require improved integration between primary, secondary and tertiary services. This will allow patients to easily 
move between community and hospital settings in line with their care needs. 
Significant progress has been made already in the provision of cancer treatment, much of it taking place in acute hospitals 
under the direction of specialist clinicians and multidisciplinary teams (MDTs).  This Strategy builds on that progress by 
supporting the key role of designated centres in cancer treatment. There is also a need for clear care pathways for the 
diagnosis and treatment of patients who have rare cancers, with particular emphasis on timely treatment planning at 
national MDT level, involving subspecialty expertise in diagnosis and treatment and with linkages to international centres 
of excellence for specialist advice and intervention. Appropriate palliative care supports will also be provided, both for 
management of symptoms and end of life care.
The designated cancer centres will be further developed to ensure that they play an optimal role in diagnosis, treatment 
planning and delivery, education and research. An aim of this Strategy will be that investment in cancer centres will have 
the goal of ultimately establishing at least one comprehensive cancer centre.
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Safety is fundamental to high quality health care and cancer services must be supported to deliver safe care, 
while balancing competing pressures and demands. Active leadership, governance and clinical commitment to 
quality will be shown at all levels of cancer care to assure patient safety. 
 
4.4. Goal: Maximise Patient Involvement and the Quality of Life of Those Living With 
and Beyond Cancer
Many people are now living significantly beyond cancer diagnosis and treatment and this trend will continue.  
In many cases the aim of cancer care for patients will be to return to work, or to play a full part in life in 
whatever way is appropriate to the person.  
This Strategy will aim to create an environment that empowers patients to become active participants in 
their own healthcare and supports them in making decisions about their treatment. Programmes will be put 
in place to ensure that patients are supported to return to their normal life as much as is possible following 
treatment. Individual patients will have different requirements for survivorship care and this will be taken into 
consideration in the development of survivorship programmes.
Structures will be put in place to facilitate patient involvement in policy development and planning of cancer 
services. This will ensure that the patient voice is represented at all stages of the cancer continuum, during and 
after their treatment, as well as in service planning.
4.5. Goal: Enable and Assure Change
Change is required across our cancer services to give effect to the Strategy vision.  This will include increases in 
workforce numbers, as well as changes in workforce composition and deployment, with the aim of providing 
safe, high quality and patient-centred care.
The NCCP has an integral role to play in the implementation of the recommendations of this Strategy. It will 
continue to provide leadership and direction to the cancer system to ensure that service priorities are aligned 
with desired outcomes. 
The positive impact of research activity, including clinical trials, on the care of patients is evident.  An aim will 
be to develop a culture in the cancer care system that values research and is supportive of those who actively 
engage in it.
There will be a strong focus on meeting performance, quality and outcome targets across the implementation 
of the Strategy.
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REDUCING  
THE CANCER  
BURDEN
SECTION B
5 PREVENTION 
6 SCREENING
7 EARLY DIAGNOSIS 
• Ensure prevention programmes are prioritised to reduce cancer incidence 
• Improve symptom awareness in the population 
• Increase early diagnosis
• Focus on social inequalities
OBJECTIVES
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PREVENTION  
CHAPTER 5
5.1. Introduction
Cancer prevention must be a cornerstone of the cancer 
strategy as it offers the most cost-effective, long-
term approach for cancer control19. The proportion of 
cancer incidence attributable to modifiable lifestyle and 
environmental factors is estimated to be in the 30% to 
40% range.   
Modifiable lifestyle or environmental risks exist for many 
cancers. Of these, smoking is by far the most important.  
Others include excess body weight, poor diet, physical 
inactivity, alcohol consumption, specific infections, radiation 
(ultraviolet and ionizing, including radon) and occupational 
hazards. Prevention measures will be undertaken as part 
of, or in tandem with, the overall health and wellbeing 
initiatives under the Healthy Ireland programme.
It is vital that we are effective in getting the message 
across to the population that each person can impact 
significantly on their own level of risk of developing cancer. 
The fact that there is a considerable time lag in prevention 
interventions feeding through to incidence figures increases 
the challenge.  However, the evidence that past changes in 
behaviour in regard to smoking under previous strategies 
has led to current better health for individuals is something 
that we can build on to drive further behavioural change.    
Reducing health inequalities is a priority of this Strategy. 
Lifestyle risk factors generally follow social deprivation, 
gender and age patterns. Smoking is a key contributor to 
socio-demographic inequalities.  Health inequalities are 
also associated with poor symptom awareness, delayed 
presentation and low uptake of services, including 
screening. Where appropriate, a robust prevention 
programme will first focus its efforts on the most deprived 
populations.
5.2. Evolving Prevention Initiatives in Ireland 
Effective health promotion and disease prevention initiatives 
result in less chronic disease and in a reduction in some 
healthcare costs.  The Government has already initiated 
policy to improve our nation’s health through Healthy 
Ireland - A Framework for Improved Health and 
Wellbeing 2013-2025, which sets the overarching context 
in which a focus on cancer prevention will be driven as a 
cornerstone of this Strategy.  Healthy Ireland takes a whole-
of-Government and whole-of-society approach to improving 
health and wellbeing, with a focus on prevention, reducing 
health inequalities and keeping people healthier for longer. 
The goals of Healthy Ireland are to increase the proportion 
of people who are healthy at all stages of life, to reduce 
health inequalities, to protect the public from threats to 
health and wellbeing and to create an environment where 
every individual and sector of society can play their part in 
achieving a healthy ireland. 
The initial implementation of Healthy Ireland in the health 
services is focused on strategic priorities which will embed 
health and wellbeing goals into reform objectives. It 
identifies the development of a National Brief Intervention 
Model as a key driver to support and leverage the leadership 
role of healthcare professionals and teams in making every 
contact count. This Model aims to exploit the opportunities 
that arise for providing health advice and intervention across 
the many interactions with patients and the public and 
to strengthen the capacity of healthcare professionals to 
incorporate prevention and support for behaviour change as 
a routine part of healthcare delivery. The NCCP and cancer 
care services have a significant leadership role to play in 
driving this culture of making every contact count to support 
a focus on cancer prevention.
19  World Health Organisation, Cancer Prevention:  http://www.who.int/cancer/prevention/en/
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The NCCP will develop a cancer prevention function to support the implementation of Healthy Ireland and to fulfil an 
important part of its role as a comprehensive cancer control programme.  The NCCP will prioritise the implementation of 
evidence-based interventions to reduce cancer lifestyle risks and to increase public protection from known carcinogens. 
It will also address emerging areas for prevention in high risk groups, e.g. chemoprevention. The NCCP will work with 
the Department of Health, other Directorates of the HSE and voluntary organisations such as the Irish Cancer Society to 
ensure a co-ordinated approach.  Cancer awareness and prevention initiatives will prioritise disadvantaged populations 
and hard to reach groups.  The European Code Against Cancer (2014)20, which focuses on actions that individuals 
can take to prevent cancer, will continue to inform policy formulation and will feed into public awareness campaigns on 
cancer prevention.
Recommendations
The Department of Health will ensure that 
policies under the Healthy Ireland framework 
are implemented in full and that opportunities 
to address cancer prevention measures under 
those policies are maximised. In particular, 
measures aimed at further reducing smoking 
levels will be pursued.
Lead: DoH
The NCCP will develop a cancer prevention 
function, working in conjunction with the 
broader Healthy Ireland initiative, and 
will lead in relation to the development 
and implementation of policies and 
programmes focused on cancer prevention.
Lead: NCCP
1 2
20    World Health Organisation, European Code Against Cancer: http://cancer-code-europe.iarc.fr/
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5.3. Cancer Risk Factors
5.3.1 Smoking 
Smoking is the main cause of preventable mortality in 
Ireland and results in 5,950 deaths, including 2,900 cancer 
deaths each year.  At least 85% of lung cancers are due to 
smoking, and smoking also causes over half of oral cavity, 
pharyngeal, oesophageal and laryngeal cancers.  Tobacco 
Free Ireland, the national tobacco control strategy, has the 
key goal of making Ireland tobacco-free by 2025 (defined 
as a prevalence rate of less than 5% - (KPI no. 1).  Two 
key themes underpinning Tobacco Free Ireland are the 
protection of children and the denormalisation of smoking. 
A modelling analysis of the effect of tobacco control 
policies in Ireland over the period 1998-2010 has suggested 
that these policies were responsible for a 22% relative 
reduction in smoking prevalence by 2010 - equating to 
1,716 fewer deaths due to smoking by 2010 and fifty 
thousand fewer deaths due to smoking by 2040.21
Where health personnel provide smoking cessation 
advice, support and pharmacological treatment, smoking 
cessation success rates among their patients are doubled.  
Implementation of the National Brief Intervention/making 
every contact count model and training, in relation to 
smoking cessation as a core component of undergraduate 
health education programmes, will facilitate prevention and 
support for behaviour change becoming a routine part of 
healthcare practice and delivery.
5.3.2 Obesity
Excess body weight increases the incidence of a variety of 
cancers such as colon and breast cancers. Approximately 
400 new cases of colorectal and breast cancer combined 
each year in Ireland are due to excess body weight.  A 
National Obesity Policy & Action Plan22 was published 
in September 2016 and takes a cross-sectoral approach to 
tackling the multitude of determinants which impact on 
levels of overweight and obesity in the population. 
5.3.3 Diet and physical activity
Healthy eating and physical activity confer multiple health 
benefits and can significantly reduce the risk of a range 
of diseases, including cancer. High consumption of fruit 
and vegetables reduces the risk of several cancers such as 
those of the colon, oesophagus and stomach and more 
than one in ten bowel cancers are linked to a low fibre diet. 
Physical inactivity is increasingly recognised as a leading risk 
factor for poor health and is associated with higher risk of 
colon and breast cancers. The National Obesity Policy 
& Action Plan and the National Physical Activity Plan 
detail a range of actions to promote and support healthier 
food choices among the population. 
5.3.4 Alcohol
Each year, 900 newly diagnosed cancers in Ireland are 
caused by alcohol. Over half of cancers in the upper aero-
digestive tract are caused by alcohol, and when combined 
with smoking, the risk of developing these cancers 
increases. The public health approach to addressing alcohol 
misuse, including the Public Health (Alcohol) legislation, 
aims to reduce overall consumption as well as patterns of 
harmful use.
21    L.M. Currie, K. Blackman, L. Clancy et al, ‘The Effect of Tobacco Control Policies on Smoking Prevalence and Smoking-attributable Deaths in Ireland  
        Using the Ireland SS Simulation Model’, Tobacco Control 22 (2013) 
22   Healthy Ireland,  A Health Weight for Ireland: Obesity Policy and Action Plan (2016); http://health.gov.ie/wp-content/uploads/2016/09/A-Healthy- 
       Weight-for-Ireland-Obesity-Policy-and-Action-Plan-2016-2025.pdf
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This is made up of 19% who are daily smokers and 4% who are 
occasional smokers. This compares with an average of 24% of  
the EU-28 population who were smokers in 2014, 19% of whom 
were daily smokers and 5% of whom were occasional smokers. 
(European Health Interview Survey).
of the Irish population aged 
15 and over are smokers 
compared with 29% in 2007.
23% 
Smoking prevalence 
is higher among those 
living in most deprived areas
Recruitment of new smokers continues with 20% of 
15-24 year olds currently smoking. This compares to 
an average of 24% among the EU-28 countries in 2014.  
(European Health Interview Survey)
Smokers want to quit 
with 48% having made 
an attempt to quit 
during the last year.
of the population are exposed to second 
hand smoke on a daily basis. This compares  
to a 22% average among EU-28 countries in 
2014. (European Health Interview Survey)
18% 
SMOKING DIET & NUTRITION
WEIGHT
PHYSICAL ACTIVITY SEXUAL HEALTH
ALCOHOL
of the population drinks alcohol and 
55% of these do so at least once a 
week. This compares with an average 
of 29% of the EU-28 population who 
drank alcohol at least once a week.  
(European Health Interview Survey)
75% 
of drinkers binge drink on a 
typical drinking occasion – 
54% of those aged under 25.
37% 
and vegetables a day. This 
compares with an EU-28 
average of 14% in 2014. 
(European Health Interview Survey)
27% 
60% eat snack foods every day with  
42% eating six or more portions daily.
drink sugar sweetened drinks 
daily, rising to 22% of those 
aged 15-24.
14% 
37% normal 
37% overweight 
23% obese.
Men are more likely to be 
overweight than women  
(43% compared to 31%);  
the proportion of men and 
women who are obese is  
closely aligned  
(men: 25%; women: 22%).(Data from 2015 Healthy Ireland Survey)
43% 31%
of the population 
reports being 
highly active.
32% 54% of men who  
most recently had  
sex with men did  
not use a condom.  
(2015 Data)
35% 
The Healthy Ireland Survey (2016) of almost 7,500 people aged 15 and older provides robust data on cancer risk 
factors to inform prevention priorities.  The main findings relevant to cancer lifestyle risk factors are:
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5.3.5 Sexual health
A number of sexually transmitted infections (STIs) can 
lead to an increased risk of developing cancer. People 
living with Human Immunodeficiency Virus (HIV) have an 
increased risk of Kaposi sarcoma, lymphoma, and a number 
of other cancers, while people chronically infected with 
the Hepatitis B virus are at an increased risk of developing 
liver cancer. Infections with high-risk types of Human 
Papilloma Virus (HPV) cause nearly all cervical cancers, 
as well as  most anal cancers and many oropharyngeal, 
vaginal, vulval, and penile cancers.  The first National 
Sexual Health Strategy23, which was published in 2015, 
takes a nationally coordinated approach to address sexual 
health and wellbeing and to reduce negative sexual health 
outcomes.
Since 2010 first year post-primary girls are offered HPV 
vaccination as part of the national vaccination programme 
to prevent cervical cancer. In at-risk populations, this 
vaccine can reduce the risk of HPV associated malignancies, 
which include most cervical cancers as well as some 
vaginal, vulval, oropharyngeal, anal and rectal cancers. It 
is absolutely vital that there is a high uptake rate of this 
vaccine to ensure herd immunity. 
The vaccine is also available for men, between the ages 
of 16 and 26, who have sex with men, as this cohort 
does not benefit from the herd immunity provided by 
vaccinating girls. The international evidence and policy 
considerations in relation to HPV vaccination for adolescent 
males will continue to be monitored. The health technology 
assessment examining the extension of the HPV vaccination 
programme to adolescent males will be completed as a 
priority.
5.3.6 Ultraviolet radiation 
Non-melanoma skin cancer (NMSC) is the most common 
cancer diagnosed in Ireland.  Ultraviolet radiation (UVR), 
whether natural or artificial, causes over 95% of skin 
cancers (both NMSC and melanoma).  More than 75% 
of the Irish population has a Celtic type complexion 
(Fitzpatrick Skin Type 1 and 2) which greatly increases skin 
cancer risk.  Melanoma incidence is increasing by 5% per 
year in men, and 3% per year in women.  
Recommendation
The Department of Health will develop a national skin cancer prevention plan and oversee its 
implementation as a priority. The plan will prioritise children, outdoor workers, sunbed users and 
those who pursue outdoor leisure activities.
Lead: DoH
3
23  Department of Health, National Sexual Health Strategy 2015-2020 (2015).
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5.3.7 Radon
Radon, a radioactive gas, is naturally produced in the 
ground from uranium present in small quantities in rocks 
and soil.  It presents a significant radiation health risk. The 
National Radon Control Strategy (2014)24 points the way to 
address this significant cancer risk. 
5.3.8 Occupational hazards
Most occupations do not pose a cancer risk.  The ban on 
workplace smoking greatly reduced exposure to second 
hand smoke.  In Ireland, the most common occupational 
hazard is ultraviolet radiation to outdoor workers. 
Occupational related cancers are preventable and strong 
workplace regulation, worker education and surveillance 
are needed. 
5.3.9 Additional cancer risks specific to women
Hormone replacement therapy (HRT) increases the risk of 
breast and ovarian cancer and uterine cancer risk is linked 
to oestrogen-only HRT.  For every 1,000 women taking 
HRT at age 50 for a period of five years, two extra cases 
of breast cancer will arise and one extra case of ovarian 
cancer.  For women who are contemplating starting HRT or 
for those already using it, a discussion with their doctor on 
risks versus benefits is essential. 
Breast feeding, especially cumulative breastfeeding for 
over one year, has a protective effect on breast and ovarian 
cancer risk.  Despite the evidence of the importance of 
breastfeeding for a wide range of health benefits for both 
mothers and babies, rates in Ireland remain among the 
lowest in the OECD. Creating a Better Future Together: 
National Maternity Strategy 2016-2025 emphasises 
that particular focus is required to improve support for 
breastfeeding in the health services, as well as highlighting 
that a broader societal change is required in order to 
promote a more positive culture around breastfeeding.  
5.3.10 Secondary and tertiary cancer prevention
Additional cancer risks exist for those who have been 
treated for cancer previously. Therefore, it is important that 
cancer prevention initiatives target cancer patients and 
ensure that they are fully informed of warning signs. These 
initiatives should also inform patients with regard to the 
actions they should take if they have concerns about their 
health.
 
5.4. Chemoprevention and Other Prevention-
focused Medications 
Chemoprevention for higher risk groups involves the use 
of medication to prevent the development of cancer in 
well people.  While some research has involved the general 
population, chemoprevention has primarily focused on 
those known to be at increased risk of cancer, e.g. due to 
a strong family history, lifestyle risks or the diagnosis of a 
premalignant, or predisposing, condition.
Opportunities for chemoprevention have been identified 
from epidemiological and molecular research and these 
have led to the testing of a range of agents in randomised 
controlled trials.  Even where agents show promising risk-
reduction in clinical trials, challenges remain in ensuring 
clinical application.  These include the careful consideration 
of the risks versus benefits in a well population, and how 
best to define the population who would benefit. 
The challenge for all such medications is the identification 
of those populations at risk of the relevant cancer and the 
balance between benefit and adverse effects. The NCCP 
prevention programme should evolve over the next decade 
to evaluate and ultimately implement chemoprevention 
strategies with the relevant professional bodies (e.g. the 
ICGP) as the available data support such interventions.
24   Department of Environment, Community and Local Government, National Radon Control Strategy (2014)
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5.5. Future Prevention Initiatives
While major strides have been made in promoting 
cancer-preventing behaviours in recent years, there is still 
much to be done. As more evidence emerges regarding 
the development of cancer, and the environmental and 
lifestyle risks that can contribute to cancer, there will be a 
need to identify the most effective prevention methods. 
This will need to be done in a timely manner to ensure 
that as many cancers are prevented as possible.
In order to facilitate this, the NCCP will develop a 
systematic, evidence-based mechanism to ascertain the 
potential benefits and the cost-effectiveness of various 
initiatives which will inform future cancer prevention 
programmes.
Recommendation
The NCCP will develop a 
systematic, evidence-based 
mechanism to ascertain the 
potential benefits and the cost-
effectiveness of various initiatives 
(including chemoprevention) 
which will inform future cancer 
prevention programmes.
Lead: NCCP
4
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SCREENING  
CHAPTER 6
6.1. Introduction
The primary aim of cancer screening programmes is to 
detect early cancerous (or pre-cancerous) cells, with the 
aim of reducing cancer mortality in an asymptomatic 
population.  Evidence based cancer screening programmes 
are an important element of cancer control in Ireland.  
Specific cancer screening programmes have been 
recommended by international bodies such as the World 
Health Organisation (WHO) and the European Union (EU), 
based on evidence in regard to the reduction in cancer 
deaths.  EU Health Ministers unanimously adopted a 
recommendation on cancer screening in 2003. Organised, 
population-based screening programmes have been 
demonstrated to show reductions in morbidity and 
mortality related to cancer. 
Standards and quality assurance systems are essential 
to ensure that screening programmes provide safe 
and effective services that are in line with international 
guidelines. Such quality assurance and programme 
monitoring are key components of the three cancer 
screening programmes in Ireland and thus ensure that 
screening services are provided to the highest standard. 
6.2. Breast Cancer Screening
Until recently, BreastCheck, the national breast cancer 
screening programme, has offered breast cancer screening 
with biennial mammography to women aged 50-64 years.  
The screening programme was extended to women aged 
65-69 years in 2015. Implementation of this extension 
for the approximately 100,000 women in this cohort 
has commenced on an incremental basis and it will be 
completed by the end of 2021.  The decision to extend the 
target screening population was based on evidence from 
EU and international guidelines for population-based breast 
cancer screening.
To date the programme has provided over 1.37m 
mammograms to over 480,000 women and in excess 
of 8,500 cancers have been detected.  The most recent 
BreastCheck report, published in January 2016, reports a 
cancer detection rate of 6.5 per 1,000 women screened 
(KPI no. 8). 
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6.3. Cervical Cancer Screening
CervicalCheck, the National Cervical Screening Programme, 
offers cervical cancer screening, using a cervical smear test, 
to women aged 25-60 years - an eligible population of 
1.1m women. Overall coverage in the five year period to 
mid-2015 was 78.7%, approaching the 80% target set by 
the screening programme (KPI no. 9).  
The introduction of HPV testing, initially for women post 
treatment (2012) and more recently for women with 
low grade abnormalities (2014), means that a significant 
proportion of women attending colposcopy now have a 
combined smear and HPV test.  The addition of a HPV test 
(on the same sample) for this group of women allows a 
longer interval between smear tests, as well as progressively 
allowing  more women to be discharged to primary care for 
routine screening (rather than having annual surveillance 
screening following treatment).
CervicalCheck has introduced HPV triage, which involves 
HPV reflex testing of low grade cytological abnormalities 
identified in primary care screening. HPV testing is being 
considered as the primary screening mechanism for cervical 
cancer. The Health Information and Quality Authority 
(HIQA) has undertaken a HTA to independently evaluate 
the clinical, financial, ethical and organisational implications 
of establishing HPV testing as the primary screening test for 
cervical cancer. 
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6.4. Colorectal Cancer Screening
BowelScreen, the National Bowel Screening Programme, was 
introduced in 2012 with a phased implementation plan targeting 
men and women aged 60-69 years.  The total eligible population is 
approximately 0.5m, and the first round of screening was completed 
at the end of 2015 (KPI no. 10).  BowelScreen is one of the first 
national screening programmes to utilise the faecal immunochemical 
test (FIT) as the primary screening test.  From 2016, BowelScreen has 
moved to a two year round of screening, rather than the initial three 
year round.  Efforts will continue to increase uptake rates, including 
addressing the lower uptake rate among men when compared to 
women. Evidence supports the extension of bowel cancer screening 
to the full population aged between 55 and 74 years. 
As the number of patients requiring colonoscopies arising from the 
BowelScreen programme looks set to grow, a significant development 
of endoscopy services will be required. An Endoscopy Working 
Group has been set up in the HSE to address these issues, and the 
recommendations of this Group will inform the future development 
of these services.
6.5. Future Developments in Cancer  Screening
With rapid discoveries and developments in the world of genomics, 
and specifically cancer genetics, it is likely that more personalised 
and tailored cancer screening approaches will evolve over the 
period of the Strategy.  Areas of particular interest include the 
cancer control and surveillance services for those with an inherited 
familial predisposition to breast, ovarian and colorectal cancer. The 
development of such a programme will be prioritised. The aim should 
be to provide equitable access to surveillance for all patients on a 
national basis.
While no further population screening programmes are currently 
recommended, it is imperative that all cancer screening services 
continue to carry out an active research programme to inform 
improvements in approach, methodology and testing technology. 
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Recommendations
The HSE will ensure that 
the appropriate endoscopy 
capacity is provided in hospitals 
to allow for the expansion of 
BowelScreen to all aged 55-74 
by end-2021.
Lead: HSE
5
The NCCP will draw up a 
plan by end-2017 for the 
development of an integrated 
cancer control and surveillance 
service for defined population 
subgroups with an inherited 
familial predisposition to 
cancer (e.g. breast, ovarian and 
colorectal).
Lead: NCCP
6
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EARLY DIAGNOSIS   
CHAPTER 7
7.1. Introduction
Determinants of cancer survival are complex and multi-
factorial.  They include tumour biology, patient factors 
(such as smoking) and the availability of high quality 
screening, diagnostic and treatment services. Diagnosing 
cancer at its earliest possible stage is a critical first step to 
achieving higher survival rates, reducing treatment severity 
and improving the quality of life of patients. Ireland’s 
cancer outcomes are steadily improving.  Between 1994 
and 2012 the overall five year age-standardised cancer 
survival rate increased from 44.5% to 61% (See Figure 2.8, 
Chapter 2).
However, despite these significant improvements, a survival 
gap continues to exist between Ireland and the best 
performing European countries (See Figure 7.1, below).  
Further improvements in overall survival rates will require 
an emphasis on increasing the proportion of patients 
diagnosed at an earlier stage of their disease.
 
Figure 7.1  Age and case-mix standardised one year and five year relative cancer survival in Europe (2000-2007)25
25  P. Baili et al. Age and case-mix standardised survival for all cancer patients in Europe 1999-2007: Results Eurocare-5. A population-based 
      study. Eur J Cancer (2015).
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7.2. Earlier Diagnosis Improves Survival 
Enhancing early diagnosis will alter the landscape of 
cancer in Ireland by reducing mortality and improving 
survival and quality of life.  Patients who can recognise 
clinical features suspicious of cancer, and who seek early 
medical intervention, are generally more likely to have less 
advanced disease and better prospects for treatment.
When cancers are diagnosed at stages I and II, longer term 
survival is considerably better than for those patients  
diagnosed with stage III and IV disease (Figure 7.2). For 
example, when malignant melanoma is diagnosed at 
stage I and II over 90% of patients are alive ten years later, 
compared with 48% diagnosed at stage III and IV. When 
lung cancer is diagnosed at stages I or II, two-thirds of 
patients survive at least a year compared with one-quarter 
diagnosed with stage III or IV disease.  A similar pattern 
exists for other cancers, as outlined in Figure 7.2 below 
(KPI no. 4).  
Figure 7.2 Net ten year survival rate by stage at diagnosis in Ireland (2008-2012)
 
7.2.1 Deprivation, late diagnosis  and poorer outcomes
While the relationship between deprivation and cancer is multi-faceted, certain cancers are more likely to be diagnosed in 
deprived groups.  Much of this inequality relates to higher smoking rates in deprived populations resulting in an increase 
in incidence of smoking related cancers.  In addition it has been demonstrated that people living in geographic areas with 
higher levels of deprivation are more likely to have higher cancer mortality rates once they are diagnosed.    In their efforts 
to raise awareness and manage cancer service performance, the NCCP need to focus, in particular, on deprived areas, 
hard to reach groups and minority populations where cancer outcomes are currently poorest. 
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7.3. Making Earlier Diagnosis a Reality 
Early diagnosis is influenced by many factors. Public and 
health professional awareness of the importance of early 
presentation is critical, and is complemented by efficient GP 
referral guidelines, clear pathways to specialist care and timely 
access to diagnostic services.
7.3.1 Improving public awareness – the ‘unusual or 
persistent’ symptom
Raising public awareness of the ‘unusual or persistent’ 
symptom, such as unexplained lumps, bleeding, change in 
body function, skin lesions, pain or weight loss is a critical 
first step in early diagnosis.  Health professionals have 
an important role in improving public awareness and in 
encouraging prompt medical attention.  However, many 
patients do not recognise warning signs. Those who do 
recognise worrisome clinical features may still delay seeking 
medical help for a wide variety of complex reasons, including 
normalising of symptoms, misplaced stoicism, fear of a 
diagnosis and lack of confidence in the health system.  
Public awareness campaigns, that highlight key symptoms 
and give specific patient advice, are successful.  This has been 
demonstrated by the National Awareness and Early Diagnosis 
Initiative in the UK (NAEDI).  Research on the impact of the 
UK ‘Be Clear on Cancer’ campaign found that there was 
a 9.1% increase in the number of lung cancers diagnosed 
during the campaign (700 more cancers than prior to the 
campaign), as well as a significant increase in the proportion 
of patients who received surgical resection as a first definitive 
treatment.  This suggests an increase in diagnosis of patients 
at an earlier stage of the disease.  Multi-media campaigns 
to inform and educate the public are effective in promoting 
earlier diagnosis of cancer. The results of such campaigns 
should be measured and reported upon on a regular basis 
(KPI no. 2).
I wish I had been 
more aware that 
constant fatigue 
and recurrent 
cough are not 
normal
RESPONDENT, PUBLIC CONSULTATION
Recommendation
The NCCP and the HSE 
Health & Wellbeing 
Directorate, in 
partnership with the 
voluntary sector, will 
develop a rolling 
programme of targeted 
multi-media based public 
awareness and education 
campaigns, aimed at 
the early detection of 
specific cancers and with 
particular focus on at-risk 
populations. 
Lead: NCCP
HSE/Voluntary Sector
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7.3.2 Expanding the role of primary care and general practice 
While GPs treat thousands of patients every year, each 
GP will, on average, only have eight patients in their 
practice who are diagnosed with cancer each year.  
However, symptoms which may suggest cancer such as 
lumps, bleeding and weight loss are common and require 
thorough investigation, even if non-cancerous causes are 
the most common diagnosis.  Around 85% of all cancers 
present with symptoms, and primary care plays a critical 
role in assessment of these symptoms. 
In the UK, the National Institute for Health and Care 
Excellence (NICE) GP Cancer Referral Guidelines [NG12] 
highlight the critical role of GPs in early diagnosis.  Public 
health nurses also have an important role to play in this 
regard. The guidelines recommend that patients should be 
referred for investigation if they have specific symptoms 
that evidence suggests have a 3% chance of being cancer.  
The threshold is lower for children.  Ultimately 97% of 
such patients who are investigated will be reassured that 
they do not have cancer. 
In Ireland there are significant deficiencies in access to 
diagnostics and specialist opinion in the public health 
system. There are fewer GPs in deprived areas, GP 
access to diagnostics in the public system is variable and 
there are long waits for some specialist services. The 
resulting protracted patient pathway contributes to late 
diagnosis.  Urgent attention must be paid to resolving 
these problems, particularly as the requirement for testing, 
referral and specialist investigations is predicted to increase 
substantially over the next ten years.  This is particularly 
challenging, given the current shortage of diagnostic 
specialists and other health and social care professionals 
such as radiographers and ultrasonographers.
Service developments required to meet this growing need 
include:  
• Better integration between primary care and specialist 
care; 
• An expanded role for GPs in cancer care, with 
significantly increased direct access to appropriate 
diagnostic services; and
• Urgent referral criteria, protocols and timelines for 
direct GP access to cancer diagnostics or specialist 
opinion.
The role that other health and social care professionals 
can play in alerting patients to early warning signs of a 
developing cancer is also vital. For example, dentists have 
an important role to play in the prevention and early 
detection of mouth, head and neck cancer. They see many 
patients on a regular basis for routine dental check-ups, 
where the oral cavity is fully examined. This form of case 
finding is important in the early detection of mouth cancer. 
Co-operation between doctors, nurses, dentists and other 
health and social care professionals will be promoted to 
allow for diagnosis at an earlier stage, leading to better 
outcomes for the patient.
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7.4. GP Referral Guidelines and Referral Processes
A Strategy for Cancer Control in Ireland (2006) recommended 
that the HSE should develop specific programmes that promote 
the early detection of cancer.  In response, the NCCP set up the 
Community Oncology Division and established a partnership between 
the NCCP and the Irish College of General Practitioners (ICGP).  
GP e-learning programmes in cancer were developed by the ICGP 
with the support of NCCP and specialist cancer teams.  GP referral 
guidelines and standardised referral processes were developed for 
common cancers.  Rapid access clinics were set up in designated 
cancer centres for breast, lung and prostate referrals.  
Performance in these Rapid Access Clinics is measured on a monthly 
basis. Key Performance Indicators (KPIs) have been developed which 
set out the target time within which patients should be seen in the 
clinic. The HSE and the Department of Health will continue to work 
together to ensure that patients who are referred to these Rapid 
Access Clinics are seen in a timely manner and that these KPIs are 
adhered to (KPI no. 5). 
Further improvements in early diagnosis, including the provision of 
additional Rapid Access Clinics for other tumour types, more extensive 
referral guidelines for patients suspected of having cancer and 
additional educational modules, are required. In the future, guidelines 
on cancer care developed as part the NCEC’s guideline development 
process should include, as appropriate, recommendations in relation 
to the establishment of Rapid Access clinics.
I found a lump 
in my breast, 
went to my GP, 
was referred to 
the symptomatic 
breast disease 
clinic and had 
surgery all in less 
than a month, 
which was great. 
RESPONDENT, PUBLIC CONSULTATION
Recommendation
The NCCP, working with the ICGP and the National Clinical Effectiveness Committee, will develop 
a three year plan to enhance the care pathways between primary and secondary care for specific 
cancers.  The plan will set out criteria for referral to diagnostics and incorporate the requirements for 
additional Rapid Access Clinics
Lead: NCCP
NCEC/ICGP
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Electronic referral processes have been implemented in collaboration with the GP IT Group and a broad range of 
stakeholders.  This followed research that identified several barriers in the referral pathway, including delays in patient 
presentation, unequal access and communication difficulties (KPI no. 3). 
Patients who are diagnosed in Emergency Departments (EDs) are more likely to have later stage cancers and consequently 
have poorer outcomes.  The extent to which these patients interact with primary care is not well understood, although 
they are more likely to come from a deprived background and they may frequently use the ED as a source of primary 
healthcare.  The achievement of a reduction in the proportion of cancers diagnosed through the ED is one of the key 
performance indicators that will be measured over the course of this Strategy (KPI no. 7). 
7.5. Initiatives to Assist in the Early Diagnosis of Cancer
In 2015 the ICGP undertook a survey of its members to document their experience of NCCP developments. Over 500 GPs 
responded. They identified a number of factors which they believe would help in the early detection of cancer, as outlined 
in Figure 7.3 below.
Figure 7.3  Factors which would assist in the early detection of cancer in primary care (2015 GP survey)
 
Recommendation
The HSE will ensure that cancer referrals from a GP into a hospital will be made electronically. Each 
Hospital Group will facilitate the phasing in of e-referral. This will be completed by the end of 2022.
Lead: HSE
NCCP/GPs
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A coordinated programme of public education and 
improved GP access to relevant diagnostics will be 
required to address the barriers which they have identified 
above.  The formation of Hospital Groups, with unified 
management structures, should enable more efficient use 
of available diagnostic resources within each Group to 
facilitate timely GP access under agreed referral guidelines.  
A Lead Radiologist and a Lead Endoscopist, who will 
liaise with the NCCP, will be nominated in each Hospital 
Group to assist in delivering these goals and in auditing 
the outcomes. This will require coordination between the 
NCCP, ICGP and Clinical Diagnostic Leads in each Hospital 
Group (KPI no. 6).  
There is also a requirement for increased capital and human 
resources to meet targets.  In this context the small number 
of radiographers (35-40) graduating from Irish universities 
each year is a real concern.  Such numbers are inadequate 
for the needs of the health service in general, and the 
implementation of this Strategy in particular, over the next 
decade. Timely recognition of the qualifications of trained 
health and social care professionals who completed their 
training overseas is also important. Ensuring that highly 
trained individuals can take up positions in Irish hospitals 
quickly and easily will help to encourage more people to 
return to Ireland to provide high-quality health services for 
patients.
Recommendations
The Department of Health will liaise 
with the Health and Education 
authorities with a view to increasing 
places in Third Level Institutions for 
the training of radiographers and 
sonographers.
Lead: DoH
10
The NCCP, working with other 
Directorates in the HSE, will develop 
criteria by end-2018 for the referral of 
patients with suspected cancer, who 
fall outside of existing Rapid Access 
Clinics, for diagnostic tests. The NCCP 
will ensure, through these criteria, that 
GPs will have direct access to cancer 
diagnostics within agreed timelines. 
Lead: NCCP/HSE
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• Ensure prevention programmes are prioritised to reduce 
cancer incidence 
• Improve symptom awareness in the population 
• Increase early diagnosis
• Focus on social inequalities
PROVISION OF 
OPTIMAL CARE
SECTION C
8 Providing an Integrated Model of Care
9 G tting the Diag osis Right
10 Getting the Treatment Right
11 Safe, High Quality, Patient Centred Care 
• Ensure effective and equitable treatment throughout the care 
pathway to improve outcomes for all patients
• Further develop treatment facilities and infrastructure 
• Maintain a strong focus on patient safety and quality assurance
• Ensure that appropriate palliative care supports are in place 
OBJECTIVES
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PROVIDING AN INTEGRATED 
MODEL OF CARE
CHAPTER 8
8.1. Introduction
A broad objective of this Strategy 
is to have models of care in place 
that ensure that patients receive the 
required care, in a timely fashion, from 
an expert clinical team in the optimal 
location.  The concept of a continuum 
of care underpins the approach to 
patient services, from prevention, early 
diagnosis, through evidence-based 
high quality patient-centred treatment, 
to appropriate follow-up and support. 
A number of elements can be set out 
as design attributes of a system that 
has this continuum approach to the 
model of care as follows: 
 
• Multidisciplinary care should be the cornerstone of cancer care: patients 
should have their diagnosis confirmed and their treatment planned in 
designated cancer centres by multidisciplinary teams of doctors and other 
professionals appropriate to the cancer type;
• Cancer patients should have access to high quality care staffed by 
appropriate specialists. While this should be as close to home as possible, 
centralisation of specialist services into the designated cancer centres is 
required to optimise outcomes for patients;
• Optimal cancer care should be closely integrated with a cancer research 
programme, including clinical trials;
• Planning for service delivery should address future demand as well as 
current  needs, and should encompass the full patient pathway;
• Decisions on services should be evidence-based, with clear provision and 
accountability for the implementation of clinical guidelines and audit;
• Designated cancer centres should be networked to other elements 
of the health system to ensure that cancer control programmes are 
comprehensive;
• The integration of services across and within primary, secondary and tertiary 
care should be a priority;
• Referral pathways should be timely, and promote the early and prompt 
diagnosis and treatment of cancer;
• Patients and their families should be active partners in their care pathway 
and patients should have an informed choice on the treatments available;
• Services should be of a high quality and aim to deliver improved outcomes 
for patients based on the implementation of clinical guidelines; and
• Outcomes should be measured and reported upon regularly. 
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8.2. The Current Model of Care
Cancer treatment is primarily centred on referrals 
from GPs and smaller hospitals to designated cancer 
centres for diagnosis and treatment, with some 
limited referral back to local hospitals and GPs 
for follow-on care. With the growth in incidence 
and prevalence, there is a need to further develop 
patient pathways to ensure that high quality 
treatment, care and follow-up is provided in a more 
efficient and effective manner.  
The current model of care for cancer treatment is 
centred on eight designated cancer centres serving 
a defined population and geographic area26. 
Chemotherapy is currently delivered mainly on a hub 
and spoke basis under the planning and supervision 
of the eight designated cancer centres. Radiation 
oncology is provided in the public system in Dublin, 
Cork, and Galway. Public access to private facilities 
is available in Waterford and Limerick, as satellites of 
the Cork and Galway services. Also, arrangements 
are now in place for patients from the North West 
to be referred to Altnagelvin Area Hospital in Derry 
for radiation therapy.
The current model of care also encompasses the role 
of GPs in primary care settings referring patients for 
investigation or diagnosis to local/regional hospitals 
or to designated cancer centres.
Since its establishment in 2007, the NCCP has worked to ensure 
that the pathway for cancer patients contains the following 
elements:
• Promotion of early accurate diagnosis;
• Primary, secondary and tertiary care services working closely 
together to:
 } provide more cohesive and better care for patients with 
cancer;
 } optimise arrangements for better co-operation and 
greater efficiency; 
 } share and collaborate actively to achieve goals;
 } ensure multidisciplinary team engagement; and
 } effect smooth and timely transition from one service to 
another; and
• Follow-on support after treatment.
8.3. Challenges for the Model of Care
8.3.1 Managing the expected growth in cancer cases
The projected growth in incidence and prevalence of cancer will 
present a challenge for the current model of cancer care. A model 
of care is required that will be capable of managing the increase 
in cancer workload – from referral and diagnostics through to 
treatment and follow-up care – in a manner that provides safe, 
high quality care in clinically appropriate locations.
8.3.2 The need for improved integration in cancer services
There is a need to ensure that patients, including patients 
with metastatic disease, receive prompt referral, diagnosis and 
treatment in an integrated manner in order to ensure that 
outcomes are optimised. Equally, all treatment and post-treatment 
care should be planned and coordinated to ensure that there is 
a seamless transfer for patients between different settings. This 
includes survivorship care, psycho-oncology care, palliative care 
and end of life care. The need for improved integration across 
primary care and hospital settings was one of the key points arising 
from both the Evaluation Group and the public consultation.
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26 The eight designated cancer centres are Beaumont Hospital, Cork University Hospital, Mater Misericordiae University Hospital, St.  
 James’s Hospital, St. Vincent’s University Hospital, University Hospital Waterford, University Hospital Limerick and University Hospital  
 Galway (Letterkenny University Hospital acts as a satellite of UHG for breast cancer services).
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Improved integration requires patient pathways based on 
the different stages of cancer diagnosis, treatment and 
follow-up care, and taking into account specific cancer 
types. Based on the needs arising at each stage of the 
patient pathway, services can be aligned with appropriate 
local, regional and national locations. The concept of a 
networked approach to cancer care is important to ensure 
that each element of the patient pathway operates in 
an integrated manner. Designated cancer centres should 
be networked to other elements of the health system to 
ensure that cancer control programmes are comprehensive. 
An integrated network approach, including the continued 
development of the nursing input, also facilitates the 
provision of services as close to patients’ homes as is 
appropriate. 
Recommendation
The NCCP will further develop the 
model of care for cancer to achieve 
integration between primary care 
and hospital settings at all stages of 
the cancer continuum, from diagnosis 
to post treatment care.
Lead: NCCP
12
C
H
A
P
T
E
R
 8
      P
R
O
V
ID
IN
G
 A
N
 IN
T
E
G
R
A
T
E
D
 M
O
D
E
L
 O
F
 C
A
R
E
67
8.3.3 Increasing the level of specialisation in  
cancer care
Evidence of the positive relationship between higher 
case volume and better outcomes for patients has been 
demonstrated for many cancers and the Evaluation Group 
pointed to a need for further centralisation of cancer care. 
Cancer care is becoming increasingly complex with the 
improved understanding of the genetic basis of some 
cancers and the development of more targeted treatments. 
This is driving increased specialisation, with requirements 
for greater levels of clinical and scientific expertise. 
The required focus on rare cancers will also increase the need 
for specialisation, given the relatively small number of cases, the 
complexity of treatments and the need for nominated clinicians 
to link with rare cancer networks overseas. 
 
8.3.4 The role of patients in improving the  
model of care
The experience of patients can inform improvements in the 
model of care.  Mechanisms will be developed to facilitate 
patient involvement in the design and review of services, 
including through the establishment of a Cancer Patient Advisory 
Committee. With the establishment of hospital groups, the 
potential exists for the better utilisation of hospital resources to 
provide services at clinically appropriate locations, governed by 
agreed patient protocols and pathways. 
8.3.5 Towards an improved model of care
Designated cancer centres will play a key role in providing 
accurate diagnoses and in directing treatment pathways, as well 
as in the provision of tertiary cancer services. The establishment 
of these centres was a key outcome from the Strategy for 
Cancer Control in Ireland (2006) and the performance of the 
centres will continue to be monitored by the NCCP with a view to 
maximising throughput and outcomes. 
The model of care being developed should also facilitate the 
use of local or regional hospitals for routine or less complex 
diagnostics, as well as for the provision of systemic therapy 
services (medical oncology and haematology) where clinically 
appropriate. However, where the diagnosis indicates a 
requirement for more specialised treatment, typically with multi-
disciplinary input, the pathway will be directly to the designated 
cancer centres.
The term quaternary care is sometimes used to describe services 
that are particularly specialised or carried out in only a very 
small number of locations. This model is currently applied where 
services for rare cancers are concentrated in a small number of 
designated cancer centres. The trend towards centralisation in 
a smaller number of designated cancer centres will continue 
for rare cancers and for common cancers where case volume, 
multidisciplinary working or infrastructural requirements are 
important determinants for patient outcomes.
NATIONAL CANCER STRATEGY  2017-2026
8.4. Requirements to Improve the 
Model of Cancer Care
8.4.1 Develop the multidisciplinary care model 
in designated cancer centres
A Strategy for Cancer Control in Ireland (2006) 
recommended that patients should have their 
diagnosis established and their treatment planned by 
Multidisciplinary Teams (MDTs). MDT working is an 
essential cornerstone of cancer care internationally.  
Key personnel from the various disciplines meet 
on a regular basis in a structured fashion to review 
and discuss newly diagnosed patients to plan their 
management and care.  The care of individual 
patients is also discussed at other critical points in 
their care pathway, e.g. post-surgery or at relapse.
Significant progress has been made in establishing 
such teams in the cancer centres. MDT working has 
led to improved decision-making, more co-ordinated 
patient care and improvements in the overall quality 
of care.  The treatment of patients whose cases 
are discussed at MDT meetings is more likely to be 
in accordance with clinical guidelines, and there 
is strong consensus that outcomes are likely to be 
better (KPI no. 12). 
However, there is variation in the functioning 
of MDTs, with some more structured and better 
supported than others. To achieve equitable patient 
benefit from the process, the NCCP should review 
current MDT working to ensure that appropriate 
composition, resourcing, structures and procedures 
are in place, as well as reporting mechanisms 
to collect and analyse outcomes. In the future, 
guidelines on cancer care developed by the NCCP 
and endorsed through the NCEC’s guideline 
development process should include, where 
appropriate, recommendations on the establishment 
and composition of MDTs.
I couldn’t fault the 
services; the clinical care 
is excellent. The flaws lie 
mainly in availability. 
There is not enough staff, 
and appointments for 
physiotherapy etc. are 
hard to get
RESPONDENT, PUBLIC CONSULTATION
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8.4.2 Providing the capital infrastructure to support  
the model of care
While cancer care is provided in a variety of locations, the majority 
of patients receive their care in the designated cancer centres. 
Many of our cancer centres have significant deficits in capacity and 
infrastructure.  For example, not all cancer centres have facilities 
for the 24/7 emergency evaluation of patients with cancer who are 
receiving treatment (KPI nos. 13 and 14), and many in-patient and day 
treatment facilities are at capacity. The Evaluation Group noted the 
need for upgrades in day-care centres, to improve patient experience, 
expand capacity and improve pharmacy facilities.  Along with the 
need for investment in personnel and services that will be required to 
implement this Strategy, a rolling plan of capital investment will be 
required to ensure that high quality facilities are available for patients 
and staff, that the potential for on-going improvements in outcomes 
is maximised and that our health personnel can progress in line with 
developments in cancer worldwide. Such an investment plan would 
cover capital intensive infrastructure such as new radiation oncology 
facilities and on-going replacement of linear accelerators, as well as 
the necessary improvements to diagnostic equipment in local/regional 
hospitals and in designated cancer centres. The capital investment 
plan will also include the optimal provision of ambulatory and day 
care facilities, including medical oncology units at hospitals closer to 
patients’ homes. 
8.4.3 Develop Comprehensive cancer centres
There is a case for the establishment of a limited number of 
comprehensive cancer centres to more fully integrate high quality 
cancer care, combined with research and education. Such services 
would most likely be located on the site of existing designated cancer 
centres. Decisions on the establishment of at least one comprehensive 
cancer centre during the Strategy period will be made by the 
Department of Health, in consultation with the NCCP, and in the 
light of available resources and developments in the best performing 
centres worldwide.
The most effective cancer centres worldwide have been developed 
to integrate high quality clinical cancer care with teaching, as well 
as with basic, translational and clinical research focused on cancer.  
Comprehensive Cancer Centres provide a structural focus to facilitate  
leaders in cancer medicine and research, cancer doctors, nurses and 
health and social care professionals across all disciplines to work 
Recommendations
Patients diagnosed with 
cancer will have their case 
formally discussed at a multi-
disciplinary team meeting.  
The NCCP, working with the 
Hospital Groups, will oversee 
and support MDT composition, 
processes and reporting of 
outcomes.
Lead: NCCP
The NCCP, working with 
other Directorates in the HSE 
and with the Department of 
Health, will develop a rolling 
capital investment plan, to be 
reviewed annually, with the 
aim of ensuring that cancer 
facilities meet requirements.
Lead: NCCP
13
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together with the common goal of improving outcomes for patients.  Cancer centres are usually located within, or 
adjacent to, major tertiary academic hospitals with strong University links and are frequently a local, regional and national 
resource for the development and promotion of cancer education and prevention.  While the size, complexity and design 
of these centres vary, they share some key features:
 
• A focus on cancer clinical care, education and scientific endeavour;
• Breadth and depth of experienced high quality staff across all disciplines; 
• High volume multidisciplinary cancer services in diagnostics, surgery, radiation oncology, medical oncology and 
haematology;
• Dedicated resources within a designated building usually linked with an associated University Hospital;
• Dedicated modern clinical facilities, including outpatient, day care, inpatient and associated interdisciplinary shared 
resources;
• Clinical and other research facilities, with programmatic support for clinical cancer research;
• Integration with scientific institutions to perform translational and basic cancer research, and to develop clinical and 
public health intervention strategies from basic and other scientific discoveries; and
• Recognition of the Comprehensive Cancer Centre as a formal organisational structure.
Internationally the integration of cancer services within a functioning Comprehensive Cancer Centre is the most 
successful model of care delivery.  It must be our goal to ultimately have one or more such centres in Ireland.  Eight 
hospitals have already been designated cancer centres.  While this represents a major step forward, in many cases they 
are made up of a range of services, that themselves have a wider scope than cancer alone, located in different parts of a 
hospital. They are not comprehensive cancer centres when compared to some of the most advanced centres in countries 
such as the USA and Canada, where many of our cancer specialists worked and trained. 
Transforming some of our facilities into functioning cancer centres with research commitment, scientific collaboration and 
breadth of facilities would consolidate current achievements and facilitate improved cancer services and outcomes.   The 
planning and implementation of infrastructural and programmatic initiatives by the NCCP should ideally lead to at least 
one of our cancer centres meeting the criteria for Comprehensive Cancer Centres by the end of the Strategy period.
Recommendation
The Department of Health will ensure that investment in infrastructure, facilities, personnel and 
programmes in the designated cancer centres will have a goal of ultimately developing at least one 
comprehensive cancer care centre that will optimise cancer prevention, treatment, education and 
research during the Strategy period.
Lead: DoH
15
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GETTING THE  
DIAGNOSIS RIGHT
CHAPTER 9
9.1. Introduction
As outlined in Chapter 7 on Early Diagnosis, diagnosing 
cancer at the earliest possible stage is a critical first step 
in improving survival rates. Cancer diagnosis is a complex 
process and it is essential that the systems, structures and 
clinicians are in place to deliver the required services. It 
is important that specialists in radiology, endoscopy and 
pathology are involved in multidisciplinary team meetings, 
so that confirmation of diagnosis can be made.  The aim 
of this strategy is to strengthen the various processes for 
cancer diagnosis so that it continues to play a key element 
of the multi-disciplinary model of care.
Quality assurance (QA) plays an important role in improving 
practice and the quality of care. National Quality Assurance 
Programmes are now in place for radiology, endoscopy 
and histopathology. These QA programmes aim to ensure 
patient safety and accurate diagnosis through the provision 
of timely, complete reports on the results of diagnostic 
tests. 
9.2. Radiology
Along with surgical pathology, accurate, timely and 
high-quality diagnostic radiology services are a critical 
requirement for effective multidisciplinary management of 
cancer patients.  Radiology services are capital intensive and 
there are substantial deficiencies in access to such services.  
This is affecting access to diagnostics for patients suspected 
of having cancer, as well as timely staging and evaluation of 
patients with documented disease.
Imaging capacity, particularly for MRI, CT and PET scanning, 
will need to be increased in all cancer centres. This will require 
additional equipment and staff.  Ideally, cancer imaging 
should be mainly done in an outpatient setting, separate from 
inpatient and emergency services.  Dedicated imaging centres 
should be included in future cancer centre design.
The current equipment base in our cancer centres needs to be 
expanded and modernised, and the on-going capital provision 
for replacement and new investment significantly enhanced.  
Planning and management of capital provision needs to be 
improved, and there may be scope for the exploration by 
the HSE of other models of equipment provision, such as 
managed equipment and services contracts.
Reference has already been made to the critical shortage 
of radiographers in Ireland even before any expansion to 
increase capacity.  Too few are trained and it can be difficult 
to retain staff in the public workforce. Accordingly, the 
number of radiography training places at undergraduate and 
post graduate level needs to be increased. 
As should be the case with other disciplines (e.g. pathology, 
haematology and medical oncology), proper sub-speciality 
radiology services must be provided in the cancer centres. 
Cancer services should be planned around having integral 
radiology services on site relevant to the area of expertise 
of the centre.  In particular, cancer centres have an absolute 
requirement for dedicated interventional radiology services 
to assist in therapy. This will require capital and staff 
provision.  With expansion of existing services, or the 
development of new services, radiology appointments to 
facilitate such improvements must be made conjointly with 
other appointments, such as those of surgeons and medical 
oncologists.
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The NCCP must set, resource and enforce simple KPIs for 
all aspects of cancer imaging. All cancer centres must be 
connected to the National Integrated Medical Imaging 
System (NIMIS) as a matter of priority.
9.3. Endoscopy
A high quality national endoscopy service is essential 
for the timely diagnosis and management of the vast 
majority of gastrointestinal (GI) malignancies. GI endoscopy 
also has a significant role in facilitating therapy and in 
managing complications of many non-GI cancers. Most 
importantly, through appropriate surveillance and screening 
programmes, endoscopy has the potential to facilitate both 
prevention and early identification of cancers that could 
have fatal prognoses. 
Diagnostic endoscopy, provided for the most part by 
gastroenterologists and GI surgeons, comprises the majority 
of the national endoscopy workload.  Projected increases 
in endoscopy demands will give rise to a requirement for 
increased staff resources at physician, surgeon and nursing 
levels, with an associated need for the expansion of current 
training programmes. 
At an institutional level, major determinants of ability 
to deliver high quality endoscopy services include 
infrastructure and access to quality equipment. Significant 
capital expenditure is necessary to bring endoscopy services 
in several cancer centres up to minimum international 
standards.  Furthermore, a rolling programme of equipment 
replacement is required to maintain modern, safe 
endoscopy stock and to allow the decommissioning of 
obsolete equipment. 
The national colorectal cancer screening service, 
BowelScreen, has demonstrated a clear benefit for the 60 
to 69 year old cohort involved.  However, difficulties are 
arising in meeting the demand for colonoscopies that arise 
from it.  Such colonoscopies are considered to be urgent 
and should be done within the current KPI period of 20 
working days.  Significant investment and comprehensive 
planning will be required to achieve the recommendation 
on the extension of BowelScreen to all aged 55 to 74.
Therapeutic endoscopy is a relatively new subspecialty.  
While some aspects of this have been practiced for many 
years in Ireland, other procedures are recent additions, 
or have yet to be established here.  All are important in 
diagnosing and treating GI cancer according to the highest 
international standards.  Such services require high levels of 
training, as well as ready access to ancillary services such as 
general anaesthesia.  
9.4. Histopathology
Histopathology plays a key role in the multidisciplinary 
approach to cancer care, underpinning diagnosis 
and guiding treatment. It is crucial, therefore, that 
histopathology services at designated cancer centres 
are adequately resourced, both in terms of staffing and 
equipment.
Best practice dictates that these services are delivered 
by a minimum of two consultant histopathologists 
subspecialised in each of the subspecialty areas catered 
for at the cancer centre.  Particular attention should be 
paid to ensuring that appropriate subspecialty expertise 
is available in areas such as haematopathology and skin 
pathology.  Only about 80% of the required number of 
histopathologists are currently in post in Ireland, and some 
cancer centres have had difficulty in filling key posts.  
As new services are developed, and existing ones expand, 
consultant appointments in histopathology must be made 
contemporaneously with those of oncological surgeons 
and physicians. Supportive laboratory and ancillary staff 
required to run new and expanding services must also to be 
appointed in this way.
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Consultant pathologists are overqualified for some of 
the tasks that they currently perform and this work 
could be safely delegated to appropriately up-skilled 
biomedical scientists.  This would free up pathologist time 
for more highly skilled tasks.  Developing extended roles 
for biomedical scientists in areas such as macroscopic 
dissection should be promoted to ensure optimal use of 
highly trained personnel.
Diagnostic laboratory equipment must be budgeted for 
replacement and upgrading in a rolling programme to 
facilitate modern practice and to meet the demands of 
increasingly sophisticated oncological practice.  A national 
laboratory information management system (MedLIS) 
is now being developed.  In some centres the current 
information systems are over 20 years old and are near 
obsolete. Priority should be given to rolling out the MedLIS 
programme as soon as possible.
Recommendation
The NCCP will ensure that consultant 
appointments for radiology, endoscopy 
and histopathology, where necessary, are 
made in conjunction with appointments 
in other disciplines such as surgery and 
medical oncology. 
Lead: NCCP
9.5. Molecular Cancer Diagnostics
An accurate pathologic diagnosis is at the core of 
multidisciplinary management of any patient diagnosed 
with cancer. Over the past two decades a scientific 
revolution has taken place in understanding the molecular 
basis for cancer and the genetic alterations that underlie 
the development, growth, spread and persistence of 
cancer.  The term molecular cancer diagnostics essentially 
refers to any such test which evaluates the status of 
tumour cells. The recent rapid expansion in knowledge 
of the human genome has led to the need for nucleic 
acid based testing in a wide variety of clinical situations 
including cancer. Such molecular testing in oncology has 
the potential to fulfil many roles, including risk assessment, 
disease diagnosis, classification and prognosis, prediction 
and monitoring of response to therapy, toxicity prediction 
and dose determination. Such tests already have routine 
daily application in a variety of common malignancies, 
including breast, colon, lung, melanoma, haematological 
malignancies and paediatric cancers. In a rapidly advancing 
field, scores of novel therapeutics are being developed 
for a variety of cancers with defined molecular targets.  
These molecular targets will need to be assessed to 
ensure therapeutic effectiveness for the patient and cost 
effectiveness for the health system.
9.5.1 Molecular diagnostics: current situation
Molecular cancer diagnostic services for solid tumours in 
Ireland are poorly organised and fragmented.  Solid tumour 
molecular testing throughout the country has evolved 
in a reactive, ad-hoc manner with various molecular 
tests being performed by a variety of methodologies in 
different laboratories. At present the NCCP partially funds 
testing at two hospitals operating under a collaborative 
Memorandum of Understanding for solid tumour 
(oncology) diagnostics.  Limited testing takes place at other 
sites and some hospitals use external commercial service 
providers.  While statistics are not available, it is unlikely 
that we are meeting patient needs in this area.  
There is a lack of strategic direction in regard to molecular 
cancer diagnostics in solid tumours in Ireland. A mechanism 
is required to determine how well current tests are being 
done, how effective the service is for patients and clinicians, 
where the tests should be done, how they should be paid 
for, when they should be replaced and when new tests 
16
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should be considered. The goal of this Strategy must be to 
ensure that all patients who need a particular molecular 
test will have that test performed at the appropriate time 
and on the appropriate tissue.  
9.5.2 Main challenges
It is essential to establish a national implementation 
framework, informed by experience internationally, such 
that molecular testing is carried out in a co-ordinated and 
standardised way within accredited laboratories, working 
through a networked programme.  There is no justification 
for multiple laboratories reporting small numbers of cases 
each year.   Overview at a national level, and networking 
in terms of service delivery, is needed to ensure the delivery 
of established tests, the on-going assessment of new tests, 
the commissioning of such tests, the validation of all new 
tests and the on-going assessment of the validity of current 
test repertoires so that those no longer clinically relevant 
are discontinued in a uniform and co-ordinated way.   
This approach will facilitate the commencement of target 
validation for new drugs ahead of time to ensure that Irish 
patients with cancer can be offered novel therapeutics, if 
appropriate, as soon as approval is given and acceptable 
pricing levels have been agreed.
It is important to note that, not only is this a rapidly 
evolving field in terms of test type, but it is also a 
rapidly evolving field in terms of technology and test 
methodologies.  The move towards massively parallel 
sequencing (next generation sequencing - NGS) provides a 
good example of a testing platform that not only has high 
throughput capacity but that will potentially produce an 
extensive range of genetic information.  A clear strategy 
for dealing with patient information obtained from genetic 
testing will need to be developed.  
A further major challenge is to ensure that the education 
and training of all those involved in this area keep 
pace with the scientific and technical developments. 
Engagement with the relevant stakeholders, particularly 
the Faculty of Pathology of the Royal College of Physicians 
of Ireland, will be required to ensure the appropriate 
incorporation of molecular diagnostics into the curriculum 
for trainee pathologists and trainee laboratory medical 
scientists. 
  
In order to address the challenges in this area, the 
NCCP will appoint a National Lead for Cancer Molecular 
Diagnostics. The Lead will chair a Steering Group to oversee 
the organisation, location and delivery of cancer molecular 
diagnostic services in Ireland. This Group will include 
representatives from pathology, haematology, genetics, 
laboratory science and oncology.
17
Recommendations
The NCCP will appoint a National Lead 
for Cancer Molecular Diagnostics for 
solid and liquid malignancies. 
Lead: NCCP
The NCCP will establish a Steering Group 
for Cancer Molecular Diagnostics, chaired 
by the National Lead.  This Steering 
Group will set out the framework for the 
organisation, location and delivery of 
cancer molecular diagnostic services.
Lead: NCCP
18
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9.6. Genetics in Cancer Care
Genetics is the study of how particular diseases or features 
are inherited through genes passed down from one 
generation to the next. The incorporation of genetics into 
mainstream cancer care began in the early 1990s with 
the discovery of the BRCA1 and BRCA2 genes.  However, 
it is now clear that in most cases it is not a mutation in 
a single gene that determines whether cancer develops 
but more likely a combination of multiple mutations in 
different genes that work together to allow the aberrant 
proliferation of cells. Genomics allows for the examination 
of mutations in cancer cells on a genome-wide basis and 
can provide insights into interactions between genes which 
can result in cancer. 
 
Much technological progress has been made in this field 
and it will continue to advance rapidly.  These innovations 
will improve people’s health by making treatment more 
precise, and it will increasingly transition healthcare towards 
risk assessment, surveillance and prevention. Internationally, 
oncology is leading the translation of genetics into 
healthcare and, over the lifespan of this Strategy, we face 
the challenge of progressing cancer genetics to maintain 
top quality oncology services by international standards. 
This will involve significant investment. At the same 
time, the pace of innovation provides an opportunity for 
Ireland to rapidly move towards the current international 
standard of cancer genetics, and even to become a leading 
example of how to incorporate genetics into healthcare.  
This Strategy aims to create a national framework for the 
delivery of genetics-based cancer care that can be adopted 
by other medical specialities.
In recent years the core business of genetics in cancer care 
has changed from being focused on prevention. Genome-
wide association studies can identify mutations and can 
allow for a more thorough understanding of the cancer 
and more precise and effective diagnosis and treatment. 
Treatment decision-making based on timely genetic 
test results in a minority of patients with an inherited 
predisposition is rapidly becoming an international standard 
of care.  Genetic test results guide surgical decisions and 
direct choice of medication.  Targeting medication according 
to genetic test results (pharmacogenetics) is at the forefront 
of precision medicine.  
9.6.1 Cancer genetics in Ireland
At present cancer genetics services in Ireland are 
underdeveloped and underfunded. The NCCP established 
a Hereditary Cancer Programme in 2012, in response 
to advances in diagnostics and increasing demand for 
services. This programme operates in collaboration with the 
Department of Clinical Genetics at Our Lady’s Children’s 
Hospital Crumlin (OLCHC) and aims to improve access to 
assessment and genetic testing for those patients and their 
families whose cancer may have a genetic component. 
The NCCP recently appointed a National Clinical Lead for 
Cancer Genetics (St James’s Hospital) who is charged with 
developing the national cancer genetics service.
A genetics service is currently offered in OLCHC, St 
James’s Hospital and the Mater Misericordiae University 
Hospital, though none of these are in a position to provide 
comprehensive national quaternary care.  Approximately 
1,800 new patients avail of the cancer genetics service each 
year. Increased patient and doctor awareness has resulted in 
an exponential growth in cancer genetics referrals in recent 
years.  The majority of these referrals are healthy individuals 
concerned about their genetic predisposition to cancer.  
Waiting lists in the three hospitals are extensive, and patients 
often have prolonged waits for their results. Thus, results 
with therapeutic relevance for patients undergoing treatment 
are delayed and healthy individuals are not being informed 
of their inherited cancer risk in a timely way.  
It is likely that many new patients diagnosed with breast, 
colorectal, ovarian and endometrial cancers will soon 
benefit from genetic testing.   Other patients, such as those 
with prostate, thyroid, gastrointestinal stromal tumours 
and phaeochromocytomas will also require testing in the 
future.  Clinical cancer genetics in Ireland requires a strategic 
approach that will include increased infrastructural and 
financial support.
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As science continues to advance, it is important to ensure that the introduction of new tests and phasing out of others 
is informed by specific guidelines, and that this will be audited. Audits will ensure that equitable access is available 
irrespective of patients’ age, geographic location and socioeconomic status.
Recommendation
The NCCP will further develop the Programme for Hereditary Cancers to ensure that evaluation, 
counselling, testing and risk reduction interventions are available as appropriate, and that services 
are available to patients on the basis of need. 
Lead: NCCP
9.6.2 Development of the Irish cancer genetics service over the next ten years
Amalgamation of services
The new children’s hospital offers an opportunity to merge the existing cancer genetics services into one National Cancer 
Genetics Service. This would facilitate the development of a national quaternary referral clinical service for children and 
adults, operating closely with a national molecular laboratory and delivering translational bench to bedside care. 
Recommendation
The HSE will ensure that the existing cancer genetics services are amalgamated into one National 
Cancer Genetics Service and will identify the most appropriate site for its location. 
Lead: HSE
New consultant, nursing/genetic counselling appointments   
Oncology care in all designated cancer centres will require input from the Clinical Cancer Genetics Service.  Oncologists 
with subspecialty genetics training, and/or geneticists with a subspecialty interest in cancer genetics, will be required to 
lead this service. Individuals with such training are in short supply and a directed effort to train Irish oncology graduates 
in genetics will be required. To meet present demand, additional full-time consultant appointments will be required in the 
National Cancer Genetics Service to facilitate the delivery of a high quality service, using a hub and spoke model involving 
the active participation of surgeons and/or physicians in individual cancer centres to generate a deeper engagement with 
cancer genetics at a local level. 
19
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77
Regular multidisciplinary clinics should be established for less 
common cancer predisposition syndromes to ensure appropriate 
care for patients with these disorders, as well as to facilitate Ireland’s 
participation in international efforts to develop a unified approach for 
such cases. 
We have an opportunity now to develop an integrated cancer 
genetics service, which will provide an infrastructure for a time when 
genetics-based clinical care is commonplace, by appointing at least 
one cancer genetics nurse specialist/counsellor in each designated 
cancer centre.  National management protocols for common 
predisposition syndromes will enable decentralisation of care for 
common genetic disorders, and facilitate nurse/counsellor-led clinics 
in cancer centres nationally, backed up by appropriate consultant-led 
clinical governance.
9.6.3 Genetics in general practice
Direct to consumer genetic testing is now a reality. Well individuals are 
coming to their GPs with genetic test results that predict their future 
risk of disease. These people, and others who have not had genetic 
testing but are worried about their family history, are being referred 
to the Cancer Genetics Service. The evolution of cancer genetics in 
Ireland should include an assessment service for GP referrals. 
9.6.4 Infrastructure
Other issues include the need for a coordinated national recording 
of genetic test results and an associated method of communication.  
This could be incorporated into a National Electronic Health Record 
utilising the new Individual Health Identifier.  Telemedicine services 
between hospitals will facilitate the delivery of genetics counselling. 
There is also a need for a comprehensive biobanking27 programme.
27  A cancer biobank stores blood and other human tissue samples donated by patients for research into cancer. It also requires the 
informatics capabilities to store and analyse vast quantities of data
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GETTING THE  
TREATMENT RIGHT
CHAPTER 10
10.1. Introduction
Three major treatment modalities are used to treat solid tumours. These are surgery, radiation oncology and medical 
oncology. As discussed in Chapter 8, the development of a fully integrated model of care requires cooperation and 
communication between many different facets of the health service. This is particularly important for cancer treatment. 
Some patients can require surgery, chemotherapy and radiation therapy. It is important that these disciplines share 
information and work in a coordinated way to ensure optimum outcomes for the patient. It is an aim of each cancer centre 
to have designated beds to meet the needs of patients with cancer.
Certain patient cohorts, such as those with rare cancers, older patients and children and adolescents/young adults with 
cancer, require a specific focus to be placed on their care. This can involve centralisation of services, specialist training for 
healthcare professionals and the development of protocols to ensure the efficient, timely transfer of care between settings.
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10.2. Surgical Oncology
Surgery plays a pivotal role in the management of non-
haematological cancer and is curative as the sole treatment 
in a high percentage of cases. As one of the major pillars 
of cancer care and control, it can be preventive, diagnostic, 
curative, supportive, palliative and/or reconstructive. While 
the primary benefit of successful surgery is improved 
survival and quality of life, it also leads to reduced costs of 
on-going treatment in many cases.
Arising from A Strategy for Cancer Control in Ireland 
(2006), an implementation group was established that 
recommended:
• the designation of eight cancer centres (with one 
satellite centre of University Hospital Galway in 
Letterkenny University Hospital for breast cancer); and 
• the centralisation of initial diagnosis, treatment 
planning and primary surgery for many cancers.
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While there has been considerable progress in 
implementing these recommendations, the work is not 
complete. The rationale for the reorganisation of services 
was based on clear evidence that patients who are 
operated on by surgeons who carry out higher volumes 
of surgery in specialist centres, that themselves have high 
volumes, achieve better outcomes. The centralisation of 
services, and the establishment of the NCCP as part of an 
overall programmatic approach to cancer control, is in line 
with international best practice and has led to significant 
improvements in the treatment of patients.  Designation 
of hospitals for cancer surgery on a site specific basis 
is centred on patient needs and the volume of surgery 
involved per hospital, taking best international evidence 
into consideration and subject to review as new evidence 
becomes available. 
Advances in surgical techniques and centralisation of 
complex surgery have led to improvements in the quality 
of cancer treatment. More operations are being carried out 
by specialist surgeons with particular expertise, resulting 
in less invasive procedures, shorter recovery times and 
better outcomes for patients. There is broad consensus 
that surgical services should be configured in a way 
that results in patients receiving the highest standard of 
multidisciplinary care. 
Progress has been made towards the centralisation of 
cancer surgery in line with proposals drawn up in 2007 - 
e.g. all breast cancer surgery now takes place in the eight 
designated cancer centres (with LUH acting as a satellite 
of UHG).  However, significant centralisation remains to be 
attained.  The following will be achieved:
• All cancer surgery will be carried out in a designated 
cancer centre28.  This will be achieved during the 
period of this Strategy (KPI no. 11);
• The centralisation of surgical services for various cancer 
sites will be broadly in line with the 2007 proposals, 
revised in the light of the review of current evidence 
and new treatment modalities; and
• Surgery for the majority of tumour types will be 
delivered in a maximum of four designated centres. 
The NCCP will draw up a plan for the prompt completion 
of the centralisation programme, to be agreed with the 
Department of Health. Meanwhile, the NCCP will continue 
to work with the Hospital Groups to ensure that all cancer 
patients receive their surgery in an appropriate setting. 
This further centralisation of cancer surgery will require 
leadership from the NCCP, collaboration with Hospital 
Groups, flexibility from clinicians and, in some cases, further 
investment in personnel and infrastructure.  
Further innovations in surgery, such as laparoscopic and 
robotic surgical techniques, will be monitored in the coming 
years with a view to introducing innovative approaches as 
appropriate, following the outcome of health technology 
assessments. Such technologies require particular expertise 
and would involve substantial investment. 
28  With the addition of LUH for breast surgery.
21
Recommendation
The NCCP will draw up a plan setting 
out the number/location of designated 
cancer centres in which surgery will 
take place for the various tumour types.  
Timescales for the implementation of the 
plan will be included for each tumour 
type. 
Lead: NCCP
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10.3. Radiation Oncology
Radiation oncology (or radiotherapy) is a primary curative 
modality in a number of cancers (prostate, cervix, head 
and neck and early lung) and increases cancer survival 
as an adjunctive therapy in others (e.g. breast cancer).  
Radiation oncology is also a highly effective palliative 
treatment.  Modern radiation oncology is more accurate in 
the delivery of radiation dose, thus sparing more normal 
tissue, reducing side effects and leading to improvements 
in patient outcome. It is delivered through external beam 
teletherapy (90% of treatments) or through brachytherapy. 
Currently, radiation oncology treatment is available in five 
public hospitals in Ireland: St. James’s Hospital, Beaumont 
Hospital and St. Luke’s Hospital (which three together 
form the St. Luke’s Radiation Oncology Network - SLRON), 
Cork University Hospital and University Hospital Galway.  
Public sector radiation oncology services are provided in 
two private facilities in Waterford and Limerick. Radiation 
oncology services are available to patients from the 
Republic of Ireland at the North West Cancer Centre in 
Altnagelvin Area Hospital, Derry.  
The following issues arise in relation to radiation oncology 
services: 
• Demand for radiation oncology is expected to increase 
in line with increases in cancer incidence;
• The NCCP expects that up to 60% of patients will 
require radiation oncology for primary treatment and 
palliative care;
• Additional radiation oncology facilities are required in 
Dublin, Cork and Galway to meet increasing service 
need, as well as the planned replacement of current 
equipment; and
• A lead-in time of up to four years is required to plan, 
build and commission new radiation oncology facilities
 
The National Plan for Radiation Oncology (NPRO) 
envisions the further development of radiation oncology 
facilities in Dublin, Cork and Galway.  It is critical that the 
NPRO be progressed to ensure that the required facilities 
for radiation oncology are available over the period of 
this Strategy.  For the greater Dublin region, new linear 
accelerators (linacs) are being installed in St. Luke’s Hospital, 
pending the provision of additional capacity for the region 
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in Beaumont Hospital.  Additional facilities at St. James’s Hospital 
are also required. New facilities with increased capacity in Cork and 
Galway are planned and will be required during the first half of the 
Strategy period.
Matched to this infrastructural development, the NCCP will continue 
to manage the recruitment of appropriate levels of specialised staff 
for this treatment modality. In addition to ensuring the provision 
of adequate capacity in the public network, a health technology 
function to assess new treatment options as they become available 
will be developed.
In addition to the provision of adequate radiotherapy facilities to 
meet demand, it is also important that patients who require radiation 
therapy are provided with adequate multi-disciplinary care pre- and 
post-treatment (e.g. pre-radiation dental assessment and treatment).
10.4. Medical Oncology 
Medical oncology involves the treatment of cancer with medicine, chemotherapy in particular, and is now commonly 
referred to as Systemic Anti-Cancer Therapy (SACT). The use of SACT has increased markedly over the last ten years, 
with a variety of new and effective therapeutics becoming available that has led to improved cure rates and long-term 
remission rates, better quality of life and longer survival.  Chemotherapy and other systemic therapies are estimated to 
contribute to around one in ten cancer cures in their own right.  They also play a crucial role in combination with other 
treatment modalities such as surgery or radiotherapy.  Systemic therapy services are currently provided at 26 public 
hospitals (Figure 10.1).
22
Recommendation
In line with the National Plan 
for Radiation Oncology, public 
sector radiation oncology 
facilities in Dublin, Cork and 
Galway will be expanded to 
meet patient demand and a 
planned National Programme 
of Equipment Refreshment 
and Replacement will be 
implemented across the 
Strategy period. 
Lead: NCCP
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Figure 10.1  Publicly-funded hospitals currently providing SACT
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Approximately 33,000 people receive treatment with 
cancer drugs each year. This involves oral anti-cancer 
medicines largely taken at home and parenteral29 drugs 
administered in hospital, with all patients assessed, 
supported and followed through their treatment in 
specialised oncology or haematology day units.  The NCR 
has predicted that the number of new patients receiving 
chemotherapy will increase by between 42% and 48% 
in the period 2010 to 2025.  The last ten years have 
already witnessed a huge increase in the complexity and 
volume of chemotherapy administered.  The growth 
in both the incidence of cancer, and the prevalence of 
patients on active treatment with new drugs, is giving rise 
to a significant increase in the volume and complexity of 
medical oncology work. 
Given the current low number of medical oncologists in 
Ireland against international standards, as identified in the 
Evaluation Report on A Strategy for Cancer Control in 
Ireland (2006), as well as the increasing patient numbers 
and the increasing complexity of these therapies requiring 
a higher level of site specialisation among oncologists, a 
significant increase in the number of consultant medical 
oncologists, specialist nurses and hospital pharmacists will 
be required. The NCCP will address this shortfall on an 
incremental basis, with the aim of meeting international 
standards over the next five years. The number of health 
and social care professionals supporting patients under 
SACT care needs to be expanded.
SACT services operate on a hub and spoke model, with 
29  Parenteral chemotherapy is chemotherapy administered as an injection or infusion.
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oncologists and haematologists based in designated cancer 
centres travelling to provide agreed services to satellite 
centres. In many cases, patients have their treatment 
planning done initially in the cancer centre hub hospital and 
may have at least some of their treatment closer to home.  
More complex chemotherapy and associated services are 
provided at designated cancer centres.  Access to in-
patient beds is required where complex haemato-oncology 
services are provided. The NCCP has established national 
programmes for medical oncology and haemato-oncology. 
They have also established a multidisciplinary group to 
develop a model of care for systemic cancer treatment.  The 
aim is to produce a comprehensive model of care that will 
form a roadmap for the planning of SACT services for the 
ten year strategy period.  
Oral Anti-cancer Medicines (OAMs), while prescribed in 
hospitals by specialists, are mainly dispensed in community 
pharmacies and administered in the patient’s home. OAMs 
have the same potential for risk as parenteral SACT in 
terms of treatment-related toxicities and potential for 
serious medication errors leading to patient harm. Patients 
receiving OAMs, including oral chemotherapy and newer 
targeted therapies, should have access to trained specialist 
oncology doctors, nurses and support staff, appropriate 
to their needs in an oncology unit, regardless of where 
the oral therapies are dispensed. Also, some OAMs are 
significantly more toxic than others and patients receiving 
such drugs require careful monitoring in oncology day 
units.
The first dispensing of these drugs provides an important 
opportunity for in-depth counselling and consultation in 
the hospital setting. All patients receiving these complex 
medicines should have access at the outset to trained, 
specialist pharmacists, in a hospital setting, who can 
advise them on how to take their medication correctly, the 
implications for misuse of the medication and an awareness 
of possible side effects. These specialist pharmacists should 
be utilised effectively throughout the new hospital group 
structure to ensure that all patients can benefit from their 
expertise.  
In addition to providing patients with access to specialist 
pharmacists in hospitals, it is important to ensure that 
community pharmacists are adequately trained to dispense 
OAMs and to counsel their patients. The development 
of dispensing protocols and training programmes for 
community pharmacists will aim to ensure that these 
medications are dispensed in a consistent, effective manner. 
Processes for information sharing, clinical handover and 
shared protocols for dispensing and checking prescriptions 
can ensure a common approach and standardise care 
between hospital and community settings.  
Overall, the objective is to ensure that OAMs are dispensed 
safely and effectively to patients and that the optimum 
balance between hospital and community dispensing is 
achieved.
A national Medical Oncology Clinical Information System 
(MOCIS) to deliver an Electronic Patient Record (EPR) 
for medical oncology and haemato-oncology services is 
planned for implementation from 2017. MOCIS will provide 
a complete overview of each patient’s treatment history 
(including care delivered in different locations) and will 
support the safe and efficient delivery of SACT. 
23
Recommendation
The NCCP will examine the model of 
care for patients receiving oral anti-
cancer medicines and recommend steps 
to ensure that all patients receive such 
medicines in a safe and effective manner, 
with appropriate and proportionate 
supports, both in the hospital and 
community setting. 
Lead: NCCP
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New-to-market cancer therapeutics are exceedingly 
expensive. The NCCP Technology Review Committee 
appraises the clinical effectiveness of new cancer drugs 
with input from the relevant healthcare professionals and 
consideration of peer-reviewed research and guideline 
publications. This approach is underpinned by clinical 
evidence and health technology assessment techniques. 
The National Centre for Pharmacoeconomics (NCPE) 
produces both rapid review and pharmacoeconomic 
assessments for new drugs. Drug treatment may also be 
included in NCEC National Clinical Guidelines as relevant. A 
defined structure and pathway is in place to approve new 
anticancer drugs, assessing the overall value of a new drug 
both in terms of the benefit of the drug to defined patient 
groups and the cost of providing the treatment.  While 
overall the current system is working effectively to provide 
new drugs to patients in Ireland, the approach needs to 
be kept under on-going review to ensure that the balance 
between patient care and value for money is optimised 
against a background of competing needs.  
10.5. Haematological Malignancies/
Lymphoma
10.5.1 Introduction
Treatments for haematological malignancies30 can vary 
significantly in intensity from surveillance, through 
outpatient chemotherapy and immunotherapy, to complex 
inpatient therapy up to the level of allogeneic stem cell 
transplantation.  Administration of the most intensive 
curative treatments is influenced by the age of the 
patient and the co-morbidities involved. Diagnostics and 
therapeutics have developed hugely over the past five years 
resulting in improved outcomes for patients.  However, 
haematology services in Ireland are now faced with severe 
challenges in coping with complex treatment programmes 
and increased patient numbers.
10.5.2 Organisation of clinical services
Haematology services have been provided using a hub and 
spoke configuration for many years.  Current referral routes 
reflect functional relationships built over time.  They may not 
always be aligned to hospital groups or to cancer centres.  
Haematologists have a presence in smaller hospitals because 
of the need to provide clinical consultation and laboratory 
services.  This presence has been leveraged to provide local 
care with links to larger cancer centres.  
Acute haematological malignancies require complex 
treatment and are resource intensive.  Such treatment should 
be delivered in a limited number of centres.  
10.5.3 Haematological malignancies: outcome- 
focused groupings 
Haematological malignancies span a wide range of 
neoplasms, with varying levels of complexity and prognosis. 
They can be roughly divided into three outcome-focused 
groups. These are:
• haematological malignancies treated with curative intent 
requiring complex inpatient care;
• Hodgkin Lymphoma and other aggressive non-Hodgkin 
lymphomas; and
• lower grade chronic haematological malignancies.
These cohorts should be considered separately when 
organising services, as patients will require different facilities 
depending on the type and aggressiveness of their cancer and 
the expected outcome. 
Some haematological malignancies (such as acute 
leukaemias in patients aged less than 65-70 years and some 
aggressive non-Hodgkin lymphomas) require comprehensive 
multidisciplinary team availability at all times, single high-
efficiency particulate air-filtered (HEPA) rooms and day unit 
and admission facilities that are separate from the general 
hospital emergency department. The NCCP will examine 
the data available relating to patient outcomes for acute 
30  Haematological malignancies are cancers that begin in blood forming tissues (such as bone marrow) or in the cells of the immune  
      system and include acute leukaemia, lymphomas, multiple myeloma, myelodysplastic syndromes, myeloproliferative and 
      lymphoproliferative disorders. 
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leukaemias/Burkitt/CNS lymphoma and, by end-2017, 
recommend a designated number of centres to deal with 
such patients. These centres will be capable of accepting 
patients on transfer within 24 hours of diagnosis.
Other haematological malignancies (such as Hodgkin 
lymphoma and other aggressive non-Hodgkin lymphomas) 
also require MDT discussion and planning but receive less 
complex treatment that can be delivered in haematology/
oncology day units. The NCCP will, by end-2017, 
designate a limited number of centres for the treatment of 
patients with potentially curable high grade non-Hodgkin 
lymphomas and Hodgkin lymphoma. These patients will 
have their treatment directed by an MDT.
Lower grade chronic haematological malignancies have 
median survivals of five to 20 years. Most of these patients 
will have the majority of their care in hospitals where 
chemotherapy is administered in haematology/oncology 
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day units, and will require access to complex integrated 
diagnostic and surveillance expertise. The NCCP will 
ensure that patients with chronic and low grade malignant 
haematological disorders are managed in cancer hospitals 
where chemotherapy is administered. This treatment will be 
planned and conducted in collaboration with an MDT in a 
cancer centre.
Given the wide range of treatment modalities that are 
required for haematological malignancies, centralisation 
of these services is required. Arising from A Strategy for 
Cancer Control in Ireland (2006), it was recommended 
that haematology services be provided in four of the eight 
cancer centres. The NCCP will examine the data available 
relating to outcomes for each of the three patient cohorts 
and designate an appropriate number of centres to provide 
comprehensive care for all patients with haematological 
malignancies.
24
Recommendation
The NCCP will develop appropriate 
MDT, centralisation and treatment 
arrangements to meet the diverse 
needs of patients with haematological 
cancers. 
Lead: NCCP
NATIONAL CANCER STRATEGY  2017-2026
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10.5.4 Haematological malignancies: services for adolescents/young adults (AYA) 
The development of the treatment of AYA patients with haematological malignancies will require strong working 
relationships and effective co-operation between the new children’s hospital and adult haematology services in 
designated cancer centres so that patients can be treated in a shared care context where appropriate (see Section 10.7).
10.5.5 Haematological malignancies/lymphomas: diagnostic services
Haematological malignancy diagnoses are complex and require integration of morphology, immunophenotyping, 
cytogenetics and molecular diagnostics to make an accurate diagnosis that will direct optimal therapy.  The development 
of a national laboratory information system (MedLIS) will make integrated reporting more feasible and will aim to ensure 
that complex immunophenotyping and molecular diagnostics (even if performed centrally) will be uniformly available for 
all treating centres. Information on all elements of haematology diagnosis should ultimately be available through MedLIS.
The National Clinical Lead for Molecular Diagnostics (when appointed, see Section 9.5) should examine the centralisation 
of acute leukaemia immunophenotyping to ensure adequate throughput and expertise and to facilitate the management 
of minimal residual disease (MRD) monitoring.  Such a service must focus on equitable provision of quality controlled 
critical results to treating centres in a timely, sustainable, auditable and resilient fashion.  The potential to combine/
develop haematological cytogenetics (currently based at OLCHC) with malignant haematological molecular diagnostic 
services should be evaluated.  As with other areas of cancer molecular diagnostics, the economic model elaborated must 
provide a sustainable funding stream to develop molecular assays which direct therapy.  Specialist haematopathology 
review, particularly for patients with lymphomas, must be timely and integrated early into MDT planning.  This may 
require the appointment of new staff as well as the more widespread use of telemedicine, virtual pathology and hub and 
spoke arrangements.  
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10.6. Rare Cancers
There are many less common cancers where a focus on coordination 
of care in an expert setting is equally as important as for the more 
common cancers. Rare cancers are defined as those with an annual 
incidence of less than six per 100,000 per year and approximately 
5,200 new cases are diagnosed annually in Ireland. However, 
although they collectively comprise about 20% of all cancers, 
individually each rare cancer affects a relatively small number of 
patients every year. Improving awareness of rare cancers among 
both the public and healthcare practitioners is important as they can 
be difficult to diagnose and can require complex treatment. As a 
result, there is a need for clear care pathways for the diagnosis and 
treatment of patients, with particular emphasis on timely treatment 
planning at national MDT level, involving subspecialty expertise in 
diagnosis and treatment and with linkages to international centres of 
excellence for specialist advice and intervention.
National MDTs have already been established for several rare cancers. 
These include soft tissue sarcomas and neuroendocrine tumours.  The 
NCCP will ensure that all patients diagnosed with these cancers have 
their cases presented at these MDTs. For other rare cancers, while 
informal processes may be in place (the informal network to care for 
patients with high risk germ cell tumours is an example), there is a 
need to develop a formalised national model of care.
The NCCP will promote the assessment of all patients who present 
with rare tumours at specialised MDTs. The establishment of further 
national MDTs for rare cancers should be informed by evidence. 
Surveillance data from the National Cancer Registry, combined with 
international best practice, will facilitate the assessment process. 
International links are vital in this area, with a view to learning from 
advances made in other countries and to sharing our experiences with 
others. An EU Joint Action on Rare Cancers has now commenced. 
This initiative will inform progress in relation to rare cancers in Ireland 
during the Strategy period.
25
Recommendation
The NCCP will develop a 
systematic, evidence-based 
mechanism to prioritise the 
establishment of MDTs for 
further rare cancers. The 
centralisation of diagnosis, 
treatment planning and 
surgical services for these 
cancers will be organised in 
line with best international 
practice. 
Lead: NCCP
HSE/DoH
  Lack of 
information about 
rarer cancers can 
lead to patients 
and families 
feeling more 
isolation and 
distress
RESPONDENT, PUBLIC CONSULTATION
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10.7. Child and Adolescent/Young  
Adult Cancers
10.7.1 Introduction
There is a need to develop a uniform service specification 
that ensures that all children with cancer have equitable 
access to an appropriate range of clinical and laboratory 
services for diagnosis, treatment planning and follow-up.  
International recommendations suggest that adequately 
trained and experienced staff in a wide range of specialties 
and services should be available within a cancer centre to 
provide an acceptable standard of care for children.  
10.7.2 National Paediatric Haematology and 
Oncology Centre
The National Paediatric Haematology and Oncology Centre 
(NPHOC) at Our Lady’s Children’s Hospital Crumlin (OLCHC) 
was established in 2002.  Approximately 200 children and 
young adolescents (0-16 years of age) are diagnosed with 
cancer in the Republic of Ireland every year.  All of these 
children are referred to NPHOC to have their diagnosis 
established, treatment planned and follow-up mapped out.  
The comprehensive cancer care model for children and 
young adolescents delivered by NPHOC includes: 
• co-ordination of the delivery of services (both in the 
hospital and in the community), while liaising with 
affiliated regional centres and appropriate community 
agencies; 
• a 24-hour advisory and response service for regional 
centres, GPs, hospital doctors, patients and families; 
• participation in international clinical trials; 
• a diagnostic and reference laboratory service;
• specialist follow-up and intervention (post original 
treatment); 
• counselling, palliative care and bereavement services; 
and
• a range of research, development and educational 
programmes.
10.7.3 The NPHOC shared care network
As 60% of patients live outside the Dublin catchment 
area, the NPHOC Programme is supported by 16 shared 
care paediatric units across Ireland (Figure 10.2). These 
shared care hospitals provide essential supportive care and 
components of treatment locally under the supervision 
of the NPHOC and in accordance with the NPHOC 
Programme Supportive Care Guidelines. The model of 
shared care also extends to primary care, allowing the 
family involved to have access to three tiers of healthcare, 
combining the survival benefits of specialist care with the 
comforts of a more local service.
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                   Figure 10.2 Shared Care Paediatric Units in Ireland
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To ensure that a high standard of care for children and adolescents with cancer 
continues, NPHOC at Our Lady’s Children’s Hospital Crumlin will be recognised as 
a designated cancer centre.
10.7.4 NPHOC at the new children’s hospital 
Child and young adolescent cancer services will be further developed in the new 
children’s hospital.  The schedule of accommodation of the new haematology 
and oncology unit in that hospital will significantly increase the capacity to 
deliver more comprehensive cancer care. This could include treatment of 
specific clinically-driven conditions for adolescents/young adults (AYA) who have 
paediatric-centric tumours and are aged between 16-20 years inclusive. The 
aim is to ensure that patients are treated in the centre (adult or paediatric) most 
appropriate to their needs. 
  Children 
with cancer 
often need 
to visit their 
local hospital 
for infections, 
platelets, 
bloods, etc. 
and often are 
not treated 
[by] the same 
knowledgeable 
staff that 
Crumlin have
RESPONDENT, PUBLIC 
CONSULTATION
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10.7.5 Service delivery for adolescent/young adult patients
Care for cancer patients in the AYA group poses a significant health 
challenge. While paediatric cancers continue to be seen in this population, 
some patients in this age group will have cancers (e.g. germ cell tumours, 
Hodgkin lymphoma) that require treatment in an adult cancer centre. In 
recent years AYA has been recognised as a distinct population within the 
oncology community.  While recent studies show that child and young 
adolescent cancers have seen a large increase in survival rates, the same 
cannot be said for AYA patients with solid tumour cancers.
It is now widely accepted internationally that traditional models of cancer 
care do not adequately meet the needs of the AYA population.  A more 
tailored comprehensive multidisciplinary approach to the specific service 
needs of this population, who are undergoing intensive physiological and 
psychosocial change during their cancer journey, needs to be developed.  
To achieve this in Ireland, a joint integrated programme will be developed 
involving paediatric and adult haematologists/medical oncologists, in 
partnership with the patients and their families.  
An AYA Cancer Service Network, involving the designated cancer centres, 
will be established.  This will function on a hub and spoke model, with the 
NPHOC/the new children’s hospital as the hub, but with strong input from 
dedicated adult haematologists/ oncologists. The creation of AYA Units in 
up to four of the eight designated cancer centres will be considered. 
26
Recommendation
The HSE will ensure that an age 
appropriate facility is designated 
for adolescents and young adults 
with cancer within the new 
children’s hospital. 
Lead: HSE
10.7.6 Psychosocial care
A challenge for healthcare professionals is to support the normal 
development process throughout the complex cancer journey.  For AYA 
during this crucial stage of development, a cancer diagnosis creates many 
unique challenges that persist beyond the cancer diagnosis and treatment. 
Numerous studies have identified a significant unmet psychosocial 
need in the AYA population.  Various guidelines31  have been published 
highlighting the essential elements for multidisciplinary care of AYA with 
cancer.  Such guidelines will inform the basis for the provision of care to 
the AYA cohort in collaboration with the National Clinical Lead for Psycho-
oncology (See Section 10.9).
27
Recommendation
The HSE will develop closer links, 
on a hub and spoke model, 
between the National Centre 
for Child and Adolescent Cancer 
and the other designated cancer 
centres to provide appropriate 
and flexible transition 
arrangements for adolescents/
young adults. This will include the 
joint appointment of adolescent/
young adult oncologists and 
haemato-oncologists and the 
provision of age-appropriate 
psycho-social support for these 
patients 
Lead: HSE
NCCP
31  European Society for Paediatric Oncology (SIOPE), European Standards of Care for  
 Children with Cancer (2009); National Institute for Health and Care Excellence  
 (NICE), Improving Outcomes in Children and Young People with Cancer (2005);  
 and Teenage Cancer Trust,  A Blueprint of Care for Teenagers and Young Adults  
 with Cancer (2012)
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10.7.7 Survivorship
The cure rate among the AYA cancer population exceeds 
80% and hence there are a growing number of survivors.  
AYA cancer survivors can experience a wide range of long-
term treatment-related toxicity which results in an increased 
risk of later health effects in this population.  The unique 
medical needs of AYA cancer survivors will be recognised 
within the proposed survivorship programmes (See Chapter 
13: Survivorship).
 
10.8. Cancer in Older Patients
10.8.1 Introduction
The ageing population is a significant driver of increased 
cancer incidence and prevalence in Ireland (See Chapter 
2: Cancer in Ireland).  In addition, older patients (generally 
those over 75 years) with cancer pose their own unique 
challenges.  Older patients are less likely to have tumour 
directed treatment. For some cancers they tend to present 
at a later stage and are often more commonly diagnosed 
after an emergency presentation.  For these and other 
reasons, older patients have poorer outcomes than the 
general population with cancer, with a decline in survival 
from cancer with increasing age. Older patients are 
significantly more likely to have non-cancer comorbidities. 
They can also lack social support and so it can be more 
difficult for them to access, or to tolerate, what would be 
optimal cancer treatment for others. 
Multidisciplinary care of older patients with cancer requires 
a focused and coordinated approach, informed by the 
emerging discipline of geriatric oncology.  Formalised 
geriatric input needs to be built into the multidisciplinary 
assessment of the care of older patients with solid 
and haematological malignancies.  For many patients 
this can be performed by oncology and haematology 
nurse specialists, while for others frailty assessments, or 
sometimes comprehensive geriatric and/or palliative needs 
assessments, may be required.
To determine the degree to which such services may be 
required, the age, morbidity and socio-economic profiles 
of patients with cancer treated in the eight cancer centres 
should be assessed by the NCCP.  To coordinate the 
elaboration of such an approach, the NCCP will appoint a 
National Clinical Lead for Geriatric Oncology.  This person 
will coordinate education and training in geriatric oncology 
(both for medical and nursing oncology specialists) in 
collaboration with national training bodies; work with 
cancer centres to improve care of older patients; and 
utilise programmes (such as the Irish Longitudinal Study on 
Aging (TILDA) research consortium) to advise the NCCP on 
developing care pathways for older patients.
10.8.2 Key requirements
Education
There is an urgent need to improve health care providers’ 
knowledge of geriatric oncology. Steps should be taken 
to include geriatric oncology in the core undergraduate 
nursing and medicine curricula.  Geriatric oncology should 
be included in the teaching modules for both geriatric and 
oncology specialist trainees, national workshops jointly for 
oncology and geriatric trainees should be established and 
opportunities for participation in international fora should 
be promoted.  The National Geriatric Oncology Conference, 
held for the first time in 2015, will provide an opportunity 
to deepen co-operation in the coming years. National 
oncogeriatric training, as part of on-going continual 
professional development, should also be formulated.
Clinical Practice
Broadly speaking, the goal of geriatric oncology is to 
improve the quality of prevention measures, diagnosis, 
treatment and follow-up of older patients with cancer.  
Geriatric evaluation must be incorporated into oncology 
decision-making, in line with the core recommendation 
of the International Society of Geriatric Oncology.  In 
this context, collaboration between oncologic and 
geriatric disciplines is essential, ultimately leading to the 
establishment of interdisciplinary geriatric oncology clinics/
MDTs, with lead physicians, appropriate nurse specialists 
and health and social care personnel identified.
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Research
Improving research in the field of geriatric oncology will 
inform and encourage excellence in clinical practice.  This is 
an area on which organisations such as Cancer Trials Ireland 
(formerly ICORG) and the Irish Cancer Society might place 
more focus in the coming years.
10.9. Psycho-Oncology Services
10.9.1 Introduction
Psycho-oncology is concerned with the psychological, 
social, behavioural and ethical aspects of cancer. It 
addresses the two major psychological dimensions of 
cancer: the psychological responses of patients to cancer 
at all stages of the disease (and that of their families and 
carer); and the psychological, behavioural and social factors 
that may influence the disease process.
Access to appropriate psycho-oncology services within 
cancer centres has not developed as envisaged in A 
Strategy for Cancer Control in Ireland (2006), an issue 
highlighted in the report of the Evaluation Group. Only two 
of the eight designated cancer centres have a dedicated 
psycho-oncology service, and one of these is part-time.  
This needs to be addressed, particularly given the predicted 
growth in incidence of cancer and demand for cancer 
services.
28
Recommendation
Links between cancer services and 
geriatric services will be strengthened, 
facilitated by the appointment of 
a National Clinical Lead in Geriatric 
Oncology in the NCCP. 
Lead: NCCP
    The hospital I attended was fantastic and 
the care was superb, but the effects of treatment were 
gruelling…I raised my mental health concerns with my 
consultant and she advised that really there were only 
ad hoc services available 
RESPONDENT, PUBLIC CONSULTATION
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In addition, other issues highlighted in the Evaluation Report will impact upon psycho-oncology and psychosocial service 
requirements in the coming years.  These include the deployment of new models of care, as well as hereditary cancer and 
survivorship initiatives that have the potential to place additional demands on already insufficient psycho-oncology and 
psycho-social care service providers. 
Two essential issues need to be considered when planning psycho-oncology and psycho-social support services:
• The appropriate level of expertise and intervention required relative to patients’ needs; and
• The development of a model for psycho-oncology that has the capacity to cross the voluntary, primary and acute 
services.  
10.9.2 Proposed model of hospital-community psycho-oncology and psycho-social care
The term ‘distress’ is the preferred term to describe the psychological challenges that patients with cancer experience.  
Cancer related distress is best conceptualised as existing on a continuum of severity ranging from mild (adaptive, ‘normal’ 
levels of sadness and fear) to severe (disabling symptoms such as clinical depression, anxiety, panic disorder, body image 
problems or relationship and family breakdown).  The degree of severity experienced by the cancer patient will dictate 
the level of intervention and expertise required.  The model presented below (Figure 10.3) is based on this understanding 
and has a range of specific psychological interventions, matching each level of intervention with the level of distress or 
morbidity experienced by the patient with cancer.  As a stepped care approach to service provision, this model is flexible 
to meet the needs of all patients with the intervention selected according to the type and severity of psychological 
morbidity.  As such, it ensures the most efficient use of resources, while also ensuring that interventions received are 
appropriate to the level of distress. 
Figure 10.3 Proposed Model of Hospital-Community Psycho-oncology and Psycho-social Care32 
32 Model adapted from O’Dwyer and Collier, St. James’s Hospital, 2003
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Level 1 care is provided to patients and families, supported by public lectures and information 
leaflets/booklets produced by the cancer centres and the voluntary sector.  
Level 2 care is for patients with more significant morbidity who can be managed in cancer centres 
by cancer clinical nurse specialists or in primary care by staff such as GPs, community mental 
health nurses and health promotion officers. Services should provide care to both patients and 
their families. The staff involved in providing the support should receive appropriate training from 
psycho-oncology services based in the cancer centres.  In some cases cancer support services in 
the community will provide programmes at this level, bridging between hospital services and 
community care.  
Level 3 care is for patients with moderate degrees of distress and should be managed by trained 
mental health practitioners in hospitals and in the community (including cancer support centres). 
This includes clinical/counselling psychologists, cognitive behavioural therapists, clinical cancer nurse 
specialists and social workers.  
Level 4 and 5 care is for patients with severe and pervasive distress and requires more intensive 
input from senior specialist mental health professionals, such as principal psychologists and 
consultant psychiatrists.  It will be necessary for patients at this end of the continuum to attend 
psycho-oncology services in a cancer centre where specific expertise in cancer-related morbidity, 
including steroid-induced psychosis, severe cancer-related fatigue or body image disorder, will be 
available in a manner similar to services for physical treatments in cancer.
The establishment of multi-disciplinary psycho-oncology teams in each of the cancer centres is 
required.  These teams will deliver a comprehensive hospital-based clinical service and will also 
provide a community support function into community cancer support groups.  This model will also 
facilitate the provision of psycho-oncology support to centres where patients are being treated in a 
hub and spoke model. The teams will comprise psychologists, psychiatrists, clinical nurse specialists 
(CNSs) and social workers. 
The Evaluation Report of A Strategy for Cancer Control in Ireland (2006) suggests the need for 
a co-ordinated approach to the education of all cancer care workers in the psychosocial support 
needs of patients, including the sensitive management of communication around diagnosis and 
prognosis.  The psycho-oncology MDT (at levels 3 - 5) will provide such education and training.  
To develop psycho-oncology services nationally, the NCCP will appoint a National Clinical Lead for 
Psycho-oncology.  She/he will ensure the delivery of the networked services outlined above, with a 
view to achieving a significant beneficial impact on the quality of life for patients and their families.
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10.10. Palliative Care
Palliative care is defined as an approach that improves the quality of 
life of patients and their families facing the problems associated with 
life-threatening illness, through the prevention and relief of suffering 
by means of early identification and treatment of pain and other 
problems, physical, psychosocial and spiritual. Palliative care services 
are organised into specialist and generalist services that operate in 
partnership, as part of an integrated network of providers.   
Traditionally, many people think of palliative care as care provided at 
the last stage of life - around the time of death. However, in the last 
twenty years the scope of palliative care has broadened to providing 
care at an earlier stage in the disease trajectory. In this model of 
integrated palliative care provision, such care is not dependent on 
prognosis. Instead it is provided on the basis of need, and may be 
delivered at the same time as curative treatment. 
Palliative care in Ireland is recognised as a core component of 
healthcare provision and services are structured in three levels of 
ascending specialisation: 
• Level 1 – Palliative Care Approach: All health care professionals 
appropriately apply palliative care principles;
• Level 2 – General Palliative Care: Health care professionals who, 
although not engaged full time in palliative care, have had some 
additional training and experience in palliative care;
• Level 3 – Specialist Palliative Care: This involves services whose 
core activity is the provision of palliative care.
The role of generalist palliative care (levels 1 and 2) is fundamental 
to the provision of high quality care for children and adults with 
cancer. Indeed, generalist palliative care providers can appropriately 
and effectively meet the needs of many people with cancer. GPs and 
broader Primary Care providers can play a key role in providing such 
palliative care.
29
Recommendations
The NCCP will appoint a 
National Clinical Lead for 
Psycho-oncology to drive 
the delivery of networked 
services. 
Lead: NCCP
30 Each designated cancer centre 
will establish a dedicated 
service to address the psycho-
social needs of patients with 
cancer and their families. This 
will operate through a hub and 
spoke model, utilising the MDT 
approach, to provide equitable 
patient access. 
Lead: NCCP
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However, should an individual experience uncontrolled 
symptoms, or problems of high intensity, complexity and/
or frequency as a consequence of their illness, then input 
from specialist palliative care services is needed to ensure 
best possible outcomes.  The aim is that cancer services, 
specialist palliative care services and community care 
services will work in an integrated way to ensure that 
all cancer patients with palliative care needs receive that 
care in a timely manner and in the appropriate location. 
Symptom control is an integral component of this care. 
The Palliative Care Clinical Programme has led two NCEC 
National Clinical Guidelines which were published in 
2015 and which offer evidence based guidance for the 
management of patients with cancer pain and constipation.
 
Palliative care may be provided in a variety of locations - at 
home, in a primary care setting, in hospital or in a hospice. 
It may be provided for varying periods of time - days, 
weeks, months or, for some, episodically over a number of 
years.
Systems of care should be sufficiently flexible to ensure 
that specialist services remain aligned to the changes in 
level of need, respond promptly and collaborate effectively 
with generalist providers.  It is important that generalist 
staff receive the necessary training and education to 
ensure that they are competent in their appropriate 
level of palliative care provision. It is recommended that 
guidance be developed in order to ensure safe transition, 
including clinical handover, between settings and to 
promote continuity of care. Staff in the community, 
such as GPs, community nurses, occupational therapists, 
physiotherapists and pharmacists should also be offered 
training to ensure that they have the appropriate skillset to 
address the palliative care needs of patients outside of the 
hospital setting.
The NCCP and the National Clinical Programme for 
Palliative Care will work together, with particular focus on 
the coordination of organisational, clinical and information 
systems, to progress the further integration of cancer and 
specialist palliative care services. 
31
Recommendations
Designated cancer centres will 
have a sufficient complement 
of specialist palliative care 
professionals, including psycho-
oncologists, to meet the needs of 
patients and families (such services 
will be developed on a phased basis 
to be available over seven days a 
week).  
Lead: HSE
Designated Cancer Centres
32 Oncology staff will have the training and education to ensure 
competence in the identification, 
assessment and management 
of patients with palliative care 
needs and all patients with cancer 
will have regular, standardised 
assessment of their needs.
Lead: HSE
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At present, the majority of specialist palliative care in Ireland is 
provided by voluntary hospices, which are funded both through 
service level agreements with the HSE and through their own 
fundraising activities.  Currently in the region of 80% of the patients 
seen by specialist palliative care providers have a cancer diagnosis, 
though this proportion is decreasing. However, for the foreseeable 
future, patients with cancer will continue to comprise the majority of 
palliative care patients (KPI no’s. 18 and 19).
While Ireland’s commitment to the provision of palliative care has 
been recognised internationally, limitations in service availability 
remain. It is therefore necessary to continue to develop our national 
services in order to ensure that all people with cancer, who have 
palliative care needs, including a small cohort of children, can readily 
access appropriate services.  
33
Recommendation
The HSE will oversee the further 
development of children’s 
palliative care to ensure that 
services are available to all 
children with a life limiting 
cancer. 
Lead: HSE
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SAFE, HIGH QUALITY,  
PATIENT CENTRED CARE
CHAPTER 11
11.1. Introduction
The primary aim of all cancer services is to provide effective, 
safe, high quality and patient-centred care.  Systems are 
required across the health service so that technologies and 
treatments are designed for efficacy and efficiency. The 
overall aim is to ensure that informed decisions are made 
on the provision of high quality and equitable health care.
Safety is fundamental to quality healthcare and cancer 
services must be enabled to deliver safe care, while 
balancing competing pressures and demands.  Assurance 
of patient safety requires active leadership, governance 
and clinical commitment to quality at all levels.  Each 
cancer service will have a defined patient safety and quality 
operating framework to address service user advocacy, 
complaints, incident management and response, learning 
systems and service improvement, and to foster a patient 
safety culture.
A National Patient Safety Office (NPSO) has been 
established within the Department of Health.  This Office 
leads a programme of patient safety measures.  This patient 
safety programme involves new legislation and centres on 
initiatives such as the establishment of a national patient 
advocacy service, measurement of patient experience, 
introduction of a patient safety surveillance system, 
extending the clinical effectiveness agenda and setting up a 
National Advisory Council for Patient Safety
11.2. Improving Evidence Based Practice
Cancer diagnostics and treatments are advancing at a 
rapid pace. Cancer policies and services will need to be 
both responsive and anticipative over the lifetime of this 
Strategy in order to ensure the provision of high quality and 
equitable cancer services with the aim of optimising patient 
outcomes.
The opportunity to improve cancer outcomes and survival 
rates should be grasped in an equitable manner across 
the Irish health system. Scientific advances have created 
opportunities for individual patients to have access to 
new therapies, including the development of personalised 
treatments and more accurate diagnostic techniques. 
Policy decisions for cancer care must endeavour to achieve 
a balance between creating opportunities for individuals 
and the provision of population-based equitable care. A 
process that supports and guides policy in prioritisation and 
decision making in a cost effective manner is required.
The use of economic evaluations and health technology 
assessments should underpin the models for cancer service 
delivery across prevention, screening, diagnostics and 
treatment. This approach will ensure that an enhanced 
analytic approach to evaluating the clinical effectiveness, 
costs and health consequences of alternative courses of 
action becomes the norm. The aim is to provide a coherent, 
equitable and transparent prioritisation process for planning 
for cancer service delivery for our population over the 
lifetime of this Strategy.
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11.3. Health Technology Assessments
Health technology assessments (HTAs) are increasingly 
being utilised internationally to judge value for money. A 
HTA is a form of research that generates information about 
the clinical and cost-effectiveness of health technologies. 
These technologies can include drugs, medical devices, 
diagnostic techniques, surgical procedures and public 
health programmes (e.g. cancer screening programmes). 
They are relevant to the assessment of both new and 
existing technologies. A HTA may also look at the social, 
ethical, medico-legal and organisational aspects associated 
with use of a technology, including its resource implications 
and budget impacts. The information provided by the 
HTA is used to inform health policy decisions regarding 
investment/disinvestment.
Advances in cancer care have led to questions of the 
sustainability of the cost of new treatments and how these 
new treatments can be assessed, trialled and integrated 
into mainstream care. The process by which existing 
treatments are assessed and potentially discontinued is also 
important. 
While in Ireland HTAs are often performed by HIQA, 
other areas of the health services also conduct HTAs and 
economic assessments. Examples include the HSE National 
Centre for Pharmacoeconomics (NCPE), which examines 
the efficacy and cost effectiveness of new drugs. HTAs and 
Budget Impact Assessments form part of the development 
of National Clinical Guidelines for approval by the NCEC. 
Less formal assessments of new and existing technologies 
and therapeutics are also carried out.
11.4. National Standards
    
Standards help to set public, provider and professional 
expectations and they enable those involved in cancer 
services, and all involved in healthcare, to play a vital part 
in safeguarding patients and in delivering continuous 
improvement in the quality of care provided.  The HIQA 
National Standards for Safer Better Healthcare (2012) 
provide a strategic approach to improving safety, quality 
and reliability across health services. 
11.5. National Patient Advocacy Services and 
Measurement of Patients’ Experience
Patient advocacy is well developed in relation to cancer 
services in Ireland.  The Irish Cancer Society plays a primary 
role in this regard, with many other organisations also 
focusing on cancer patients.  This was recognised with the 
establishment of a Cancer Patient Forum to represent the 
views of patients and patient groups in the development of 
this Strategy, and through the public consultation process 
(see Chapter 12). 
Advocacy activities in regard to healthcare occur at an 
individual level and at a macro level. Increasingly, patient 
advocacy services are assisting cancer patients to navigate 
the health system, as well as helping them to cope with 
psychological and social effects of illness. At the macro 
level patient advocates give patients a voice in public fora. 
Work on a new national model for patient advocacy has 
commenced.  The NPSO will define the core components 
for the national advocacy model.  
The patient’s voice is essential to inform and evaluate the 
care given, and to guide quality improvement initiatives 
at all levels.  A joint partnership between HIQA, the 
Department of Health and the HSE is progressing a plan for 
the measurement of patient experience across in-patient 
acute care.  This will facilitate a comparison between Irish 
and international patient experiences.  
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34
Recommendations
The NCCP will ensure that each hospital 
has a clearly defined framework for 
cancer patient safety and quality.
Lead: NCCP
35 The NCCP will define focused cancer 
patient experience surveys to 
incorporate treatment and survivorship 
in line with HIQA’s standard approach 
for the National In-Patient Acute Care 
Patient Experience Survey.
Lead: NCCP
HIQA
11.6. National Patient Safety Surveillance 
The NPSO will establish a National Patient Safety Surveillance 
System which will provide the evidence to inform patient 
safety policy decisions.  This system will produce patient 
safety profiles by bringing together data from various 
health information resources.  For cancer services, such a 
surveillance system is likely to include, but is not limited 
to, elements on clinical activity, safe structures, optimal 
workforce, supportive culture, appropriate behaviour, 
notifications to the Health Products Regulatory Authority 
(HPRA), the Hospital Patient Safety Statement, information 
from the Coroner, State Claims Agency data and temporal 
issues.  The surveillance of patient safety profiles for service 
and clinical cohorts will form part of a cyclical quality 
improvement process.
11.7. National Healthcare Quality  
Reporting System 
The Department of Health is committed to public reporting 
of indicators that reflect the quality and safety of healthcare, 
including cancer care, through the National Healthcare 
Quality Reporting System (NHQRS). The NHQRS framework 
sets out five domains against which quality is delivered33. 
Such public reporting helps to drive improvements in the 
quality of care provided to patients.  The Department of 
Health published the third NHQRS Annual Report in June 
2017.  The following were included in respect of cancer 
services:  
Cancer Screening Rates Cancer Survival Rates Cancer Surgery
Percentage uptake of breast screening Five year relative survival rate for 
breast cancer
Breast cancer surgical activity
Percentage uptake of cervical screening Five year relative survival rate for 
cervical cancer
Colon cancer surgical activity
Five year relative survival rate for 
colorectal cancer
Rectal cancer surgical activity
33  Helping people to stay healthy and well; supporting people with long term conditions; helping people when they are being treated and cared for in our  
      health services; supporting people to have positive experiences of health care; treating and caring for people in a safe environment.
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The Department of Health will develop further indicators as appropriate under the NHQRS to assess progress in achieving 
the objectives of this Strategy.
 
36
Recommendation
The NCCP will develop, publish and 
monitor a programme of national 
quality healthcare indicators for 
cancer care, involving both process 
and outcome measures, in line with 
international standards.
Lead: NCCP
11.8. Adverse Events, the National Incident 
Management System and Open 
Disclosure
The further development and rationalisation of cancer 
care, as proposed in this Strategy is intended to enhance 
the quality of care to patients. However, the delivery of 
healthcare is inherently risky, and its scale and complexity 
is without parallel in other sectors and businesses.  It is 
essential that we are always vigilant with regard to quality 
and that we have a strong patient safety culture.   
The reporting of adverse events is one indicator of a strong 
patient safety culture.  Healthcare services covered by the 
Clinical Indemnity Scheme are legally obliged to report all 
adverse events, including Serious Reportable Events (SREs), 
on the National Incident Management System (NIMS) to the 
State Claims Agency. Legislation is being progressed which 
will require providers to report SREs to the State Claims 
Agency, HIQA and the Mental Health Commission. Cancer 
services will report adverse events and will support open 
disclosure with patients and their families in parallel with 
other services in the health system. 
11.9. Clinical Effectiveness
The National Clinical Effectiveness Committee (NCEC) 
is charged with prioritising and quality assuring, to the 
level of international methodological standards, a suite 
of National Clinical Guidelines and National Clinical 
Audit for the Irish health system. Clinical guidelines are 
internationally recognised methods for defining healthcare 
interventions, improving the effectiveness of care and 
treatment and reducing variation in care delivery.  Policies, 
procedures, protocols and guidelines are also a source of 
robust, quality information for patients.  Development of 
these Guidelines is informed by the NCEC Standards for 
Clinical Practice Guidance (2015) to promote consistency 
of approach.  Within cancer services, the most appropriate 
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clinical practice guidance should be prioritised in a systematic manner, in line with the service need and the methodological 
rigour required.  
NCEC National Clinical Guidelines and National Clinical Audit endorsed by the Minister for Health are mandated for 
implementation in the Irish health system and their implementation will be monitored through HSE Performance Assurance 
Reports, compliance with the National Standards for Safer Better Healthcare and increased alignment with the Clinical 
Indemnity Scheme.  There should be a focus on guideline implementation and audit performance, and on ensuring that 
the resources and clinical leadership to support the development and implementation of prioritised guidelines and audit are 
available. Where appropriate, high quality international guidelines should be formally adapted for the Irish healthcare setting.
Fourteen NCEC National Clinical Guidelines have been published to date.  A number of these relate directly to cancer 
services as outlined below. Further guidelines in relation to lung, colon, rectal, pancreatic and oesophageal cancer are being 
developed by the NCCP.
National Clinical Guidelines Relating to Cancer and Palliative Care
NCG No. 7 Diagnosis, Staging and Treatment of Patients with Breast Cancer, June 2015
NCG No. 8 Diagnosis, Staging and Treatment of Patients with Prostate Cancer, June 2015
NCG No. 9 Pharmacological Management of Cancer Pain in Adults, Nov 2015
NCG No. 10 Management of Constipation in Adult Patients receiving Palliative Care, Nov 2015
NCG No. 13 Diagnosis, Staging and Treatment of Patients with Gestational Trophoblastic Disease, Nov 2015
Future National Clinical Guidelines relating to cancer should include where appropriate recommendations on MDT location 
and composition, and on centralisation of services, as well as descriptions of how care should be structured at a community, 
regional and national level. Where necessary, these guidelines should also include recommendations relating to the 
establishment of Rapid Access Clinics.
37
Recommendation
The NCCP will develop further guidelines for cancer care in line with National Clinical 
Effectiveness Committee (NCEC) Standards.  Audits will also be developed in accordance with the 
NCEC Framework for National Clinical Audit. 
Lead: NCCP/NCEC
11.10. Leadership in Safe, High Quality Cancer Care
Leadership, governance, clinical commitment and clinical effectiveness approaches are required to deliver safe, high quality 
cancer care at national, regional and local level. There is a need for investment in capacity development for quality and 
patient safety in our cancer services.  This requires that each service/hospital has a dedicated patient safety and quality 
leadership and oversight function, which encompasses both cancer patient safety elements (e.g. complaints procedures, 
advocacy, and management of risk and adverse events) and cancer quality elements such as standards, clinical effectiveness 
guidelines, audit and key performance indicators.
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MAXIMISE PATIENT 
INVOLVEMENT AND 
QUALITY OF LIFE 
SECTION D
12 Involving Patients in their Cancer Care
13 Survivorship
• Strengthen the role of patients in the delivery of cancer care, including 
through the establishment of structures for patient involvement
• Develop and implement survivorship care programmes
OBJECTIVES
NATIONAL CANCER STRATEGY  2017-2026
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INVOLVING PATIENTS IN  
THEIR CANCER CARE
CHAPTER 12
12.1. Introduction
It is recognised internationally that patient involvement 
should be an integral part of both cancer care and 
service development. Patients who are fully informed 
about their care are patients who are empowered, active 
participants in their treatment. Additionally, cancer patients 
are in a position to provide a unique perspective on the 
development of cancer services at a local, regional and 
national level. This Strategy aims to put structures in 
place to allow for increased patient involvement into the 
development of cancer services in Ireland.
12.2. Patient Advocacy
Patients with cancer and their families and friends have 
long been to the fore in advocating for the needs of cancer 
patients locally and nationally and there is a recognition 
that patient advocacy needs to be developed and enabled 
in a more structured way. Elements of advocacy relate 
to patient rights, matters of privacy, confidentiality and 
informed consent, patient representation, awareness 
building and support and education of patients and their 
carers. Advocacy services can also assist cancer patients to 
navigate the healthcare system. At national level, advocacy 
provides a patient voice at public fora.
This approach is being developed more broadly across 
health services and the National Patient Safety Office in the 
Department of Health will define the core components for 
the national advocacy model and oversee its introduction 
(See Chapter 11).
12.3. Providing for a Structured Engagement 
with Cancer Patients
The development process for this Strategy saw the 
establishment of a Cancer Patient Forum, to provide a 
strong patient input and to consider how patient input into 
cancer services can be facilitated more broadly.  The Cancer 
Patient Forum was represented on the Cancer Strategy 
Steering Group to enable it to make a direct contribution 
to the development of this Strategy. In implementing 
this Strategy, it is proposed to establish a Cancer Patient 
Advisory Committee to facilitate continued patient input 
into cancer control measures. 
Service providers, including hospital groups, designated 
cancer centres and community healthcare organisations 
(CHOs) are encouraged to develop structures to 
facilitate patient and public input into cancer services. 
Some hospitals already have patient councils or similar 
programmes for involving patients. In some cases, patients 
will not be in a position to take on a representative role 
until their course of treatment has finished. It is intended 
that patient representation at local level will be expanded 
over the lifetime of this Strategy.
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12.4. Patient Information
A central principle of cancer care is that patients should be 
involved in decisions on their condition and their treatment. 
Cancer is a complex collection of diseases and the number 
of available treatments is expanding. While much of this 
information will be made available to patients as part of their 
diagnosis, treatment and follow up, views expressed in the public 
consultation included that the provision of information should 
go beyond the handing out of leaflets.34 Clinicians and providers 
of services to cancer patients must ensure that information 
is available to patients and their carers in a manner that is 
appropriate, accessible and understood. Specialist oncology 
and haematology nurses have an important role to play in the 
provision of such information to patients. The development of 
Patient Treatment Summary and Care Plans, as outlined below, will 
provide information and empowerment to patients. 
The voluntary sector also provides much information to cancer 
patients through cancer support centres, through ICS Daffodil 
Centres in hospitals and through the work of many charitable 
organisations.
12.5. Treatment Summary and Care Plans for 
Cancer Survivors
Care plans, consisting of a treatment summary and follow-up care 
plan, are useful tools to communicate and coordinate survivorship 
care.  These plans were strongly recommended by the Cancer 
Patient Forum as a vital resource for patients. A number of 
templates and frameworks have been developed internationally 
to advance the use of such plans. Also, a number of barriers 
have been identified to the use of care plans, ranging from time 
constraints, multi-modal treatment records, a lack of role clarity 
and a paucity of data linking care planning and patient outcomes. 
The trend towards electronic patient records and individual health 
identifiers will facilitate the implementation of care planning 
initiatives. Patient Treatment Summary and Care Plans should 
include information about the patient’s cancer, the treatments they 
had and their follow-up care (KPI no. 17).
38
Recommendations
The Department of Health will 
ensure that patient representatives 
are involved in policy making, 
planning, practice and oversight 
of cancer services at local, regional 
and national levels. 
Lead: DoH
The Department of Health will 
establish a Cancer Patient Advisory 
Committee to provide input into 
the development of programmes 
for patients with cancer. 
Membership of this committee 
will reflect the diverse nature of 
patients living with the effects of 
cancer, and will ensure that the 
needs of patients living in more 
remote areas are represented 
Lead: DoH
All hospitals will offer patients a 
Patient Treatment Summary and 
Care Plan as part of their support. 
These plans will allow patients 
to store information about their 
cancer, their cancer treatment and 
their follow up care. The plans 
will also inform future healthcare 
providers. 
Lead: NCCP/HSE
 Designated  Cancer Centres/ 
 Primary Care settings
39
40
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13.1. Introduction
Cancer survivorship begins at the time of diagnosis and 
continues until end of life. There are currently more than 
150,000 cancer survivors in Ireland.35 Survival for some 
common cancers has greatly improved in recent years - 
breast cancer five year survival is now over 80%, while 
the rates for testis, thyroid and prostate cancers are over 
90%. The increased number of survivors underscores the 
importance of addressing survivor health and care needs.
Internationally, survivorship care has been developing 
rapidly in recent years.  There has been increasing 
awareness of cancer survivorship as a distinct period in 
the continuum of cancer care which includes prevention, 
diagnosis, treatment and post treatment care and life 
beyond cancer (Figure 13.1). 
Figure 13.1: The Continuum of Cancer Care
 
SURVIVORSHIP
CHAPTER 13
While caregivers and family members are often seen as 
cancer survivors too, the focus of this Strategy is on people 
who have, or who have had, cancer. For those who have 
metastatic cancer the ‘survivor’ label may not always be 
considered appropriate as these people continue to live 
with cancer every day. Also, since many forms of cancer are 
chronic yet highly survivable, the definition of successful 
treatment can be seen to have shifted toward maximising 
the quality of life of individuals diagnosed with cancer for 
as long as they live. In short, it is not a question of “just 
surviving” - the aim is to maximise quality of life.
The need to develop and promote effective survivorship 
care pathways for patients was highlighted both in the 
public consultation and in the deliberations of the Cancer 
Patient Forum. 
Two main themes emerged:
• The need for a continuum of care so that people 
would have a means of access back to their treatment 
providers as required. Some spoke of being ‘on their 
own’ once they exit the hospital system and the link 
is partly needed for reassurance and psychological 
support, rather than for renewal of treatment; and
• The realisation of a life beyond cancer in the sense 
of optimising the quality of life. This could range 
from achieving a level of pain-free contentment to 
assimilation back into the workforce.
35 Data collected from 1994 onwards.
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Much of the focus of care for cancer survivors is on services, 
information and resources for patients after curative 
treatment is complete, or for those on maintenance and 
prophylactic therapy.  The number of male and female 
survivors is similar and approximately half of all survivors 
comprise women with breast cancer and men with prostate 
cancer. In a significant number of cases, a greater emphasis 
on long term surveillance will be required in view of the 
increased risk of likely health complications, including the 
development of second cancers. With the increasing overall 
numbers involved, this is likely to require considerable effort 
on the part of healthcare professionals and is likely to have 
an increasing impact on overall resources.
A focus on high quality survivorship can empower patients 
to achieve their best possible health outcomes while living 
with and beyond a diagnosis of cancer.  The goal for many 
cancer survivors will be to return to as normal a life as 
possible, including return to work in many cases. Employers 
should endeavour to support the successful transition 
of cancer survivors back to work.  As survivor numbers 
continue to rise, and as treatment improves, the overall 
beneficial economic impact of people returning to work will 
be substantial.36 To ensure a coordinated national approach 
to addressing the multiple issues that arise, the NCCP will 
undertake a Cancer Survivorship Needs Assessment with 
the aim of developing an appropriate model of survivorship 
healthcare for Ireland.
Recommendation
The NCCP, in conjunction with the ICGP, cancer centres, the Irish Cancer Society and cancer support 
centres, will conduct a Cancer Survivorship Needs Assessment to ascertain the most suitable model of 
survivorship healthcare. The Needs Assessment will be completed by the end of 2018.
Lead: NCCP
41
36  OECD, Health at a Glance 2015 (2015).
13.2. Elements of Survivorship Care
Survivorship care involves the delivery of health care services specifically designed for cancer survivors, including patients 
who are living with cancer until the end of life. Figure 13.2 below describes the main components of survivorship care.
Figure 13.2: Elements of Survivorship Care
• Prevention and detection of new cancers 
and surveillance for recurrent cancer
• Monitoring and interventions for long term 
and late effects of cancer and its therapies
• Coordination between specialists and 
primary care providers to ensure that 
survivors’ needs are met and providing 
referral as needed
• Monitoring and intervention as needed for 
psychological and social effects 
• Encouragement of self-management with 
support
• Information and health education
• Familial genetic risk assessment, if deemed 
necessary
110
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13.3. Quality in Survivorship Care
Cancer survivors can require life-long, evidenced-based health care, both preventive and general 
medical, as well as psychosocial care and care specific to the cancer diagnosis.  The patient pathway 
is complex and requires co-ordination across the health service. In particular it requires coordination 
between specialist and primary care to provide safe, high quality and effective responses. Follow-up and 
surveillance should be standardised and delivered close to the patient in an evidence-based manner with 
facilitated re-entry to specialist care as required.  Survivorship care should address the general health 
needs of patients with respect to chronic disease management and co-morbidities.  Programmes of 
information, advice and engagement, that highlight the importance of lifestyle and cancer prevention, 
should be provided. 
Recommendation
The NCCP, in conjunction with the cancer centres, will develop shared care 
protocols for patients with cancer following treatment.  These protocols will span 
the hospital and primary care settings. 
Lead: NCCP
While the majority of cancer survivors live well and do not have significant on-going needs, some 
survivors face distinct and serious health care issues. It is estimated that 25% of cancer survivors will 
have one or more physical or psychological consequences of their cancer treatment that affects their life 
to a greater or lesser degree in the long-term. Those who are poor, isolated, living alone or elderly are 
likely to have the greatest need.
13.4. Survivorship and Lifestyle
Although research into the lifestyle benefits (e.g. from good nutrition or physical exercise) for cancer 
survivors is at an early stage, there is emerging evidence that appropriately modified lifestyle behaviours 
can reduce recurrence rates for certain cancers.  Evidence in breast, prostate and colorectal cancer, 
in particular, suggests the possibility of decreased mortality with physical activity for cancer survivors.  
Physical activity improves heart health and may also counteract long-term effects of cancer treatments 
such as chronic fatigue and cardiotoxicity.  The evidence on smoking cessation for cancer survivors is 
incontrovertible and, where necessary, smokers should be given appropriate smoking cessation supports 
as part of their treatment regime and care planning.  Generally cancer survivors will be encouraged to 
follow the same guidance for reducing cancer risk as the general population. 
42
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13.5. Late and Chronic Effects of Cancer Treatment 
Cancer and its treatment can have a wide range of adverse effects, 
including physical, psychosocial, social and financial, on patients and their 
families.  Exacerbations of pre-existing conditions may also develop. Effective 
management of these effects is central to good survivorship care.  Adverse 
effects that are not addressed in the first year post completion of acute 
treatment are significantly more likely to become chronic requiring greater 
levels of on-going care.
Some side effects from cancer treatment are inevitable given the nature 
of that treatment.  The effect on quality of life varies with the cancer type, 
treatment and stage at diagnosis. Although some treatment effects can 
be short-term, for a substantial minority of patients problems following 
treatment can persist and become long-term.  These can include urinary 
and sexual dysfunction, lymphoedema and reduced fertility.  Late effects of 
cancer treatments, such as osteoporosis, heart disease and the development 
of second cancers, may not arise for many months or years after treatment.  
This highlights the need for information on late and chronic effects to form 
part of appropriate treatment summaries and care plans for all patients.  
Childhood and adolescent/young adult cancer survivors require specific late 
effects support as they can experience a wide range of treatment related 
toxicities that, in some cases, result in serious health complications. In 
developing survivorship programmes, particular attention will be required to 
address the needs of this group.
 
13.6. The Role of Primary Care 
Primary care services are the appropriate setting for a greater proportion 
of protocol-driven survivorship care. Currently much survivorship care is 
delivered in follow-up clinics in hospitals.  Primary care must be supported 
to increase its involvement in follow-up care through the provision of 
appropriate guidelines, with educational support and through clear lines of 
communication, while maintaining easy access back to the hospital setting as 
required.  
Coming through a 
cancer diagnosis 
brings many new 
physical, mental 
and emotional 
challenges. We 
need to concentrate 
on creating strong 
supports for these 
areas so as to 
allow people to 
integrate back 
into family and 
society so that they 
can contribute 
competently and 
rebuild themselves 
strongly 
RESPONDENT, PUBLIC CONSULTATION
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Patients often garner considerable reassurance from 
follow-up care delivered in hospital clinics.  Evaluation of 
alternative models of care has found that both primary 
care services, and nurse-led care, are equally effective for 
detecting recurrence.  Patients need to be encouraged to 
realise the benefits of convenience, familiarity, physician 
knowledge of family circumstances and the treatment 
of co-morbidities that general practice can deliver.  This 
is particularly important given that many older cancer 
survivors have complex health conditions such as diabetes 
and coronary artery disease.  Primary care services will 
be supported by hospital-based care with specialist 
oncology nurse-led clinics, using remote follow up where 
appropriate.
13.7. Self-care for Cancer Survivors 
A key goal of survivorship care is to empower patients to 
achieve their best possible health. This involves providing 
knowledge, guidance and support to survivors and 
families in relation to healthy lifestyle, disease prevention 
and disease control so as to aim for a good quality of life 
and prolonged survival.  Patients should be educated to 
recognise the warning signs of potential recurrence or 
new cancers.  Supported self-management can improve 
general physical health, including preventing and managing 
co-morbidities. Programmes should be developed to 
encourage survivors to take responsibility for their follow-
up care and their general health and services should offer 
self-management support.
13.8. Psychosocial Care for Cancer Survivors 
Dedicated psycho-oncology services and strengthened 
psycho-social support are essential across the patient 
pathway.  Approximately 20% to 30% of patients with 
cancer will develop some form of psychological disorder 
across their cancer trajectory, including in the survivorship 
phase. Development and delivery of comprehensive psycho-
oncology services, from diagnosis into the survivorship 
phase, is a major focus of this Strategy (See Section 10.9).  
Such support can greatly impact on the patient experience 
of cancer care. Furthermore, available evidence indicates 
that patients with cancer who have their psychosocial 
needs addressed have better outcomes and superior quality 
of life. 
 
13.9. The Role of the Voluntary Sector
A Strategy for Cancer Control in Ireland (2006) 
recognised the need for the organisation of voluntary 
sector psychosocial support services in Ireland.  In response 
to this, the ICS developed a programme of activities aimed 
at supporting good practice and governance in cancer 
support centres throughout Ireland.  This programme 
includes good practice guidelines and policy templates 
that cancer support centres can use/adapt for their 
services.  This approach has facilitated the development 
of broadly standardised high quality services that provide 
much needed support to patients outside of the acute care 
setting.  While not every cancer support centre is affiliated 
to this process, almost all centres adhere to standards that 
ensure equity of access that is free of charge. 
Drop in centres…provide the 
security blanket and get you 
to take baby steps to get you 
back living and managing 
and taking responsibility 
for your own health
RESPONDENT, PUBLIC CONSULTATION
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While cancer support centres in the community are a 
valuable resource, many patients are not aware of the 
existence of these services, and there are no structured 
referral pathways between hospitals and support 
centres.  Development and implementation of dedicated 
survivorship programmes, as envisaged in this Strategy, 
could have a profound impact on the quality of life of 
many who are living with the effects of a cancer diagnosis.  
Such programmes will address both the physical and 
psychosocial aspects of survivorship, and will include the 
provision of practical support in areas such as lifestyle and 
financial advice.
  The patient is 
pointed to charity 
support units and this 
is not easily accessed 
by all, it is location 
dependent. Support 
is dependent on local 
funding
MEMBER, PATIENT FORUM
Recommendation
Designated cancer centres working with the NCCP, the ICGP, primary care 
services, patients and voluntary organisations will develop and implement 
survivorship programmes. These programmes will emphasise physical, 
psychological and social factors that affect health and wellbeing, while 
being adaptable to patients with specific survivorship needs following their 
treatment.  
Lead: NCCP 
          Designated Cancer Centres
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ENABLING AND  
ASSURING CHANGE 
SECTION E
• Strengthen the role of the NCCP in the oversight of cancer control 
and in implementing the recommendations of the Strategy
• Ensure on-going workforce planning to fulfil changing needs
• Utilise technology, research and data to create a sustainable, high 
quality and accountable cancer service 
• Build better systems and processes to ensure evidence-based 
prioritisation and service delivery
OBJECTIVES
NATIONAL CANCER STRATEGY  2017-2026
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14.1. Introduction
Strong governance is highlighted by the WHO, the OECD 
and the European Union as a key requirement of cancer 
control systems.  Effective governance structures, together 
with a comprehensive approach to the prevention, 
detection and treatment of cancer, are necessary to 
ensure that the objectives of this cancer strategy will be 
implemented.  A well designed system will provide for 
effective cancer control policies and plans across the full 
spectrum of cancer services and across all elements of the 
patient pathway, encompassing prevention, screening, early 
diagnosis, treatment and survivorship.  
The Evaluation Report on the implementation of A 
Strategy for Cancer Control in Ireland (2006) stated 
that the most significant factor that has contributed to 
driving changes in the system was the establishment of the 
National Cancer Control Programme (NCCP) in the HSE in 
2007.  The Evaluation Report emphasised that the NCCP 
should continue overseeing the development of the Irish 
cancer care system. 
GOVERNANCE AND 
MANAGEMENT OF CANCER 
SERVICES AND THE ROLE 
OF THE NATIONAL CANCER 
CONTROL PROGRAMME
CHAPTER 14
14.2. Strengthening the Role of the NCCP 
The adoption of a programmatic approach to cancer 
control is recommended internationally in order to harness 
the necessary policy responses, ensure equity of access 
to services and ultimately deliver improved outcomes for 
patients.  The NCCP works with the Department of Health, 
the Health & Wellbeing Directorate of the HSE, Hospital 
Groups, community healthcare organisations and training, 
accreditation and professional bodies to achieve these aims.
The NCCP provides leadership across the continuum of cancer 
care.  It promotes the provision of high quality evidence-
based care to optimise outcomes and patient experience. The 
functions, work areas and achievements of the NCCP since its 
establishment have been documented in its seven year report, 
published in 2014. The overall strategic input and impact of 
the NCCP will continue to be in the following areas:
• Leading on the implementation of cancer policy and on 
the development of cancer services including in the areas 
of prevention and survivorship;
• Defining evidence-based guidelines and practice in cancer 
care;
• Commissioning and monitoring service provision;
• Leading on the implementation of capital projects to 
ensure optimum patient access to diagnostics and 
treatment; and
• Developing programmes to promote best practice in 
cancer care, including workforce planning and education/
training programmes.
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The attainment of the vision, goals and objectives of 
this Strategy requires a continued commitment to the 
population based approach to cancer control through an 
improved model of care with leadership from the NCCP.
14.2.1 Leadership and direction 
The NCCP, including through its role on the HSE Leadership 
Team, will continue to provide leadership and direction 
to the cancer system to ensure that service priorities are 
aligned with desired outcomes. The NCCP will work 
closely with Hospital Groups and community healthcare 
organisations to lead service reorganisation and to ensure 
that integrated care pathways are provided for those 
affected by cancer. The NCCP will be the lead actor in the 
HSE in the implementation of this cancer strategy and will 
work to ensure that the objectives of the Strategy underpin 
decisions on cancer care across the health services.
14.2.2 Funding and commissioning
The NCCP is actively engaged in the funding and 
commissioning of cancer services. It currently coordinates 
funding for new cancer developments, including oncology 
drugs. The NCCP’s role in the commissioning of services 
is supported by its membership on the Consultants 
Applications Advisory Committee which allows it to 
influence the appointment and location of new consultant 
posts.
In order to strengthen its leadership of the cancer services 
and to drive service improvements, the NCCP will take on 
an enhanced role in the funding and commissioning of 
cancer services, including through Service Level Agreements 
(SLAs) aligned to the implementation of Activity Based 
Funding (ABF). This will include the linking of funding with 
strategic priorities and performance monitoring. The NCCP 
will retain responsibility for all new HSE funding for cancer 
services and related posts in the annual national service 
planning process. The enhanced funding role envisaged for 
the NCCP will extend to the use of existing funding and 
will not be confined to additional funding. This approach 
will involve rewarding good performance and reviewing the 
continued provision of funding to hospitals not providing 
the high quality services mandated by the NCCP including 
adherence to National Standards and NCEC National 
Clinical Guidelines as appropriate. ABF will facilitate the 
promotion of high quality cancer services. 
  
The NCCP currently plays a central role in the development 
of new radiation oncology facilities in the public sector. In 
the future, it must play a more central role in the planning 
and commissioning of new and replacement of all health 
infrastructures with a cancer component.    
14.2.3 Oversight and performance review
The NCCP will continue its strong oversight of cancer 
services, including monitoring the provision of services 
against agreed performance criteria as set out in the HSE 
Performance and Accountability Framework. SLAs will be 
entered into with the Hospital Groups. Implementation of 
these services will be audited with a focus on achieving 
agreed outputs and outcomes. Findings will be published 
annually. This process will be supported by the cancer 
intelligence function within the NCCP and will also build 
on other data sources such as the National Cancer Registry.  
The audit mechanism is essential to support the evidence 
base for the provision of services, including the provision of 
specialist services in designated cancer centres. The NCCP 
will support best practice and the SLAs with the hospital 
groups will provide a mechanism to address suboptimal 
performance issues.
The NCCP has significant authority over cancer control 
services in the public sector in order to ensure that they are 
in line with national policies and international best practice. 
This includes the authority to direct the discontinuation 
of any services that are not in line with agreed policy, or 
that do not meet required standards. Where clinical and 
performance targets are not being met, the NCCP will be in 
a position to move specific services and related resources to 
other designated cancer centres. There may also be scope 
to define details of the indemnity cover provided for HSE 
funded hospitals on the basis of specific surgical oncology 
procedures. 
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14.2.4 Developing a mechanism for prioritising new 
developments in cancer care
New developments in cancer care are emerging rapidly. It 
is essential that a robust, evidence-based mechanism for 
assessing, evaluating and prioritising the implementation 
of these new developments is put in place. The NCCP will 
develop such a mechanism and ensure that it is used to 
evaluate new developments in a manner that takes into 
account the potential benefit to patients in terms of quality 
of life and outcomes and also ensures that it makes the 
best possible use of available resources. 
14.2.5 Leading service improvements
The NCCP will lead on the development and introduction 
of service improvements through an on-going review of 
cancer control measures in Ireland and internationally. This 
will be based on an assessment of best practice and, where 
appropriate, may involve the use of economic evaluations 
and HTAs. The main area of focus will of necessity continue 
to be on the diagnosis and treatment of cancer. However, 
other areas in which the NCCP can play a significant 
role include prevention, screening and survivorship.  The 
development of the NCCP’s cancer intelligence function to 
collate and interrogate the multiple sources of cancer data 
currently available, and coming on stream, should also be 
a priority.  This latter function will inform a further area of 
significant need - the provision and implementation of a 
coherent and comprehensive cancer workforce plan.
The NCCP will continue to develop standards for cancer 
care in Ireland through its National Guideline Development 
Groups. 
14.2.6 The role of the NCCP with regard to cancer care 
in the private sector
A significant proportion of cancer care is provided in the 
private sector. However, the NCCP has no statutory role in 
the supervision or regulation of cancer care in such settings. 
In order to ensure optimum patient care in all sectors 
of cancer care, the NCCP and private sector providers 
should work together to achieve voluntary participation 
in data collection, audit, compliance with guidelines and 
Recommendation
The central role of the NCCP in 
ensuring that the National Cancer 
Strategy 2017-2026 is implemented 
across the health service will be 
strengthened, including through 
the use of Service Level Agreements, 
and through a direct role in financial 
allocations to Hospital Groups under 
Activity Based Funding.
Lead: NCCP
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reporting of outcomes.  Such a programme should be 
designed to offer reassurance to patients, many of whom 
move between the public and private sector care on the 
patient pathway, and funders concerning the standards 
being achieved in the private sector. The forthcoming 
Patient Safety (Licensing of Healthcare Facilities) Bill, which 
includes provisions on hospital licensing, will aim to ensure 
that cancer treatment only takes place in hospitals, public 
or private, that meet criteria set out in relation to data 
collection, audit, compliance with guidelines and reporting 
of outcomes.
Recommendation
The NCCP will work with the private 
sector providers to achieve voluntary 
participation in cancer data collection, 
audit, compliance with guidelines and 
reporting of outcomes.
Lead: NCCP
45
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15.1. Introduction
The positive impact of research activity, including clinical 
trials, on the care of patients is universally accepted. The 
development of  a culture in the cancer care system that 
values research to the benefit of patients, and is supportive 
of those who engage in it, is an aim of this Strategy.  
Cancer research supports the recruitment, retention and 
motivation of clinical staff who will drive the development 
of quality services.  Research is multi-disciplinary and 
engages professionals from a variety of backgrounds, from 
basic science through to translational, clinical and health 
services research.  It requires infrastructure and supports 
appropriate to these different environments, as well as 
a healthcare system that is supportive.  Also, academic 
and clinical researchers are a major skill base asset for the 
pharmaceutical sector, which is itself a major contributor to 
the Irish economy.  
National state funding for cancer research is estimated 
to be in the region of €25m- €30m per annum.  This 
represents approximately 20% of the overall health 
research spend, a similar percentage to that applying in 
the UK, though the overall funding for health research 
in Ireland relative to the size of the healthcare budget is 
significantly lower than in the UK.
RESEARCH
CHAPTER 15
15.2. The Environment for Cancer Research
Cancer research is carried out across all the designated 
cancer centres, Universities and in many other settings.  
The breadth of research ranges from the discovery and 
validation of biomarkers for diagnosis, to nutritional 
studies, psychological and social supports for patients with 
cancer and survivors, clinical trials of new interventions 
and research on the sustainable configuration of cancer 
services.  The cancer research community is represented by 
the Irish Association for Cancer Research (IACR), a non-
profit organisation focused on bringing multidisciplinary 
researchers together to generate a world-class research 
environment in Ireland.  Where access to patients, their 
samples or their data is needed for research, the HPRA and 
the recognised Research Ethics Committees (RECs) play a 
key role in overseeing and regulating research.  
The National Cancer Registry (NCR) collects, collates and 
analyses data on cancer incidence, staging, treatment and 
survival. Mortality data is collected and published by the 
Central Statistics Office.  The NCR also contributes to the 
majority of epidemiological and statistical research in this 
field. The National Centre for Pharmacoeconomics (NCPE) 
carries out HTAs for cancer drugs.  For clinical research, 
infrastructure supports such as the Health Research 
Board (HRB) Clinical Research Facilities and the HRB Trials 
Methodology Research Network are synergistic.  Although 
they are not disease-specific, these infrastructures support 
high quality cancer research.  University-based research is 
supported by a variety of departments including medicine, 
nursing, health and social care, psychology, health 
economics, mathematics, business schools and engineering. 
In addition, HIQA provides guidance for conducting 
HTAs and a HTA service for assessment of appropriate 
technologies.
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The largest collaborative cancer research infrastructure 
in Ireland is Cancer Trials Ireland. Cancer Trials 
Ireland, which has almost 500 members, is a 
network encompassing a central office in Dublin 
(hub) supporting clinical cancer trials units in the 
cancer centres (spokes).  Virtually all oncologists and 
haematologists in Ireland are active participants, as 
well as research specialists such as research nurses and 
translational researchers.  In 2014, Cancer Trials Ireland 
had almost 8,800 patients on active studies.  They 
are funded by the HRB, the Irish Cancer Society (ICS) 
and by industry.  Some pharmaceutical and clinical 
diagnostics companies have a clinical cancer research 
base in Ireland and they work closely with Cancer Trials 
Ireland, and cancer treating hospitals, to evaluate the 
impact, relevance and utility of emerging diagnostic 
and treatment approaches.  Arising from this, Irish 
patients have often had unique access to vital new 
therapeutic advances.  In 2014 approximately 3% of 
all patients with cancer in Ireland were taking part in a 
clinical trial, and another 6% were involved in a non-
interventional study (KPI no. 20).
15.3. Funding for Cancer Research
Cancer research in Ireland is funded from a variety of 
sources.  The HRB’s investment in such research over 
the last decade has accounted for 20% of its budget, 
a significant portion of which has gone to support the 
work of Cancer Trials Ireland.  Since its foundation in 
2000, Science Foundation Ireland (SFI) has invested 
approximately €100m in cancer research. This includes 
the recent establishment of a Blood Cancer Clinical Trial 
Network jointly funded with the ICS. Cancer research 
is also funded by some charities, principally the ICS 
which has invested over €25m in research over the 
last decade.  From a background of funding individual 
Fellows and projects, the ICS has moved to funding 
larger, co-operative awards.  (e.g. funding of €7.5m for 
Breast Predict as a large inter-institutional collaboration 
across disciplines).  
15.4. Planning and Coordination
To significantly increase the beneficial impact of clinical, 
laboratory, translational and population research on 
outcomes for patients in Ireland, a number of steps need 
to be taken over the coming years.  A key challenge is 
the absence of an overarching national framework for 
cancer research in Ireland.  There is potential for better 
coordination between different initiatives and research 
entities, as well as between Governmental and private 
agencies.  Also, research investment across different 
cancers may not reflect their relative incidence, emerging 
patient needs or the national burden of disease.
Research priorities, linked to this Strategy, should be 
defined within the first year of the Strategy’s publication.  
The NCCP will establish a National Cancer Research Group: 
• to monitor and influence national investment in cancer 
research;
• to foster and promote a supportive environment for 
cancer research; and 
• to improve co-ordination of cancer research, aligned 
to this Strategy and to the priorities identified by the 
NCCP over the lifetime of the Strategy.  
It is envisaged that the HRB will be represented on this 
Group, and that the newly appointed HSE lead for research 
will also be included. 
Recommendation
The NCCP will establish a National Cancer 
Research Group by end-2017 to improve the 
coordination of cancer research, to foster a 
supportive environment for research within 
the health service and the universities, 
to set research priorities in line with the 
overall cancer strategy, to seek to ensure 
that funding allocation is linked to these 
priorities and to work to achieve continuity 
of funding. 
Lead: NCCP
46
122
C
H
A
P
T
E
R
 1
5
  
  
 R
E
S
E
A
R
C
H
NATIONAL CANCER STRATEGY  2017-2026
15.5. People and Leadership
The absence of recognition, stable funding and defined 
paths of career progression for research staff represent 
significant impediments to the progress of cancer research 
in Ireland.  There is a lack of appreciation within the health 
service that research is a relevant, vital and critical activity.  
Cancer clinical trials should be a core activity of cancer 
centres.  The current funding mechanism for staff in cancer 
clinical trials units is via recurrent iterations of HRB grants.  
This has resulted in the proliferation of temporary positions 
in these units that are unattractive to highly trained staff 
and, thus, are difficult to fill.  The National Cancer Research 
Group should work to address this problem.  This Group 
should also examine the stability of funding of Cancer Trials 
Ireland, with a view to enabling it to support longer-term 
multi-annual commitments and to complete research of 
critical national importance.
Finally, the NCCP and the National Cancer Research 
Group should examine mechanisms to ensure that newly 
appointed consultant cancer specialists have truly protected 
time to pursue research interests in their new posts.
Recommendations
The HSE will ensure that clinical cancer 
research, and the staff who deliver it, 
become a fully integrated component 
of cancer care delivery.
Lead: HSE
The NCCP and the National Cancer 
Research Group will examine 
mechanisms to ensure that newly 
appointed cancer consultants and 
Advanced Nurse Practitioners have 
protected time to pursue research 
interests in their new posts.
Lead: NCCP/National Cancer Research 
Group
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15.6. Cancer Research Infrastructure
Ireland has made significant progress with the development of 
infrastructure for cancer research, including Cancer Trials Ireland, the 
NCR and a network of Clinical Research Facilities/Clinical Research 
Centres.  It is most important that we grow and support integrated 
translational and clinical trial infrastructure.  Enrolling 6% of patients 
with cancer on therapeutic trials annually is a goal of this Strategy 
(see KPIs in Chapter 17). This will result in a doubling of the current 
figure of 3% described above.
The National Cancer Research Group should also develop proposals 
for a coherent and integrated approach to cancer biobanking, in 
line with broader national developments on biobanking, and with a 
focus on standards, quality and access, to achieve an internationally 
compliant biobanking resource within the lifetime of the Strategy. 
Effective ethical supervision is critical to the successful conduct of 
clinical trials. Under the EU Directive and the Clinical Trials Regulations 
2004 for medicinal products, studies evaluating investigational new 
drugs only require approval from one Recognised Ethics Committee.  
However, for other studies, such as translational, epidemiological 
or biomarker studies, Ethics Committees supervising each individual 
research site require separate approvals.  It is envisaged that the 
research ethics approval process for such studies will in future be 
streamlined under the proposed Health Information and Patient 
Safety Bill.   Under this legislation, it is proposed that a single ethical 
approval will be involved for national or regional human health 
research.  Among the other measures proposed in the Bill is the 
nomination of HIQA, as the supervisory body for Approved Research 
Ethics Committees. 
15.7. Patient Engagement in Research 
Patient involvement in cancer research improves the relevance of 
research questions, the quality, acceptability and feasibility of research 
conduct and the likelihood of uptake of research outputs. The 
National Cancer Research Group will look at ways to optimise patient 
input to cancer research.
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WORKFORCE PLANNING
CHAPTER 16
16.1. Introduction
Cancer care, like many other areas of health care, is 
resource intensive.  Staffing is a key part of this resource 
and is the major contributor to both processes and 
outcomes in cancer care. Without highly trained and 
educated staff, the significant improvements in cancer 
care seen in the past decade would not have occurred.  A 
key aim of this Strategy is to ensure that the appropriate 
workforce is in place to deliver on its goals and 
recommendations. This implies an adequate number of 
staff, with core competencies in cancer care, working at the 
top of their scope of practice. This will include addressing 
immediate workforce gaps in areas such as medical 
oncology, urology and nursing. The provision of additional 
staff across all disciplines will require a coordinated effort 
by the NCCP, other Directorates in the HSE, the Department 
of Health, the education sector and regulatory authorities.
It is difficult to quantify the number of staff involved in 
cancer care in Ireland.  Many health professionals, such as 
general practitioners, for example, play a significant role 
in the early assessment and referral of patients and are 
also involved in the follow up of patients after treatment.  
Similarly, in our hospitals, many staff in departments such 
as radiology, dermatology, pathology, physiotherapy, 
surgery, haematology and gastroenterology are involved in 
the care of patients with benign and malignant conditions.  
The increased cancer workload, and increased complexity 
of therapy, will have significant implications for workforce 
planning in several of these specialities where cancer forms 
a major component of day to day working.  Examples 
include the core diagnostic specialities of radiology and 
pathology, as well as dermatology, where the implications 
of the increased burden of skin cancers for workforce 
planning are clear.  
Of course many health professionals are wholly, or 
predominantly, involved in cancer care, such as specialist 
oncology nurses, radiation therapists and consultant 
radiation and medical oncologists. Other staff who may 
work exclusively in cancer care include data managers, MDT 
coordinators and cancer research staff.
16.2. Evaluation Group Assessment of the 
Current Workforce
In its report on A Strategy for Cancer Control in Ireland 
(2006), the Evaluation Group made a number of findings and 
recommendations in relation to the cancer workforce.  The 
Group believed that there are significant opportunities for the 
deployment of new models of care.  They recommended the 
establishment of comprehensive multidisciplinary oncology 
teams, underpinned by service specifications that embrace a 
major and increased role for clinical nurse specialists (CNS), 
advanced nurse practitioners (ANP) and health and social 
care professionals (HSCP) in patient assessment, delivery of 
treatment, survivorship and end-of-life care.  
The Evaluation Group recommended that acute staffing 
shortages in all areas of cancer care in Ireland, including 
medical, nursing, health and social care professions be 
addressed as soon as possible.  They made particular 
reference to nursing shortages in chemotherapy units, the 
lack of ANPs, the widespread use of agency nurses, a severe 
shortage in health and social care disciplines, including 
pharmacists and dieticians, and a lack of rehabilitation 
staff.  They were of the opinion that the number of medical 
oncologists in the country was just over half that which 
international standards would suggest as appropriate. They 
also pointed to a shortage of urologists leading to regional 
variations in access to rapid access prostate cancer clinics. 
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A clear model of care is the starting point for the 
development of a workforce plan in any area of the health 
service. A number of the HSE clinical programmes have 
recently developed models of care, which have informed 
their workforce plans (e.g. orthopaedic surgery and 
paediatrics). Experience gained in developing these plans 
should be useful in the development of a workforce plan 
for oncology services.
16.3. Areas that Require Investment
While it is not possible at this point to make definitive 
assessments of the changing or additional needs for the 
cancer workforce over a ten year period, the following are 
areas which require urgent attention:
16.3.1 Surgical oncology services
Surgical staff are a critical part of the cancer MDT 
workforce but, unlike some other specialists, most surgeons 
work on both cancer and benign disease.  This makes 
it more difficult to predict workforce needs for cancer 
separate to overall requirements. The Evaluation Report 
highlighted consultant staff requirements in urology, in 
particular, as requiring urgent attention. Other staff clearly 
required to support surgical oncology programmes include 
specialist nurses, physiotherapists, speech and language 
therapists and dieticians, with the specific skills mix required 
being dependent on site specialisation and the completion 
of the programme for centralisation of cancer surgery. 
16.3.2 Radiation oncology services
These services have expanded in line with increased 
demand and developments in technology.  Along with 
this, radiation oncology therapy has become increasingly 
tumour-site specialised. There is, therefore, a need for 
consultant staffing to take account of specialisation within 
the profession, while maintaining the requirements for 
comprehensive cover at each centre. In addition, there is 
a need to increase the number of advanced practice roles 
for radiation therapists and nurses to manage patients 
both through the acute phase of their radiotherapy and in 
follow-up care. 
16.3.3 Medical oncology services
As referenced in the Evaluation Report, there is a pressing 
need to increase staffing in medical oncology units. This 
involves an immediate need to address existing deficits 
for consultant medical oncologists and also to plan for 
the additional requirements resulting from the forecasted 
increase in cancer incidence, as well as the increasing 
complexity of medical oncology therapies.  Staffing 
of haematology services also needs to be addressed.  
Additional medical oncology nursing resources (including 
CNSs and ANPs) are also required, not only to manage 
the increasing numbers of patients on therapy, but also 
to develop nurse-led follow-up programmes. There is also 
a need for more pharmacists and other health and social 
care professionals, as well as liaison psychiatry, in medical 
oncology units. 
 
16.3.4 Oncology and haematology nursing
 Nurses comprise one third of the total healthcare 
workforce and are ideally placed to play a variety of 
essential roles in cancer care, some in highly specialised 
posts and others contributing to multiple phases of the 
patient pathway. There is a growing body of international 
evidence outlining the beneficial impact of emerging 
nursing roles in the delivery of care. In the cancer setting, 
these include generalist nurses, specialist oncology and 
haematology nurses, CNSs and ANPs.
There is very significant scope and need to expand 
the number and roles of CNSs and ANPs in our cancer 
services, in areas such as nurse-led clinics for new patient 
assessment, oral chemotherapy, follow-up support and 
survivorship. The immediate expansion of such nursing 
roles will be a priority for workforce planning by the NCCP.
The provision of additional specialist cancer nurses will 
require a coordinated effort by the NCCP, the HSE more 
broadly, the Department of Health, nursing regulatory 
authorities, hospitals and universities.  At present there are 
significant impediments to the training, recruitment and 
retention of specialist oncology nurses that need to be 
addressed. Various issues, such as support for postgraduate 
education, will need to be reviewed.  Specialist nurses will 
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require administrative support to enable them to effectively 
fulfil their clinical roles.  
The long and complicated pathway to advanced nursing 
practice has acted as an impediment to the recruitment 
to, and development of, such roles. A new developmental 
pathway for graduate, specialist and advanced practice 
nurses is being established.  This will include tackling 
the barriers that discourage nurses from pursuing higher 
qualifications, reducing the  time involved in  developing 
the skills, knowledge and experience to take up advanced 
nursing practice positions and breaking the individual 
nurse/advanced nursing post link to better facilitate 
continuity of high level services.  To drive these changes in 
the cancer area, and to maximise their impact on cancer 
nursing services to the benefit of patients, the NCCP will 
appoint a national clinical lead for cancer nursing. 
Recommendation
The NCCP will appoint a National 
Clinical Lead for Cancer Nursing.  
This person will work with other 
Directorates in the HSE and with the 
Department of Health to determine 
an integrated nursing leadership 
infrastructure for cancer nursing 
services at national, regional and local 
levels to support practice and research.
Lead: NCCP
49
16.3.5 Health and social care professionals 
Health and social care professionals (HSCPs) comprise a wide range of grades and professions that are involved at many 
stages of the cancer care pathway, including radiographers, sonographers, pharmacists, physicists and medical scientists, 
medical social workers, psychologists, dentists and the therapy professions. Speech and language therapists, occupational 
therapists and physiotherapists, for example, are vital for patient recovery from surgery and radiation therapists and 
physicists are an essential part of radiation oncology services. Pharmacists play an important role in the treatment of 
cancer patients, both in the hospital and the community, and greater support for community pharmacists is required 
to allow them to provide oral anti-cancer medicines and to counsel patients in a safe and effective manner. Our cancer 
services in general suffer from a lack of these vitally important staff and this will need to be addressed on a phased basis 
focusing initially on areas of most critical need. The number of HSCPs graduating from Irish Universities, particularly in the 
area of radiography, is also a concern, and this will need to be addressed over the course of the Strategy.
16.3.6 Research
As outlined in Chapter 15, there is a need to review the career structure of research staff to align the research and clinical 
needs of organisations conducting research, including cancer clinical trial units. Such staff should integrate fully into the 
mainstream of cancer care.  
16.3.7 Leadership
Additional leadership roles for clinicians and non-clinicians will need to be developed to support the implementation 
of the Strategy.  In addition, clinical leads to develop specific areas outlined in the Strategy are required in, geriatric 
oncology, molecular cancer diagnostics and psycho-oncology.  An oncology nursing leadership development programme 
should also be considered, as recommended by the Strategy Evaluation Group. There is also a need to ensure that the 
leadership role of the NCCP, across all disciplines, is supported.
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16.3.8 Other cancer staff
A number of service developments outlined in this Strategy will have 
workforce planning implications. There have been rapid developments 
in several clinical areas, largely driven by technological advances and 
increased specialisation, that will require additional resources.  These 
include cancer genetics, molecular diagnostics, geriatric oncology and 
psycho-oncology.
Data managers, MDT co-ordinators and other staff should be in place 
at designated cancer centres to facilitate the efficient operation of the 
entire cancer care system.  Some additional staff will also be required 
in the NCCP to reflect their responsibilities arising from this Strategy.
16.4. A Workforce Planning Framework for Cancer Care
The Department of Health  is working on the development and 
implementation of a national integrated strategic framework for 
health workforce planning. The framework is intended to support the 
optimisation of the existing workforce, recruitment and retention, and 
the optimum mix of skills and competences for the future, across the 
health system. Once the framework is in place, it is expected that a 
collaborative multi-disciplinary approach to health workforce planning 
will be adopted, informed by policy, strategy and the agreed model of 
care.
In the context of the national integrated strategic framework, the 
NCCP will develop a comprehensive workforce planning model for 
cancer in consultation with the Department of Health and other key 
stakeholders.  As a first step an interim assessment of staffing needs 
at medical, nursing and all health and social care professional levels 
will be carried out by mid-2018. This process will take account of 
evidence-based workforce methodologies and will be informed by 
developments internationally.
Recommendation
The NCCP, aided by a cross-
sector group, will draw up 
a comprehensive workforce 
plan for cancer services. 
This will include an interim 
assessment of staffing needs 
at medical, nursing and health 
& social care professional 
levels by mid-2018.
Lead: NCCP
50
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DELIVERING RESULTS: 
MEASURING PERFORMANCE, 
QUALITY AND OUTCOMES
CHAPTER 17
17.1. Introduction
Measuring the performance and quality of cancer care services and programmes is essential to ensure that the objectives 
of this Strategy are being met.  Provision of accurate and timely information is a central requirement of any effective 
strategy of cancer control.  Such information underpins evidence-based and informed decision making by policy makers, 
researchers, health professionals and patients.
17.2. Cancer Data
The lack of an integrated information system across the entire health service 
is the major obstacle in providing accessible and shareable management 
information to measure performance and to inform future policy.
The health system currently captures a large amount of data in a myriad 
of electronic and manual formats.  Some of the information can be used 
to measure cancer trends, record cancer system activity, improve system 
performance and, to an extent, shape policies to improve cancer control. 
Qualitative and quantitative data are available on some population and lifestyle 
issues, and there are limited data on patient experience of treatment and 
palliative care.  Further data can be captured by surveys and research projects.
The multiplicity of data collection sources do not, in general, collect data in a 
uniform manner with agreed datasets, shared definitions or standardised coding 
and classification.  In addition, while much data are available from sources 
such as the NCR or HIPE, it is not evident that these are being systematically, 
serially and consistently interrogated to generate information that can drive 
policy.  In the context of an overall approach to management of information 
and information technology across the HSE, it must be a priority to improve 
collaboration between the collectors and the users of cancer data, such as 
the NCR, the NCCP, the NSS, individual hospitals and Hospital Groups, the 
Department of Health and researchers.  It will also be essential to have a clear 
legal and administrative framework for the collection, sharing and reporting of 
cancer data. 
Recommendations
The HSE will ensure that 
all hospitals provide the 
National Cancer Registry 
with data related to 
cancer in an appropriate 
timeframe to allow for 
sufficient surveillance 
of cancer rates and 
outcomes in Ireland.
Lead: HSE
The Department of 
Health will review the 
scope of the National 
Cancer Registry with a 
view to increasing and 
optimising the use of 
available data to drive 
improvements in cancer 
care for patients.
Lead: DoH
          NCCP/NCR
51
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17.3. eHealth and Cancer Data
The introduction of the Individual Health Identifier (IHI) 
will greatly facilitate the more efficient collection of cancer 
data and the resultant reporting of outcome measures.
The eHealth Strategy for Ireland outlines how e-health 
has the potential to transform the delivery of healthcare 
into safer, higher quality, more efficient and easier to 
access systems. It will include integration of financial, 
human resource and clinical systems, facilitating the 
linkage of resource utilisation to individual patients and 
outcomes.  The implementation of eHealth Ireland will 
lead to enhanced care for patients, while facilitating 
aggregation of data for multiple uses.
The introduction of an Electronic Health Record (EHR) 
is the cornerstone of the eHealth Strategy. A national 
EHR will support the creation and sharing of key patient 
information and will consist of core operational solutions 
(such as ePrescribing and Case Management) along with 
the ability to aggregate data into a comprehensive national 
record accessible to health and social care professionals, as 
well as to patients, service users and carers.
eHealth Ireland, working with the NCCP, created a Cancer 
Care IT plan which facilitated the procurement of a new 
Medical Oncology Clinical Information System (MOCIS, 
Section 10.4) which will be integrated into other national 
solutions such as the Individual Health Identifier and the 
Electronic Health Record.  Systems such as MOCIS must 
form part of a larger electronic information network which 
will plot and report on the entire course of care and follow 
up for patients with cancer.
17.4. Reporting Structures
An annual report will be published by the Department 
of Health, with input from other stakeholders, on the 
implementation of this Strategy, with particular focus 
on the implementation of the recommendations and 
the degree to which Key Performance Indicators (set out 
below) are being met.
Regular monitoring of cancer services will be carried out 
by the Department of Health, the NCCP and the NSS.  The 
NCCP will engage with the Hospital Groups, the CHOs 
and Primary Care on a regular basis to ensure that cancer 
services are provided at all levels of the health service.
The recommendations of the Strategy will be reviewed 
towards the end of 2021 to ensure that the aims and 
direction continue to be appropriate to deliver optimum 
outcomes for patients. 
17.5. Key Performance Indicators
Key Performance Indicators (KPIs) are required to measure 
how the health system is delivering on the objectives for 
improvements in cancer care outlined in this Strategy.  They 
are essential to monitor the impact of the various elements 
of cancer control across the patient pathway.
The KPIs include internationally comparable clinical 
outcome measures, as these are the ultimate test of 
whether the system has performed for patients. Other 
indicators, such as those focused on process and activity, 
are required to provide signals in areas such as system 
performance and capacity.
KPIs will also be used to focus attention on variations 
in performance, e.g. against the targets or between 
organisations, regions and populations.  The information 
arising can inform decision making in areas such as policy 
and resource allocation.  Therefore, the KPIs outlined in this 
Strategy must be collected, collated and reported by the 
NCCP not only on a national level, but also at geographic 
or institutional level where relevant. 
The KPIs to be captured are set out below. Some 
refinement of the KPIs over the lifetime of the Strategy is 
to be anticipated.
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Table 17.1  Key Performance Indicators
KPI No. Objective/Action Performance Indicator Target Target date
Objective: Reduce the number of preventable cancers
1 Reduce the proportion of adults in 
the population who smoke
Percentage of adults (aged 15+) 
in population smoking daily
5% 2025 (Interim 
measure 17% by 
2018)
Objective: Improve the Early Detection of Cancer
2 Introduce cancer awareness 
campaigns for specific diseases 
(e.g. lung cancer)
Percentage of lung cancers 
diagnosed at stage I and II  
one year following awareness 
campaign
15% relative 
increase
One year after 
awareness campaign. 
To be reviewed 
thereafter
3 Expand electronic referrals for all 
General Practice cancer referrals
Percentage of GP referrals 
received electronically 
95% End 2022 (Interim 
Target of 75% for 
end-2019)
4 Increase proportion of cancers 
diagnosed early
Percentage of colorectal, breast, 
and lung cancers diagnosed at 
stage I and II
Combined 
10% relative 
increase 
over 2013 
figure
2020
5 Ensure that Rapid Access Clinic and 
Symptomatic Breast Disease Clinic 
targets are met
Percentage of new patients 
attending RAC or SBD clinic 
within the recommended 
timeframe
95% 2017
6 Ensure that GPs have direct access 
to diagnostics for patients meeting 
referral criteria
Percentage of patients 
accessing Imaging/ Diagnostics/ 
Endoscopy within agreed 
timelines
90% 2020
7 Reduce the proportion of 
cancers detected in Emergency 
Departments
Percentage of cancers 
diagnosed in Emergency 
Departments
50% relative 
decrease 
over 2013 
figure
2026
8 Maintain target uptake rate for 
BreastCheck
Percentage uptake rate 
for BreastCheck screening 
population
70% 2017-2026
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KPI No. Objective/Action Performance Indicator Target Target date
9 Achieve target coverage rate for 
CervicalCheck
Percentage five year rolling 
coverage of CervicalCheck in 
screening population
80% 2017-2026
10 Achieve target uptake rate for 
BowelScreen
Percentage uptake rate 
for BowelScreen screening 
population
60% 2020 (Interim 
measure of 45% by 
end 2018)
Objective: Improve the Treatment of Cancer
11 Complete centralisation of cancer 
surgical services
Percentage of surgeries 
conducted in approved  centres
95% Various target dates 
to 2020
12 Ensure that patients have their case 
discussed at an MDT meeting
Percentage of patients 
diagnosed with invasive cancers 
formally discussed at MDT 
meetings
95% End 2020
13 Ensure that patients on active 
treatment receive appropriate 
admission in emergency situations
Percentage of patients on active 
cancer treatment admitted to 
hospital for cancer treatment 
that are admitted through 
Emergency Departments
Less than 
20%
2018
14 Ensure patients with cancer are 
admitted to cancer units
Percentage of patients requiring 
active treatment for their cancer 
admitted to dedicated cancer 
units in hospitals
80% 2020
15 Reduce waiting times for surgery Percentage of patients seen 
within NCCP target surgery 
timeframes for defined cancers
90% 2017
16 Achieve the radiotherapy treatment 
target
Percentage of patients 
commencing treatment within 
15 working days of being 
deemed ready to treat
90% 2017
Objective: Improve Survivorship Programmes
17 Offer patients with cancer a 
Treatment Summary and Care Plan
Percentage of patients receiving 
a Treatment Summary and Care 
Plan
95% 2020; Interim target 
50% by 2018
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KPI No. Objective/Action Performance Indicator Target Target date
Objective: Improve End of Life Care
18 Avoid chemotherapy in patients 
with advanced cancer who are 
unlikely to benefit as they are in 
the terminal phase of their disease
Percentage of patients with 
metastatic cancer given 
chemotherapy in last month 
of life
Less than 
25%
2019
Objective: Improve Palliative Care Services
19 Increase proportion of patients 
receiving specialist palliative care
Percentage of patients with 
cancer with stage IV disease 
receiving a specialist palliative 
care assessment
90% 2019
Objective: Support Research and Clinical Trials
20 Increase patient participation in 
clinical trials
Percentage of patients on 
cancer therapeutic clinical trials
6% 2020
Overarching Objective: Improve Incidence and Survival Rates in Ireland
21 Improve Ireland’s cancer ranking 
among EU member states
Ireland to be in top quartile for 
five year survival among EU 
member states
Top quartile 
for overall 
survival
2026
22 Reduce inequalities in age 
standardised cancer incidence for 
all malignant neoplasms (excl. 
NMSC)
Comparison between bottom 
20% deprivation vs. top 20%
Difference 
no greater 
than 3%
2026
23 Reduce inequalities in five year 
survival for:
-all cancers combined (excl. 
NMSC); 
-colorectal;
-lung; and
-breast.
Comparison between bottom 
20% deprivation vs. top 20%
Difference 
no greater 
than 3%
2026
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Recommendation Lead Agency
1. The Department of Health will ensure that policies under the Healthy Ireland framework 
are implemented in full and that opportunities to address cancer prevention measures 
under those policies are maximised. In particular, measures aimed at further reducing 
smoking levels will be pursued.
Lead: DoH
2. The NCCP will develop a cancer prevention function, working in conjunction with the 
broader Healthy Ireland initiative, and will lead in relation to the development and 
implementation of policies and programmes focused on cancer prevention.  
Lead: NCCP
3. The Department of Health will develop a national skin cancer prevention plan and oversee 
its implementation as a priority. The plan will will prioritise children, outdoor workers, 
sunbed users and those who pursue outdoor leisure activities.
Lead: DoH
4. The NCCP will develop a systematic, evidence-based mechanism to ascertain the potential 
benefits and the cost-effectiveness of various initiatives (including chemoprevention) which 
will inform future cancer prevention programmes.
Lead: NCCP
5. The HSE will ensure that the appropriate endoscopy capacity is provided in hospitals to 
allow for the expansion of BowelScreen to all aged 55-74 by end-2021.
Lead: HSE
6. The NCCP will draw up a plan by end-2017 for the development of an integrated cancer 
control and surveillance service for defined population subgroups with an inherited familial 
predisposition to cancer (e.g. breast, ovarian and colorectal).
Lead: NCCP
7. The NCCP and the HSE Health & Wellbeing Directorate, in partnership with the voluntary 
sector, will develop a rolling programme of targeted multi-media based public awareness 
and education campaigns, aimed at the early detection of specific cancers and with 
particular focus on at-risk populations. 
Lead: NCCP
HSE/Voluntary 
Sector
8. The NCCP, working with the ICGP and the National Clinical Effectiveness Committee, will 
develop a three year plan to enhance the care pathways between primary and secondary 
care for specific cancers. The plan will set out criteria for referral to diagnostics and 
incorporate the requirements for additional Rapid Access Clinics.
Lead: NCCP
NCEC/ICGP
9. The HSE will ensure that cancer referrals from a GP into a hospital will be made 
electronically. Each Hospital Group will facilitate the phasing in of e-referral. This will be 
completed by the end of 2022.
Lead: HSE
NCCP/GPs
10. The Department of Health will liaise with the Health and Education authorities with a 
view to increasing places in Third Level Institutions for the training of radiographers and 
sonographers.
Lead: DoH
RECOMMENDATIONS
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Recommendation Lead Agency
11. The NCCP, working with the other Directorates in the HSE, will develop criteria by end-2018 
for the referral of patients with suspected cancer, who fall outside of existing Rapid Access 
Clinics, for diagnostic tests. The NCCP will ensure, through these criteria, that GPs will have 
direct access to cancer diagnostics within agreed timelines
Lead: NCCP/
HSE
12. The NCCP will further develop the model of care for cancer to achieve integration between 
primary care and hospital settings at all stages of the cancer continuum, from diagnosis to 
post treatment care.
Lead: NCCP
13. Patients diagnosed with cancer will have their case formally discussed at a multi-disciplinary 
team meeting.  The NCCP, working with the Hospital Groups, will oversee and support MDT 
composition, processes and reporting of outcomes.
Lead: NCCP
14. The NCCP, working with the other Directorates in the HSE and with the Department of 
Health, will develop a rolling capital investment plan, to be reviewed annually, with the aim 
of ensuring that cancer facilities meet requirements.
Lead: NCCP
15. The Department of Health will ensure that investment in infrastructure, facilities, personnel 
and programmes in the designated cancer centres will have a goal of ultimately developing 
at least one comprehensive cancer care centre that will optimise cancer prevention, 
treatment, education and research during the Strategy period.
Lead: DoH
16. The NCCP will ensure that consultant appointments for radiology, endoscopy and 
histopathology, where necessary, are made in conjunction with appointments in other 
disciplines such as surgery and medical oncology.
Lead: NCCP
17. The NCCP will appoint a National Lead for Cancer Molecular Diagnostics for solid and liquid 
malignancies.
Lead: NCCP
18. The NCCP will establish a Steering Group for Cancer Molecular Diagnostics, chaired by the 
National Lead.  This Steering Group will set out the framework for the organisation, location 
and delivery of cancer molecular diagnostic services.
Lead: NCCP
19. The NCCP will further develop the Programme for Hereditary Cancers to ensure that 
evaluation, counselling, testing and risk reduction interventions are available as appropriate, 
and that services are available to patients on the basis of need.
Lead: NCCP 
20. The HSE will ensure that the existing cancer genetics services are amalgamated into one 
National Cancer Genetics Service and will identify the most appropriate site for its location.
Lead: HSE
21. The NCCP will draw up a plan setting out the number/location of designated cancer 
centres in which surgery will take place for the various tumour types. Timescales for the 
implementation of the plan will be included for each tumour type.
Lead: NCCP
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Recommendation Lead Agency
22. In line with the National Plan for Radiation Oncology, public sector radiation oncology 
facilities in Dublin, Cork and Galway will be expanded to meet patient demand and 
a planned National Programme of Equipment Refreshment and Replacement will be 
implemented across the Strategy period.
Lead NCCP
23. The NCCP will examine the model of care for patients receiving oral anti-cancer medicines 
and recommend steps to ensure that all patients receive such medicines in a safe and 
effective manner, with appropriate and proportionate supports, both in the hospital and 
community setting.
Lead: NCCP
24. The NCCP will develop appropriate MDT, centralisation and treatment arrangements to meet 
the diverse needs of patients with haematological cancers.
Lead: NCCP
25. The NCCP will develop a systematic, evidence-based mechanism to prioritise the 
establishment of MDTs for further rare cancers. The centralisation of diagnosis, treatment 
planning and surgical services for these cancers will be organised in line with best 
international practice.
Lead: NCCP
HSE/DoH
26. The HSE will ensure that an age appropriate facility is designated for adolescents and young 
adults with cancer within the new children’s hospital.
Lead: HSE
27. The HSE will develop closer links, on a hub and spoke model, between the National Centre 
for Child and Adolescent Cancer and the other designated cancer centres to provide 
appropriate and flexible transition arrangements for adolescents/young adults. This will 
include the joint appointment of adolescent/young adult oncologists and haemato-
oncologists and the provision of age-appropriate psycho-social support for these patients.    
Lead: HSE
NCCP
28. Links between cancer services and geriatric services will be strengthened, facilitated by the 
appointment of a National Clinical Lead in Geriatric Oncology in the NCCP.
Lead: NCCP
29. The NCCP will appoint a National Clinical Lead for Psycho-oncology to drive the delivery of 
networked services.
Lead: NCCP
30. Each designated cancer centre will establish a dedicated service to address the psycho-social 
needs of patients with cancer and their families. This will operate through a hub and spoke 
model, utilising the MDT approach, to provide equitable patient access.
Lead: NCCP
31. Designated cancer centres will have a sufficient complement of specialist palliative care 
professionals, including psycho-oncologists, to meet the needs of patients and families (such 
services will be developed on a phased basis to be available over seven days a week).
Lead: HSE 
Designated 
Cancer Centres
32. Oncology staff will have the training and education to ensure competence in the 
identification, assessment and management of patients with palliative care needs and all 
patients with cancer will have regular, standardised assessment of their needs.
Lead: HSE
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Recommendation Lead Agency
33. The HSE will oversee the further development of children’s palliative care to ensure that 
services are available to all children with a life limiting cancer.
Lead: HSE 
34. The NCCP will ensure that each hospital has a clearly defined framework for cancer patient 
safety and quality.
Lead: NCCP
35. The NCCP will define focused cancer patient experience surveys to incorporate treatment 
and survivorship in line with HIQA’s standard approach for the National In-Patient Acute Care 
Patient Experience Survey.
Lead: NCCP
HIQA
36. The NCCP will develop, publish and monitor a programme of national quality healthcare 
indicators for cancer care, involving both process and outcome measures, in line with 
international standards.
Lead: NCCP
37. The NCCP will develop further guidelines for cancer care in line with National Clinical 
Effectiveness Committee (NCEC) Standards.  Audits will also be developed in accordance 
with the NCEC Framework for National Clinical Audit.
Lead: NCCP 
NCEC
38. The Department of Health will ensure that patient representatives are involved in policy 
making, planning, practice and oversight of cancer services at local, regional and national 
levels.
Lead: DoH
39. The Department of Health will establish a Cancer Patient Advisory Committee to provide 
input into the development of programmes for patients with cancer. Membership of this 
committee will reflect the diverse nature of patients living with the effects of cancer, and will 
ensure that the needs of patients living in more remote areas are represented.
Lead: DoH
40. All hospitals will offer patients a Patient Treatment Summary and Care Plan as part of their 
support. These plans will allow patients to store information about their cancer, their cancer 
treatment and their follow-up care. The plans will also inform future healthcare providers.
Lead: NCCP/
HSE
Designated  
Cancer Centres/
Primary Care 
settings
41. The NCCP, in conjunction with the ICGP, cancer centres, the Irish Cancer Society and cancer 
support centres, will conduct a Cancer Survivorship Needs Assessment to ascertain the most 
suitable model of survivorship healthcare. The Needs Assessment should be completed by 
the end of 2018.
Lead: NCCP
42. The NCCP, in conjunction with the cancer centres, will develop shared care protocols for 
patients with cancer following treatment. These protocols will span the hospital and primary 
care settings.
Lead: NCCP
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Recommendation Lead Agency
43. Designated cancer centres working with the NCCP, the ICGP, primary care services, patients 
and voluntary organisations will develop and implement survivorship programmes. These 
programmes will emphasise physical, psychological and social factors that affect health and 
wellbeing, while being adaptable to patients with specific survivorship needs following their 
treatment.
Lead: NCCP
Designated 
Cancer Centres
44. The central role of the NCCP in ensuring that the National Cancer Strategy 2017-2026 
is implemented across the health service will be strengthened, including through the use 
of Service Level Agreements, and through a direct role in financial allocations to Hospital 
Groups under Activity Based Funding.
Lead: NCCP
45. The NCCP will work with the private sector providers to achieve voluntary participation in 
cancer data collection, audit, compliance with guidelines and reporting of outcomes.
Lead: NCCP
46. The NCCP will establish a National Cancer Research Group by end-2017 to improve the 
coordination of cancer research, to foster a supportive environment for research within the 
health service and the universities, to set research priorities in line with the overall cancer 
strategy, to seek to ensure that funding allocation is linked to these priorities and to work to 
achieve continuity of funding.
Lead: NCCP
47. The HSE will ensure that clinical cancer research, and the staff who deliver it, become a fully 
integrated component of cancer care delivery.
Lead: HSE
48. The NCCP and the National Cancer Research Group will examine mechanisms to ensure that 
newly appointed cancer consultants and Advanced Nurse Practitioners have protected time 
to pursue research interests in their new posts.
Lead: NCCP/
National Cancer 
Research Group
49. The NCCP will appoint a National Clinical Lead for Cancer Nursing. This person will work 
with other Directorates in the HSE and with the Department of Health to determine an 
integrated nursing leadership infrastructure for cancer nursing services at national, regional 
and local levels to support practice and research.
Lead: NCCP
50. The NCCP, aided by a cross-sector group, will draw up a comprehensive workforce plan for 
cancer services. This will include an interim assessment of staffing needs at medical, nursing 
and health & social care professional levels by mid-2018.
Lead: NCCP 
51. The HSE will ensure that all hospitals provide the National Cancer Registry with data related 
to cancer in an appropriate timeframe to allow for sufficient surveillance of cancer rates and 
outcomes in Ireland.
Lead: HSE
52. The Department of Health will review the scope of the National Cancer Registry with a view 
to increasing and optimising the use of available data to drive improvements in cancer care 
for patients.
Lead: DoH
NCCP/NCR
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APPENDICES
APPENDIX A: MEMBERSHIP AND TERMS OF REFERENCE OF THE STEERING GROUP
Professor M. John Kennedy (Chairman)  Consultant Medical Oncologist, St. James’s and St. Luke’s Hospitals 
Ms Majella Byrne  HSE Health and Wellbeing Directorate 
Mr Donal Buggy  Head of Services, Irish Cancer Society 
Mr Tony Carlin  Principal Medical Social Worker, St. Luke’s Hospital 
Dr Jerome Coffey  Director, National Cancer Control Programme 
Dr Harry Comber  Interim Director, National Cancer Registry 
Mr Michael Conroy  Cancer, Blood and Organs Policy Unit, DoH 
Ms Sharon Foley  CEO, Irish Hospice Foundation 
Professor Liam Grogan  Chair, Irish Society of Medical Oncologists 
Professor John Hyland  President, Royal College of Surgeons in Ireland 
Dr Mary Hynes  Deputy Director, National Cancer Control Programme 
Ms Anne Jacob  Clinical Lead Manager, Carers Association 
Ms Pauline Kehoe  President, Irish Association for Nurses in Oncology 
Dr Marie Laffoy  Assistant National Director,  National Cancer Control Programme 
Dr Graham Love  CEO, Health Research Board 
Dr Kathleen MacLellan Director of Patient Safety and Clinical Effectiveness, Department of Health
Ms Mairéad Mangan  Cancer Patient Forum
Dr Deirdre Mulholland Deputy Chief Medical Officer, Department of Health36 
Professor Fergus O’Kelly  President, Irish College of General Practitioners 
Dr Susan O’Reilly  CEO, Dublin Midlands Hospital Group 
Professor Joe O’Sullivan  Clinical Director, Northern Ireland Cancer Centre 
Dr Anne-Marie Ryan  Deputy Chief Nursing Officer, DoH 
Dr Karen Ryan  HSE Clinical Lead for Palliative Care 
Professor Owen Smith  Consultant Paediatric Haematologist, Our Lady’s Children’s Hospital, Crumlin
The terms of reference of the Steering Group are set out below:
• To provide guidance and advice to the Department of Health in the development of a National Cancer Strategy;
• To review the report of the Evaluation Team on A Strategy for Cancer Control in Ireland 2006 and the NCCP’s Report 
on the implementation of A Strategy for Cancer Control in Ireland 2006;
• To assess the impact of the prevalence of cancer, taking into account the projections of the National Cancer Registry, 
particularly in regard to providing a continuum of care for patients;
• To review the policy and operational effectiveness of the current approaches to dealing with cancer with a view to 
building on the progress achieved and addressing challenges over the coming 10 years; and
• To submit a draft Cancer Strategy for consideration by the Minister for Health.
36  Dr Deirdre Mulholland was replaced by Dr Kathleen MacLellan
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APPENDIX B: MEMBERSHIP AND TERMS OF REFERENCE OF THE PATIENT FORUM
Mr Michael Conroy (Chair) Department of Health
Ms Brigid Doherty  Patient Focus
Ms Noelle Duddy  Cooperating for Cancer Care North West
Dr Nicola Elmer  Irish Cancer Society
Mr Patrick Flanagan Barretstown
Ms Helen Forristal  Marie Keating Foundation
Ms Evelyn Griffith  CanTeen Ireland
Ms Betty Holmes  Donegal Action for Cancer Care
Ms Ellen Joyce  Cork ARC Cancer Support House
Ms Mairéad Mangan ARC Cancer Support Centres (Dublin)
Mr William McDermott Men’s Cancer Alliance
Ms Fiona McEntee  Europa Donna Ireland
Ms Bernie McHugh Cancer Support Sanctuary LARCC
Ms Teresa O’Brien  Screening Participant
Ms Veronica O’Leary Purple House Cancer Support
The terms of reference of the Cancer Patient Forum were as follows:
• To facilitate a patient input to the development of a National Cancer Strategy;
• To inform the work of the Cancer Strategy Steering Group;
• To nominate one member of the Forum to sit as a member on the Steering Group; and
• To consider how the patient input into cancer services can be facilitated more broadly
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ABF Activity Based Funding IARC International Agency for Research on Cancer
ANP Advanced Nurse Practitioner ICGP Irish College of General Practitioners
AYA Adolescent and Young Adult ICS Irish Cancer Society
CHO Community Healthcare Organisations IHI Individual Health Identifier
CNS Clinical Nurse Specialist KPIs Key Performance Indicators
CSO Central Statistics Office MDT Multidisciplinary Team
CT Computed Tomography MedLIS
National Medical Laboratory Information 
System
DoH Department of Health MMUH Mater Misericordiae University Hospital
ED Emergency Department MOCIS Medical Oncology Clinical Information System
EHR Electronic Health Record MRI Magnetic Resonance Imagins
EMA European Medicines Agency MRD Minimal Residual Disease
EPR Electronic Patient Record NAEDI
National Awareness and Early Diagnosis 
Initiative (UK)
EPAAC
European Partnership for Action Against 
Cancer
NCCP National Cancer Control Programme
EU European Union NCEC National Clinical Effectiveness Committee
FIT Faecal Immunochemical Test NCPE National Centre for Pharmacoeconomics
GI Gastrointestinal NCR National Cancer Registry
GP General Practitioner NGS Next Generation Sequencing
HEPA High-Efficiency Particulate Air
HIPE Hospital Inpatient Enquiry NHQRS National Healthcare Quality Reporting System
HIQA Health Information and Quality Authority NHS National Health Service (UK)
HIV Human Immunodeficiency Virus NICE
National Institute for Health and Care 
Excellence (UK)
HPRA Health Products Regulatory Authority NIMIS National Integrated Medical Imaging System
HPV Human Papilloma Virus NIMS National Incident Management System
HRB Health Research Board NMSC Non-melanoma skin cancer
HRT Hormone replacement therapy NPHOC
National Paediatric Haematology and 
Oncology Centre
HSCP Health and Social Care Professionals NPRO National Plan for Radiation Oncology
HSE Health Service Executive NPSO National Patient Safety Office
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HTA Health Technology Assessment NSS National Screening Service
IACR Irish Association for Cancer Research OAM Oral Anti-Cancer Medicine
OECD
Organisation for Economic Co-Operation 
and Development
SJH St. James’s Hospital
OLCHC Our Lady’s Children’s Hospital, Crumlin SLA Service Level Agreement
PET Positron Emission Tomography SLRON St. Luke’s Radiation Oncology Network
PSA Prostate-specific antigen SREs Serious Reportable Events
QA Quality Assurance TILDA The Irish Longitudinal Study on Ageing
RAC Rapid Access Clinic UHG University Hospital Galway
RECs Research Ethics Committees UK United Kingdom
SACT Systemic Anti-Cancer Therapy USA United States of America
SBD Symptomatic Breast Disease UVR Ultraviolet Radiation
SFI Science Foundation Ireland WHO World Health Organisation
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APPENDIX D: GLOSSARY
Adjuvant Therapy Another treatment used together with the primary treatment. Its purpose is to assist the 
primary treatment. Also called adjunctive or adjunct therapy.
Benign Not cancerous. Benign tumours may grow larger but do not spread to other parts of 
the body.
Brachytherapy A type of radiation therapy where a radioactive source is placed in or near a cancerous 
tissue.
Cancer A term for diseases in which abnormal cells divide without control and can invade 
nearby tissues. Cancer cells can also spread to other parts of the body through the 
blood and lymph systems.
Cancer Incidence Rate The number of new cancers of a specific site/type occurring in a specified population 
during a year, usually expressed as the number of cancers per 100,000 population.
Age standardised: The rates are calculated by applying the age-specific rates for 
the location being studied to a theoretical world-wide standard population, usually 
expressed per 100,000 persons per year.
Cancer Prevalence The number of people now living who have ever been diagnosed with cancer. It 
includes people diagnosed with cancer in the past as well those who were recently 
diagnosed.
Cancer Screening Examinations to detect cancer before symptoms appear. This may involve blood 
tests, urine tests, other tests, or medical imaging. Screening is usually offered for all 
individuals in a defined population group based on criteria such as age or gender, also 
called Population Cancer Screening.
Chemotherapy The use of drugs, singly or more usually in multiple combinations, to treat or cure 
cancer.
Epidemiology The study of the distribution and determinants of health-related states or events 
(including disease), and the application of this study to the control of diseases and other 
health problems.
Every Contact Counts A behaviour change programme which encourages professionals to use every contact 
with a member of the public to have a conversation to improve health.
Genomics A discipline in genetics that applies recombinant DNA, DNA sequencing methods, 
and bioinformatics to sequence, assemble, and analyse the function and structure of 
genomes (the complete set of DNA within a single cell of an organism, )
A
P
P
E
N
D
IC
E
S     
147
NATIONAL CANCER STRATEGY  2017-2026
Germline mutation A germline mutation is a gene change in a reproductive cell (egg or sperm) that is 
passed down from parent to offspring and are incorporated into the DNA of every 
cell in the body of the offspring. Germline mutations are also known as hereditary 
mutations.
Invasive cancer Cancer that has spread beyond the layer of tissue in which it developed and is growing 
into surrounding, healthy tissues.
Malignant Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other 
parts of the body.
Metastatic Cancer The spread of cancer from the primary site to other places in the body.
Molecular Diagnostics A technique used to analyse biological markers in the individual’s genetic code in order 
to diagnose and monitor disease, detect risk, and decide which therapies will work best 
for individual patients.
Mortality rate The number of deaths occurring in a specified population during a year, usually 
expressed as the number of deaths per 100,000 population.
Oncology Oncology is a branch of medicine that deals with the prevention, diagnosis and 
treatment of cancer. The three main divisions include:
• Medical oncology: focuses on treatment on cancer with chemotherapy, targeted 
therapy, immunotherapy and hormonal therapy
• Surgical oncology: focuses on treatment of cancer with surgery.
• Radiation oncology: focuses on treatment of cancer with ionising radiation.
Secondary cancer A cancer which has spread from the site of the original cancer to another part of the 
body (see also metastatic cancer).
Somatic Mutation A somatic mutation is an alteration in DNA that occurs after conception. Somatic 
mutations can occur in any cell of the body except for germ cells and therefore are not 
passed on to any offspring. These alterations can (but do not always) cause cancer or 
other diseases.
Stage of presentation The stage at presentation describes the severity of a person’s cancer based on the size 
and/or extent of the primary tumour and whether or not cancer has spread in the body.
Survival Net: The probability of surviving cancer in the absence of other causes of death. 
Relative: The ratio of the proportion of observed survivors (all causes of death) in 
a cohort of cancer patients to the proportion of expected survivors in a comparable 
cohort of cancer-free individuals.
Survival rate The percentage of people in a study or treatment group who are alive for a given 
period of time after diagnosis.
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